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7Abbreviations
AA arachidonic acid
aa amino acids
apo apolipoprotein
apoER2 apolipoprotein E receptor 2
BSA bovine serum albumin
[Ca2+]i intracellular Ca2+
 concentration
cAMP adenosine 3’, 5’-cyclic
monophosphate
cPLA2 cytosolic phospholipase A2
Dab-1 Disabled-1
dbcAMP dibutyryl cAMP
DMSO dimethylsulfoxide
ECL enhanced
chemoluminescence
EDTA ethylene-diamine-
tetraacetic acid
EGF epidermal growth factor
ER endoplasmatic reticulum
ERK extracellular signal
regulated kinase
FAK focal adhesion kinase
FAT focal adhesion targeting
FDB familial defective apoB100
Fg fibrinogen
FH familial
hypercholesterolemia
GAG glycosaminoglycan
GFP gel-filtered platelets
GPCR G-protein coupled
receptor
GST glutathione S-transferase
HDL high density lipoprotein
HMG-CoA 3-hydroxy-3-
methylglutarylCoA
IDL intermediate density
lipoprotein
IP immunoprecipitation
ITAM immunoreceptor tyrosine-
based activatory motif
ITIM immunoreceptor tyrosine-
based inhibitory motif
JNK c-Jun amino-terminal
kinase
kDa kiloDalton
LDL low density lipoprotein
LOX-1 lectin-like oxidized LDL
receptor 1
LPA lysophosphatidic acid
LRP LDL-receptor related
protein
MAPK mitogen activated protein
kinase
MKK MAPK Kinase
mox-LDL mildly oxidized LDL
NP40 nonidet P40
ox-LDL oxidized LDL
PAGE polyacrylamide gel
electrophoresis
PAR protease activated receptor
PECAM-1 platelet-endothelial cell
adhesion molecule
PGI2 prostaglandin I2
PKA protein kinase A
PKC protein kinase C
PLC phospholipase C
PP2A protein phosphatase 2A
PRP platelet rich plasma
PTB phosphotyrosine
binding domain
RAP receptor-associated protein
Ser serine
SH Src Homology
Thr threonine
TxA2 thromboxane A2
Tyr tyrosine
VLDL very low density lipoprotein
WB western blot
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General Introduction
Lipoprotein Density (g/mL) 
 
Major Apolipoproteins  
 
Diameter 
(nm) Trig Chol PL Protein 
Chylomicrons <0.96 A-I, A-IV, B48, C, E 75-1200 80-95 2-7 3-9 1-2 
VLDL 0.95-1.006 B100, C, E 30-80 55-80 5-15 10-20 6-10 
LDL 1.019-1.063 B100 19-25 5-15 40-50 20-25 18-22 
HDL 1.063-1.21 A-I, A-II, C, E  5-12 5-10 15-25 20-30 45-55 
 
Table 1. Characteristics of lipoproteins
Trig = triglycerides, Chol = total cholesterol, PL = phospholipids
Trig, Chol, PL and protein values are provided as percentage of total weight.
Atherosclerosis and Cholesterol
Cardiovascular disease is the primary cause of death in the western world. Accu-
mulation of cholesterol in the inner layer of the arterial wall, the intima, leads to the
development of atherosclerotic lesions. It is generally accepted that most of the
cholesterol is derived from Low Density Lipoprotein (LDL). Epidemiological studies
have revealed that high plasma levels of LDL are correlated with the occurrence of
atherosclerosis and incidence of cardiovasular disease 1, 2. In contrast to LDL, High
Density Lipoprotein (HDL) plasma levels are inversely correlated with the incidence
of cardiovascular disease 3, 4. Atherosclerosis results in blockade of arteries as a
result of cell proliferation and accumulation of platelets leading to thrombus formation.
Atherosclerosis is a major cause of acute myocardial infarction in which coronary
arteries become clogged by a thrombus at the site of the atherosclerotic lesion.
Lipoproteins
Lipoproteins are the main transporters of cholesterol, phospholipids and fatty acid
throughout the human body. All lipoproteins consist of a protein and a lipid moiety.
Lipoproteins are defined by their density and vary in lipid and protein composition
(Table 1) 5, 6. The apolipoproteins that comprise the majority of the protein moiety
control transport and metabolism of the lipoproteins.
The processing of lipoproteins is regulated by lipoprotein lipase, hepatic lipase,
lecithin cholesterol acyl transferase and transfer proteins such as cholesteryl esther
and phospholipid transfer proteins 7, 8.
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Figure 1. A schematic representation of an LDL particle
Very low density lipoprotein (VLDL) is the major triglyceride carrier in plasma. VLDL
is synthesized in the liver and intestine and secreted into the bloodstream where
triglycerides in the VLDL core are hydrolyzed by lipoprotein lipase. The particle is
degraded into Intermediate Density Lipoprotein (IDL). The IDL particles are further
degraded by hepatic lipase and converted into LDL 9, 10.
Dietary lipids are transported by chylomicrons, which are synthesized in the intes-
tine. Chylomicrons are able to exchange surface components with HDL.  In addi-
tion, some of the surface lipids and apolipoproteins from VLDL are transferred to
HDL. HDL is synthesized in the liver and intestine. The partcicle enters the plasma
as nascent HDL; phospholipid bilayers with merely free cholesterol and apolipo-
proteins. Lecithin cholesterol acyl transferase converts free cholesterol to cholesterol
ester by transfer of a fatty acid from lecithin. As a result, the nascent HDL is
converted into a spherical particle with a central core of cholesterol ester. The
function of HDL resides in reverse cholesterol transport; returning plasma cholesterol
to the liver.
LDL is defined as the population of lipoproteins within the density range of 1.019-
1.063 g/mL. LDL is the major cholesterol-carrying lipoprotein in human plasma and
is atherogenic meaning that it is positively correlated with a risk for development of
atherosclerosis. The physiological role of LDL is to deliver cholesterol to peripheral
tissues. LDL particles have a diameter of 20-25 nm and consist of a hydrophobic
core of cholesteryl ester and triglycerides which is surrounded by a monolayer of
phospholipid, unesterified cholesterol and apolipoprotein B100 (Figure 1). The major
lipid in LDL is esterified cholesterol. Each LDL particle contains approximately 1600
molecules of esterified cholesterol, 700 molecules of phospholipids, 600 molecules
ApoB100
Phosphatidylcholine
Sphingomyelin
Cholesterol
Cholesteryl ester
Triglyceride
12
General Introduction
of unesterified cholesterol and 170 molecules of triglycerides 11.
The main phospholipids in LDL are phosphatidylcholine (PC) and sphingomyelin
(SM). The major protein of LDL is apolipoprotein B100 (apoB100). ApoB100 con-
tains 4536 amino acids with a calculated weight of 513 kDa 12, 13. ApoB100 en-
wraps the LDL particle like a belt and stabilizes its structure. The protein covers
approximately 30% of the particle surface and interacts with the surface
phospholipids. ApoB100 contains multiple lipid-associating regions: when LDL is
treated with trypsin, some of the apoB100 peptides formed are released from the
LDL particle and others remain associated with lipids 14. Lipoprotein(a) (Lp(a)) is
an atherogenic lipoprotein that consists of an LDL-particle with an additional
apolipoprotein(a) tail, that is attached to apoB100 via a disulfide bridge 15.
Lipoprotein receptors
When cultured cells take up LDL from the medium, the LDL particles are
endocytosed and transferred to lysosomes where the receptor releases its ligand
as a result of acidic conditions. Subsequently, the receptor is recycled back to the
cell surface 16-18. Components of LDL particles are hydrolyzed and the free choles-
terol is used for maintenance of cell function. The rate of LDL uptake is subse-
quently downregulated. The mechanism that protects cells from over-accumula-
tion of cholesterol consists of several components; (1) the enzymes 3-hydroxy-3-
methylglutarylCoA (HMG-CoA) synthase and HMG-CoA reductase are inhibited.
These enzymes are required for synthesis of cholesterol in the cell; (2) cholesterol
stimulates cells to store excess cholesterol in re-esterified cholesterol by stimula-
tion the enzyme ACAT (acylCoA:cholesterol acyltransferase); (3) the synthesis of
LDL receptors is suppressed which results in a lower amount of cell surface
receptors 19-21. Via this mechanism cells can regulate uptake of cholesterol when-
ever the intracellular pools do not provide the required cholesterol.
This process is mediated by receptors that belong to the family of the LDL receptors.
The LDL receptor family consists of members that share resemblance in structure
and function. All members contain a cytosolic part, a single membrane spanning
domain and extracellular ligand-binding-type domains, coupled to epidermal growth
factor (EGF) precursor homology domains (Figure 2) 22.
The ligand-binding domain is located at the amino terminus of the receptor and
consists of repeating sub-domains of amino acids sequences. These LA repeats
(ligand binding repeats of the complement type A) are ligand-binding-type domains
consisting of approximately 40 amino acids and are required for the interaction of
the receptors with ligands such as lipoproteins. Each LA repeat contains 6 cysteines
that form three pairs of disulfide bonds 23.
EGF precursor homology domains, which are necessary for acid-dependent ligand
13
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Figure 2. The LDL-receptor family
Schematic representation of LDL receptor family members. For description see text.
release in endosomal compartments, consist of type B repeats and YWTD modules.
Type B repeats contain six cysteine residues each. YWTD (Tyr-Trp-Thr-Asp) modules
consist of approximately 50 residues including this concensus tetrapeptide. The O-
linked sugar domain is located just outside the plasma membrane and is enriched
in serine and threonine residues. Furthermore, a short transmembrane domain of
approximately 20 amino acids is present.
Cytoplasmic tails with lengths ranging between 50-200 amino acids are of critical
importance to the ligand uptake and signaling functions of these receptors. The
tetra-amino-acid Asn-Pro-x-Tyr (NPxY) motif plays a central role in receptor endo-
cytosis through coated pits as well as in serving as a docking site for cytoplasmic
adaptor and scaffold proteins 24, 25. In mammals, the LDL receptor family comprises
five members; the LDL receptor, LDL receptor-related protein, megalin, ApoER2
and the VLDL receptor.
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The LDL receptor
The LDL receptor (LDLR) is also termed apoB/E receptor or ‘classical LDL receptor’.
Brown and Goldstein 1 described the LDLR that is the first identified receptor that
regulates cholesterol homeostasis in the cell 26. The LDLR is a cell-surface, trans-
membrane glycoprotein of 839 amino acids. The receptor contains 7 extracellular
type A ligand binding repeats. Deletion of individual repeats and site-directed muta-
genesis showed that the ligand binding repeats 3-7 and the EGF precursor domain
are required for apoB binding; ligand binding repeat 5 is essential for apoE binding 27,
28
. The short cytoplasmic part of the LDLR consists of 50 amino acids.
LDL receptor-related protein
LDLR-related protein (LRP) binds a broad spectrum of many unrelated ligands 29.
LRP is synthesized as a single polypeptide which is cleaved in the Golgi compartment
to produce two subunits of 515 and 85 kDa that remain non-covalently attached to
each other 30. LRP contains 31 type A repeats organized in four clusters with 2, 8,
10 and 11 of these modules.  At present, over 30 different unrelated ligands are
known that interact with this multifunctional receptor 31. The cytoplasmic tail contains
two NPxY motifs.
Megalin
Megalin, formerly termed gp330/LDLreceptor related protein-2 (LRP-2), is an LDLR
family member with structural resemblance to LRP and mediates LDL endocytosis
and lysosomal degradation 32, 33. The term megalin (from Greek mega) is sug-
gested by Saito et al 34 as the 600 kDa type I cell-surface receptor was the largest
plasma membrane protein identified so far in vertebrates.  Megalin is originally
identified as a primary antigen in the renal autoimmune disorder Heymann nephri-
tis 35. Megalin contains 36 type A repeats organized in four clusters with 7, 8, 10
and 11 modules and reveals two NPxY motifs in its cytoplasmic tail. Megalin shares
many, but not all ligands with LRP probably due to the high structural similarity 34, 36.
Nevertheless, megalin shows a distinct distribution pattern of cysteine residues in
the YWTD spacer regions compared to LRP 34. Megalin is predominantly expressed
in extravascular sites 37 indicating that it is not involved in LDL clearing from the
blood stream. However, megalin is present on specialized epithelial cells from pla-
centa, choroid plexus, lung alveoli and kidney proximal tubules 38. Not much is
known about the presence of LDL in the fluids to which megalin is exposed with the
exception that low levels of apoB100 are present in cerebrospinal fluid 39.
ApoER2
Apolipoprotein E receptor 2 (ApoER2) is structurally less complex than LRP and
megalin and closely resembles the LDLR 40. ApoER2 has been referred to as LR7/
8B that stands for LDLR-related protein with seven or eight type A repeats and is
15
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mainly expressed in the brain 40, 41. The occurrence of tissue- and species-specific
splice variants makes it a complex family member 42-45. For example, mice express
three variants which differ in ligand binding domain but which all lack extracellular
binding repeats 4-6 46. These variants still bind β-VLDL and Reelin but not α2-
Macroglobulin which is recognized by full length ApoER2 46.
ApoER2 is predominantly expressed in brain and placenta but also in the vascular
cells megakaryocytes and platelets 40. The ApoER2 in the surface of megakaryo-
cytes and platelets lacks the extracellular ligand binding repeats 4-6 47. The pattern
of tissue expression suggests that ApoER2 plays a role in uptake of apoE containing
HDL secreted from astrocytes in the central nervous system. Binding experiments
with radiolabeled lipoproteins revealed that ApoER2 binds β-VLDL, which con-
tains multiple copies of apoE, via apoE and in much lesser extent to VLDL and
LDL 40. Besides variation in ligand binding repeats a difference in the short intra
cellular domain is observed between the human and murine variant. Comparison
of amino acid composition of the cytoplasmic tail of ApoER2 with other members
of the LDL receptor family revealed that ApoER2 contains a unique 59 aa proline-
rich insertion 40. It is suggested that this insert might constitute a signal required
for the specific localization in specialized regions of neuronal tissues.
The VLDL receptor
The VLDL receptor (VLDLR) is also termed LR8 as it is an LDL receptor with eight
type A ligand binding repeats 48. VLDLR expression is almost absent in the liver but
is expressed in adipose tissue, striated muscle and brain 49. VLDLR binds apoE
with high affinity and plays a major role in the metabolism of triglyceride rich particles
50
. The VLDLR plays a role in the delivery of VLDL-derived fatty acids into adipose
tissue. A deficiency in the VLDLR protects from obesity 51.
LDL receptor family ligands
The members of the LDLR family share high structural homology which does not
necessarily mean that similar ligands are recognized.
Ligand LDLR VLDLR ApoER2 Megalin LRP 
ApoE + + + + + 
ApoB100 +   +  
Table 2. Apolipoprotein B100/E recognition by LDL receptor family members
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Table 3. Comparison of amino acids of the B-site and A-site of apoB100 with the receptor-binding site of apoE
The A-site and B-site represent LDL receptor binding domains of apoB100, the E-site represents the LDL receptor
binding site of apoE. Positively charged amino acids are depicted in bold. The amino acid position of the first and last
residue of the receptor binding site is given between brackets.
A-site (3147) Lys  Ala  Gln  Tyr  Lys  Lys  Asn  Lys  His  Arg  His (3157)
B-site (3359) Arg  Leu  Thr  Arg  Lys  Arg  Gly  Leu  Lys  Leu  Ala (3369)
E-site  (142) Arg  Lys  Leu  Arg  Lys  Arg  Leu  Leu  Arg  Asp  Ala (152)
Apolipoprotein E is a ligand for all members of the LDL receptor family in contrast to
apoB100. Apolipoprotein E is a 34 kDa protein present on circulating lipoproteins
(Table 1). In Table 2 the apolipoprotein binding capacity of LDLR family members is
depicted. LDLR and megalin are the only members that bind both types of
apolipoproteins indicating that they bind both HDL and LDL.
The 39kDa receptor-associated protein (RAP) is able to inhibit the binding of ligands
to LDL receptor family members and functions in ensuring correct receptor folding
within the endoplasmatic reticulum (ER) 52, 53. The ER chaperone RAP functions
intracellularly in promoting folding and maturation of LDL receptor family members
by preventing the formation of intermolecular disulfide bonds and premature ligand
binding within the early secretory pathway 54-56. Depletion of Ca2+ results in misfolding
of the LDL receptor what can be partially corrected by RAP 57. RAP contains three
highly homologous regions of approximately 100 amino acids with different functions
54, 58
. For example, repeat 1, but not repeat 3, inhibits interaction of activated α2-
macroglobulin to LRP whereas repeat 3, but not repeat 1 promotes folding of LRP 59.
RAP binds with high affinity to LRP, megalin, VLDLR and apoER2 and with lower
affinity to the LDLR 53, 57, 60.
LDL-receptor binding
ApoB100 is the major protein component of LDL. The first 89% of apoB100 enwraps
the LDL particle like a belt, which penetrates the monolayer and makes contact
with the core. The C-terminal 11% of apoB100 forms a bow that crosses the ribbon
at amino acid 3500 (Figure 3A) 61. Selective chemical modification of apoB100
revealed that the basic amino acids arginine and lysine are important in the interac-
tion between LDL and the LDL receptor 62, 63.
Once apoB100 was sequenced, two sites became candidates for receptor binding:
amino acids 3120-3156 (A-site) and 3359-3369 (B-site). One of the two basic amino
acid rich domains, the B-site, shows high homology with the receptor -binding domain
of apoE that mediates HDL binding to the receptor 64. The receptor-binding domain
of apoE is also enriched in basic amino acids arginine and lysine (Table 3).
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ApoB70.5 is a truncated form of apoB100 in which the amino-terminal 70.5% of the
amino acid residues are present . Lipoproteins containing apoB70.5 lack the B-site
but do contain the other putative LDL receptor binding site, the A-site. ApoB70.5 is
unable to bind to the LDLR but can bind to megalin 65 indicating that site A alone is
sufficient for megalin-LDL binding. Besides these two domains, a single amino acid
at position 3500 is involved in LDLR binding. This arginine residue normally interacts
with the carboxyterminal tail of apoB100. Site-directed mutagenesis indicated that
the B-site (amino acids 3359- 3369) binds to the LDL receptor and that arginine-
3500 is not directly involved in receptor binding 66. It appears that arginine 3500
functions in stabilizing the carboxyl tail in order to preserve the basic amino acids -
rich sites available for receptor interaction (Figure 3A). The carboxyl terminus inhibits
the interaction between VLDL apoB100 and the LDL receptor, but after the conversion
to LDL, arginine-3500 interacts with the apoB100 carboxyl terminus 66. This provides
an explanation for the fact that lipoproteins with truncated apoB100 containing the
amino-terminal 75% (apoB75) or 95% (apoB95, Figure 3B) of apoB100 on the LDL
surface showed enhanced LDLR binding compared to lipoproteins containing intact
apoB100 67. In these truncated forms of apoB100, the candidates for LDLR binding
are available for interaction with the receptor.
Abnormal interaction between Low Density Lipoprotein receptors (LDLR) and their
ligands, apolipoprotein E and B, causes decreased catabolism of the lipoproteins
VLDL, IDL and/or LDL thereby raising their concentrations in plasma. Familial de-
fective apoB100 (FDB) is a genetic disease that leads to hypercholesterolemia
and is the most common apoB100 mutation 68, 69.
Figure 3. Model of LDL receptor binding
(A) Normal receptor binding in apoB100 depends on an interaction between arginine 3500 and tryptophan 4369
(R3500-W4369). (B) LDL with apoB95 lack a carboxyl tail and therefore have enhanced receptor binding.
(C) Mutation of the arginine 3500 (FDB) disrupts receptor binding. Modified from Boren et al 67.
18
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At amino acid position 3500, an arginine is replaced by a glutamine residue (R3500Q,
Figure 3C) 70. The arginine 3500 has a function in stabilizing the COOH terminal part
of apoB100 at tryptophan 4369 and preventing association of the tail with the B-site
in order to maintain proper LDL-receptor interaction 67. In FDB patients, the apoB100
tail shifts to the B-site resulting in defective LDL binding to the LDLR 67, 71.
The fact that proper LDL binding to the LDLR is important for the maintenance of
cholesterol homeostasis is illustrated by Familial Hypercholesterolemia (FH) in
which the defective binding is caused by a receptor defect. FH is caused by muta-
tions in the LDLR gene that leads to expression of nonfunctional or dysfunctional
LDL receptors resulting in elevated plasma LDL and deposition of LDL-derived
cholesterol in tendons, skin and within arteries 1, 72. Homozygotes express non-
functional receptors and show enormously elevated plasma cholesterol and develop
atherosclerotic plaques at very early age. Heterozygotes express half of the normal
levels of the LDLR resulting in approximately twice the normal cholesterol level.
They also develop atherosclerotic plaques but at a slower rate compared to the
homozygotes. There are more than 600 mutations of the LDLR gene known. They
are divided into five categories that affect the synthesis of the receptor, transport to
the cell surface, binding to ligands, clustering of receptors in the endocytic vesicles
and recycling to the cell surface 73-75.
Endocytosis of LDL
The NPxY motif mediates clustering of LDL receptors in coated pits and is the only
sequence segment in the cytoplasmic tail that is conserved among all members of
the LDL receptor family 24. LRP shows the highest rate of endocytosis, whereas
the VLDLR and ApoER2 exhibit the slowest rate of endocytosis 76. The high
endocytosis rate of the LRP tail may be explained by the two NPxY motifs that
induce a more potent endocytosis signal. It should be noted however, that an YXXL
motif has been identified in the cytoplasmic tail of LRP. With use of LRP minireceptors
it became clear that YXXL but not the two NPxY sequences serve as the dominant
signal for receptor-mediated endocytosis 77. A distal dileucine motif within the LRP
tail also contributes to endocytosis. An additional mechanism in regulating endo-
cytosis lies within the fact that the LRP tail interacts with a GTP-binding protein.
Ligand binding to LRP induces cyclic AMP dependent protein kinase A (PKA) acti-
vity 78.  PKA mediates serine phosphorylation of the cytoplasmic tail of LRP that is
involved in receptor-mediated endocytosis as this process is prevented by the
PKA inhibitors H-89 and PKI 79, 80.
Signaling by LDLR family members
As described above, an important function of the LDLR family is endocytosis. The
NPxY motif plays a role in this process but this domain is also detected in receptors
that are not involved in endocytosis but in signaling. There is increasing evidence
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that members of the LDL receptor family also function in signaling 81-84. Proteins
containing a phosphotyrosine binding (PTB) domain bind via this domain to amino
acids of NPxY motifs in the cytoplasmic tails of cell-surface receptors 85. This
domain has also been termed the phosphotyrosine interaction domain (PID).
Adaptor proteins that contain a PTB domain are Shc, Dab-1, FE65. These adaptor
proteins initiate several signal transduction pathways after binding to a receptor 81.
Shc has an N-terminal PTB domain and a C-terminal SH2 domain. Once Shc
molecules are recruited to the tyrosine-phosphorylated cytoplasmic tail of the
receptor via their PTB domain, they become tyrosine phosphorylated and associ-
ate with downstream signaling components via their SH2 domain 86, 87.
The unphosphorylated NPxY motif of LDLR family members interacts with Dab-1
and FE65 proteins present in  neurons.  FE65 contains two PTB domains of which
one interacts with the NPxY motif 88. Dab-1 is a cytoplasmic protein that contains
one PTB domain and acts as an adapter protein in phosphorylation dependent
intracellular signal transduction 89.
The extracellular matrix protein Reelin is a ligand for two members of the LDLR
family; the VLDLR and ApoER2 90. Unraveling of the Reelin-induced pathway
revealed for the first time that members of the lipoprotein family exhibit a function
in cell signaling 91. Reelin binding to the VLDLR and ApoER2 leads to internaliza-
tion of Reelin in vesicles and initiates Dab1 recruitment and tyrosine phosphoryla-
tion 92. This results in cell responses required for correct cell positioning in the
developing brain 92, 93. This was the first example of a role of the LDLR family in
signal transduction. Dab1 contains a protein interaction domain that binds to
nonphosphorylated NPxY motifs in the cytoplasmic tail of the receptors 94. Phos-
phorylated Dab1 recruits non receptor tyrosine kinases and their substrates to the
membrane and interacts with their SH2 domains. C-Jun amino-terminal kinases
(JNK) are proline-directed serine-threonine protein kinases and belong to the family
of Mitogen Activated Protein Kinases (MAPKs) 95. Independently of the Dab1
signaling pathway, ApoER2 is able to recruit JNK-interacting proteins (JIPs) to the
plasma membrane of migrating neurons 91. This recruitment of signal transduction
molecules is shared by megalin that also binds JIPs 81.
LDL-proteoglycan binding
Glycosaminoglycans (GAGs) vary in the nature of sugar monomers, the type of
linkage between them and the number and location of sulfate groups 96. The most
common GAG structures are chondroitin sulfate, dermatan sulfate, heparan sulfate
and keratan sulfate, hyaluronic acid and heparin. With the exception of heparin
and hyaluronic acid, GAG chains are covalently attached to a core protein, forming
a proteoglycan. Proteoglycans are present in the extracellular matrix and function
in vascular permeability, filtration, ion exchange, transport, deposition of plasma
materials and regulation of cellular metabolism 97.
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The subendothelial retention of atherogenic apoB-containing lipoproteins is an impor-
tant step in the development of atherosclerosis 98-100. Proteoglycans are primarily
found in the extracellular matrix, are important in cell-cell interaction and are thought
to play a major role in the retention of atherogenic lipoproteins. Proteoglycans consist
of a core protein with side chains of glycosaminoglycans that are negatively charged.
The interaction between atherogenic lipoproteins and proteoglycans involves an
ionic interaction between basic amino acids in apoB100 and negatively charged
sulfate groups on the proteoglycans 101. The removal of postive charge from lysine
and arginine residues of apoB100 blocks binding of LDL to GAGs. There are specific
sequences required for GAG binding; the basic amino acids have to be appropriately
oriented. Heparin-binding proteins share the consensus sequence XBBXBX and
XBBBXXBX with B representing a basic residue and X a hydrophilic residue 102.
ApoB100 contains 8 regions that bind to heparin 103 104, 105 with two binding regions
between aa 3100 and 3500 showing the highest affinity. The binding of LDL to
proteoglycans may function by forming a bridge between LDL and the LDL receptor.
Olsson et al 106, 107 showed that LDL binding to GAGs is dependent on the presence
of regions containing five basic amino acids with intervening non-basic amino
acids within a nonapeptide. The number and type of the non-basic amino acids
within the GAG-binding site determines the affinity of the interaction. Boren et al  66
demonstrated that a mutation of a single residue in apoB100 is able to disrupt
proteoglycan binding. The strenght of the binding also depends on the type of
GAG involved 108. Chondroitin-4-sulfate shows the weakest binding followed by (in
increasing order) chondroitin-4-sulfate, heparan sulfate, dermatan sulfate and heparin.
To compare the role of LDL binding to proteoglycans versus the LDL receptor, several
transgenic mice expressing recombinant LDL were generated (Table 4). Mutation of
the tryptophane residue (W4369Y) of the carboxyl terminal tail of apoB100 which
disrupts binding to arginine 3500 resulted in defective LDLR binding but left
proteoglycan binding undisturbed (Figure 3D).
Recombinant LDL LDL receptor binding Proteoglycan binding 
Control LDL Normal Normal 
R3500Q LDL Defective Normal 
RK3359-3369SA LDL Defective Defective 
K3363E LDL Normal Defective 
Table 4. Mutants of the Human Apo-B gene
(adapted from Boren et al 109)
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LDL with a mutation in the apoB100 gene in which lysine and arginine residues are
replaced by A and S (R,K3359-3369SA) showed defective LDLR and proteoglycan
binding. This illustrates again that an available site B with positively charged amino
acids is required for LDLR binding. For proteoglycan binding, the basic cluster RKR
of site B is essential as a single point mutation of lysine residue 3363 disrupted
binding 109.
A shift of the carboxyl tail of apoB100 from arginine 3500 to the B-site (W4369Y)
has no effect on LDL-proteoglycan binding but specific B-site-residues are required.
This implies that after the shift of the carboxyltail some residues of site B are still
accessible. Mice expressing proteoglycan binding-defective LDL showed less de-
velopment of atherosclerosis compared with mice expressing native LDL. This
suggests that the atherogenicity of apoB-containing lipoproteins is linked to their
affinity for artery wall proteoglycans and that atherosclerosis is initiated by suben-
dothelial retention of atherogenic lipoproteins 99.
The interaction between LDL and human blood platelets
From patients with hypercholesterolemia it became evident that lipoproteins modu-
late platelet function and alter the response of platelets to several naturally occur-
ring agonists 110. LDL enhances fibrinogen binding, aggregation, thromboxane A2
release and secretion induced by platelet agonists 111-118. Hackeng et al 112 showed
that the enhanced responsiveness of platelets by LDL upon stimulation by collagen
and TRAP was mediated by ligand-induced outside-in signaling through integrin
αIIbβ3.
An upstream mediator of platelet signaling pathways induced by LDL is the enzyme
p38MAPK. P38MAPK is a member of the family of  the MAPKs 119. MAPKs are Serine/
Threonine kinases that are activated in response to the simultaneous phosphoryla-
tion on a threonine and tyrosine residue at amino acid position 180 and 182
respectively. Upon p38MAPK activation, Heat Shock Protein (HSP) 27 is phosphorylated
via MAPK activated protein kinase (MAPKAP). HSP 27 is an F-actin polymerization
modulator, implicated in the regulation of stress fiber formation 120, 121. Inhibition of
p38MAPK by the specific inhibitor SB203580 results in inhibition of MAPKAP and
HSP 27 phosphorylation in platelets 122.  Upon LDL binding to the platelet, p38MAPK is
phosphorylated within 10 seconds and at low concentrations (0.1 g/L LDL). With the
use of inhibitors of several platelet signaling pathways, it became clear that p38MAPK
is an early event in the signaling induced by LDL. The phosphorylation of p38MAPK is
under control of cAMP.
A second signaling protein that becomes activated upon LDL binding to the platelet
surface is the 125 kDa focal adhesion kinase, p125FAK (FAK) 123, 124. FAK is a non
receptor tyrosine kinase that is phosphorylated and activated in several cell types
after ligand binding to integrin ligation and clustering and implicated in multiple
signaling pathways including cell motility, proliferation and apoptosis 125-128.
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FAK consists of a central catalytic domain flanked by large amino- and carboxy-
terminal regions. The carboxy-terminal region is the site of the Focal Adhesion
Targeting (FAT) sequence, which mediates the localization of FAK to focal adhesions
129
. After cell activation, FAK translocates to the cytoskeleton at focal adhesions,
where it serves as a docking site for signaling proteins 130, 131. In platelet suspensions,
phosphorylation of FAK is dependent on ligand binding to integrin αIIbβ3 and aggre-
gation. Glanzmann thrombasthenia patients, who lack or have deficient integrin
αIIbβ3 on the surface of their platelets show no FAK phosphorylation in response
to thrombin or collagen in stirred suspensions 132.  In the absence of stirring, α-
thrombin failed to initiate phosphorylation of FAK 132. LDL is a unique agonist as it
induces phosphorylation of FAK in platelet suspensions independent of integrin
αIIbβ3 and aggregation 123. Antibodies against αIIbβ3 do not alter LDL-induced
FAK phosphorylation. Furthermore, Glanzmann thrombasthenia platelets show
equal phosphorylation levels as control platelets 123.
Besides studies demonstrating the signaling pathways that become activated upon
contact between platelets and LDL, several groups have attempted to unravel the
LDL binding site on platelets 117, 118. Platelets contain specific binding sites for LDL
on their surface, between 1300 and 7000 per platelet 118, 133 but the nature of the
binding sites is still not known. A first assumption was that the classical LDL receptor
(also termed apoB/E receptor) that regulates LDL binding and cholesterol
homeostasis in nucleated cells is involved in platelet sensitization by LDL. How-
ever, the classical apoB/E LDLR that is present on nuclear cells is absent on the
surface of human blood platelets. LDL binding to lymphocytes and fibroblasts and
proteolytic degradation of 125I-LDL by lymphocytes was inhibited by the monoclonal
antibody IgG-C7 directed against the LDL receptor in contrast to 125I-LDL binding
to platelets. Also other characteristics of LDL-platelet binding differed from LDL
binding to the classical receptor. LDL binding to the platelet surface was reversible,
and independent of temperature and divalent ions. Furthermore, platelets from
patients with familial hypercholesterolemia who lack the classical LDL receptor
showed LDL binding to platelets 134. So far, the receptor for LDL on platelets is still
not characterized which complicates understanding the mechanism of the interac-
tion between LDL and platelets.
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Aim of the study
Previous studies have clarified that at physiological concentrations (0.6-1.0 g/L
apoB100) LDL sensitizes platelets to aggregation- and secretion-inducing agonists
without acting as an independent initiator of platelet functions. The activation of
p38MAPK and p125FAK appear early steps in this sensitization process. In the present
study we characterized LDL-induced p38MAPK and p125FAK activation in more de-
tail to find clues that might lead to the characterization of the LDL receptor on
platelets. In an alternative approach, the role of the B-site in apoB100 which recog-
nizes the classical LDL receptor on fibroblasts was studied with respect to a possi-
ble effect on platelets. These studies pointed to a structural resemblance between
the platelet-LDL receptor and a member of the LDL receptor family and led to a
preliminary characterization of the platelet LDL receptor. Since the contact be-
tween LDL and platelets would predict that under physiological conditions platelets
circulate in a sensitized state, mechanisms were sought that might neutralize the
activating properties by LDL and thus restore the dormant state of platelets found
in healthy individuals.
Thus, following an overview of the literature (chapter 2) the following questions
were addressed;
1. Does the site-specific phosphorylation of p125FAK induced by LDL differ from
known pathways for p125FAK activation induced by integrins or seven trans-
membrane receptors (chapter 3)?
2. Does platelet activation by LDL share one or more properties of LDL activa-
tion by the classical LDL receptor (chapter 4)?
3. The p125FAK and p38MAPK activation by LDL is inhibited by RAP, an inhibitor of
ligand binding to members of the LDL receptor family, and the B-site in LDL is
responsible for platelet sensitization by LDL. Does this suggest that the recently
identified member of the LDL receptor family; platelet ApoER2, might be involved
in the interaction of LDL with platelets (chapter 5)?
4. Since the only major receptor for inhibitory signals in platelets is PECAM-1,
does this receptor contribute to downregulation of LDL-activatory signals (chap-
ter 6)?
Finally, the results of these studies are compared with findings in the literature in
order to better understand our present insight in the mechanism of LDL-induced
sensitization of platelets (chapter 7).
24
General Introduction
References
1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis.  Science.
1986; 232: 34-47
2. Fielding CJ. Lipoprotein receptors, plasma cholesterol metabolism, and the regulation of cellu-
lar free cholesterol concentration.  FASEB J. 1992; 6: 3162-3168
3. Libby P. Managing the risk of atherosclerosis: the role of high-density lipoprotein.  Am J Cardiol.
2001; 88: 3N-8N
4. Sviridov D, Nestel P. Dynamics of reverse cholesterol transport: protection against atheroscle-
rosis.  Atherosclerosis. 2002; 161: 245-254
5. Gotto AM, Pownall HJ, Havel RJ. Introduction to the plasma lipoproteins.  Methods Enzymol.
1986; 3-41
6. Lipids, lipoproteins and apolipoproteins, in Burtis CA, Ashwood ER (eds): Tietz Textbook of
Clinical Chemistry. ed2. Piladelphia, WB Saunders Co, 1994, pp 1021
7. Connelly PW. The role of hepatic lipase in lipoprotein metabolism.  Clin Chim Acta. 1999; 286:
243-255
8. Jiang XC. The effect of phospholipid transfer protein on lipoprotein metabolism and atheroscle-
rosis.  Front Biosci. 2002; 7: d1634-d1641
9. Beisiegel U. Lipoprotein metabolism.  Eur Heart J. 1998; 19 Suppl: A20-A23
10. Salter AM, Brindley DN. The biochemistry of lipoproteins.  J Inherit Metab Dis. 1988; 11 Suppl
1:4-17.: 4-17
11. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in
oxidative modification of LDL.  Free Radic Biol Med. 1992; 13: 341-390
12. Olofsson SO, Bostrom K, Carlsson P, Boren J, Wettesten M, Bjursell G, Wiklund O, Bondjers G.
Structure and biosynthesis of apolipoprotein B.  Am Heart J. 1987; 113: 446-452
13. Segrest JP, Jones MK, De Loof H, Dashti N. Structure of apolipoprotein B-100 in low density
lipoproteins.  J Lipid Res. 2001; 42: 1346-1367
14. Chen PF, Marcel YL, Yang CY, Gotto AMJ, Milne RW, Sparrow JT, Chan L. Primary sequence
mapping of human apolipoprotein B-100 epitopes. Comparisons of trypsin accessibility and
immunoreactivity and implication for apoB conformation.  Eur J Biochem. 1988; 175: 111-118
15. Scanu AM, Fless GM. Lipoprotein (a). Heterogeneity and biological relevance.  J Clin Invest.
1990; 85: 1709-1715
16. Brown MS, Anderson RG, Basu SK, Goldstein JL. Recycling of cell-surface receptors: observa-
tions from the LDL receptor system.  Cold Spring Harb Symp Quant Biol. 1982; 46 Pt 2: 713-721
17. Anderson RG, Brown MS, Beisiegel U, Goldstein JL. Surface distribution and recycling of the
low density lipoprotein receptor as visualized with antireceptor antibodies.  J Cell Biol. 1982; 93:
523-531
18. Brown MS, Goldstein JL. Receptor-mediated endocytosis: insights from the lipoprotein receptor
system.  Proc Natl Acad Sci U S A. 1979; 76: 3330-3337
19. Sato R, Takano T. Regulation of intracellular cholesterol metabolism.  Cell Struct Funct. 1995;
20: 421-427
20. Chang TY, Chang CC, Lin S, Yu C, Li BL, Miyazaki A. Roles of acyl-coenzyme A:cholesterol
acyltransferase-1 and -2.  Curr Opin Lipidol. 2001; 12: 289-296
21. Brown MS, Kovanen PT, Goldstein JL. Regulation of plasma cholesterol by lipoprotein receptors.
Science. 1981; 212: 628-635
22. Herz J. Deconstructing the LDL receptor—a rhapsody in pieces.  Nat Struct Biol. 2001; 8: 476-
478
23. Bieri S, Djordjevic JT, Daly NL, Smith R, Kroon PA. Disulfide bridges of a cysteine-rich repeat of
the LDL receptor ligand-binding domain.  Biochemistry. 1995; 34: 13059-13065
24. Chen WJ, Goldstein JL, Brown MS. NPXY, a sequence often found in cytoplasmic tails, is
required for coated pit-mediated internalization of the low density lipoprotein receptor.  J Biol
Chem.  1990; 265: 3116-3123
25. Trowbridge IS. Endocytosis and signals for internalization.  Curr Opin Cell Biol. 1991; 3: 634-
641
25
Chapter 1
26. Brown MS, Goldstein JL. Regulation of the activity of the low density lipoprotein receptor in
human fibroblasts.  Cell. 1975; 6: 307-316
27. Esser V, Limbird LE, Brown MS, Goldstein JL, Russell DW. Mutational analysis of the ligand
binding domain of the low density lipoprotein receptor.  J Biol Chem. 1988; 263: 13282-13290
28. Russell DW, Brown MS, Goldstein JL. Different combinations of cysteine-rich repeats mediate
binding of low density lipoprotein receptor to two different proteins.  J Biol Chem. 1989; 264:
21682-21688
29. Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage
scavenger receptors and LDL receptor-related protein (LRP).  Annu Rev Biochem. 1994; 63:601-
37.: 601-637
30. Herz J, Kowal RC, Goldstein JL, Brown MS. Proteolytic processing of the 600 kd low density
lipoprotein receptor-related protein (LRP) occurs in a trans-Golgi compartment.  EMBO J. 1990;
9: 1769-1776
31. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor.  J Clin Invest.
2001; 108: 779-784
32. Hjalm G, Murray E, Crumley G, Harazim W, Lundgren S, Onyango I, Ek B, Larsson M, Juhlin C,
Hellman P, Davis H, Akerstrom G, Rask L, Morse B. Cloning and sequencing of human gp330,
a Ca(2+)-binding receptor with potential intracellular signaling properties.  Eur J Biochem. 1996;
239: 132-137
33. Stefansson S, Chappell DA, Argraves KM, Strickland DK, Argraves WS. Glycoprotein 330/low
density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins
via interaction with apolipoprotein B100.  J Biol Chem. 1995; 270: 19417-19421
34. Saito A, Pietromonaco S, Loo AK, Farquhar MG. Complete cloning and sequencing of rat gp330/
”megalin,” a distinctive member of the low density lipoprotein receptor gene family.  Proc Natl
Acad Sci U S A. 1994; 91: 9725-9729
35. Kerjaschki D. Megalin/GP330 and pathogenetic concepts of membranous glomerulopathy (MGN).
Kidney Blood Press Res. 2000; 23: 163-166
36. Willnow TE, Goldstein JL, Orth K, Brown MS, Herz J. Low density lipoprotein receptor-related
protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and
lactoferrin, an inhibitor of chylomicron remnant clearance.  J Biol Chem. 1992; 267: 26172-
26180
37. Kounnas MZ, Stefansson S, Loukinova E, Argraves KM, Strickland DK, Argraves WS. An over-
view of the structure and function of glycoprotein 330, a receptor related to the alpha 2-mac-
roglobulin receptor.   Ann N Y Acad Sci. 1994; 737: 114-123
38. Lundgren S, Carling T, Hjalm G, Juhlin C, Rastad J, Pihlgren U, Rask L, Akerstrom G, Hellman
P. Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing protein.  J Histochem
Cytochem. 1997; 45: 383-392
39. Carlsson J, Armstrong VW, Reiber H, Felgenhauer K, Seidel D. Clinical relevance of the quan-
tification of apolipoprotein E in cerebrospinal fluid.  Clin Chim Acta. 1991; 196: 167-176
40. Kim DH, Iijima H, Goto K, Sakai J, Ishii H, Kim HJ, Suzuki H, Kondo H, Saeki S, Yamamoto T.
Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein
receptor family predominantly expressed in brain.  J Biol Chem. 1996; 271: 8373-8380
41. Kim DH, Iijima H, Goto K, Sakai J, Ishii H, Kim HJ, Suzuki H, Kondo H, Saeki S, Yamamoto T.
Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein
receptor family predominantly expressed in brain.  J Biol Chem. 1996; 271: 8373-8380
42. Korschineck I, Ziegler S, Breuss J, Lang I, Lorenz M, Kaun C, Ambros PF, Binder BR. Identifica-
tion of a novel exon in apolipoprotein E receptor 2 leading to alternatively spliced mRNAs found
in cells of the vascular wall but not in neuronal tissue.  J Biol Chem. 2001; 276: 13192-13197
43. Ma SL, Ng HK, Baum L, Pang JC, Chiu HF, Woo J, Tang NL, Lam LC. Low-density lipoprotein
receptor-related protein 8 (apolipoprotein E receptor 2) gene polymorphisms in Alzheimer’s
disease.  Neurosci Lett. 2002; 332: 216-218
44. Kim DH, Magoori K, Inoue TR, Mao CC, Kim HJ, Suzuki H, Fujita T, Endo Y, Saeki S, Yamamoto
TT. Exon/intron organization, chromosome localization, alternative splicing, and transcription
units of the human apolipoprotein E receptor 2 gene.  J Biol Chem. 1997; 272: 8498-8504
26
General Introduction
45. Korschineck I, Ziegler S, Breuss J, Lang I, Lorenz M, Kaun C, Ambros PF, Binder BR. Identifi-
cation of a novel exon in apolipoprotein E receptor 2 leading to alternatively spliced mRNAs
found in cells of the vascular wall but not in neuronal tissue.  J Biol Chem. 2001; 276: 13192-
13197
46. Brandes C, Kahr L, Stockinger W, Hiesberger T, Schneider WJ, Nimpf J. Alternative splicing in
the ligand binding domain of mouse ApoE receptor-2 produces receptor variants binding reelin
but not alpha 2-macroglobulin.  J Biol Chem. 2001; 276: 22160-22169
47. Riddell DR, Vinogradov DV, Stannard AK, Chadwick N, Owen JS. Identification and characteri-
zation of LRP8 (apoER2) in human blood platelets.  J Lipid Res. 1999; 40: 1925-1930
48. Nimpf J, Schneider WJ. The VLDL receptor: an LDL receptor relative with eight ligand binding
repeats, LR8.  Atherosclerosis. 1998; 141: 191-202
49. Yamamoto T, Bujo H. Close encounters with apolipoprotein E receptors.  Curr Opin Lipidol.
1996; 7: 298-302
50. Tacken PJ, Hofker MH, Havekes LM, van Dijk KW. Living up to a name: the role of the VLDL
receptor in lipid metabolism.  Curr Opin Lipidol. 2001; 12: 275-279
51. Goudriaan JR, Tacken PJ, Dahlmans VE, Gijbels MJ, van Dijk KW, Havekes LM, Jong MC.
Protection from obesity in mice lacking the VLDL receptor.  Arterioscler Thromb Vasc Biol. 2001;
21: 1488-1493
52. Bu G, Schwartz AL. RAP, a novel type of ER chaperone.  Trends Cell Biol. 1998; 8: 272-276
53. Kounnas MZ, Argraves WS, Strickland DK. The 39-kDa receptor-associated protein interacts
with two members of the low density lipoprotein receptor family, alpha 2-macroglobulin receptor
and glycoprotein 330.  J Biol Chem. 1992; 267: 21162-21166
54. Bu G, Geuze HJ, Strous GJ, Schwartz AL. 39 kDa receptor-associated protein is an ER resident
protein and molecular chaperone for LDL receptor-related protein.  EMBO J. 1995; 14: 2269-
2280
55. Savonen R, Obermoeller LM, Trausch-Azar JS, Schwartz AL, Bu G. The carboxyl-terminal do-
main of receptor-associated protein facilitates proper folding and trafficking of the very low den-
sity lipoprotein receptor by interaction with the three amino-terminal ligand-binding repeats of
the receptor.  J Biol Chem. 1999; 274: 25877-25882
56. Sato A, Shimada Y, Herz J, Yamamoto T, Jingami H. 39-kDa receptor-associated protein (RAP)
facilitates secretion and ligand binding of extracellular region of very-low-density-lipoprotein
receptor: implications for a distinct pathway from low-density-lipoprotein receptor.  Biochem J.
1999; 341: 377-383
57. Li Y, Lu W, Schwartz AL, Bu G. Receptor-associated protein facilitates proper folding and matu-
ration of the low-density lipoprotein receptor and its class 2 mutants.  Biochemistry. 2002; 41:
4921-4928
58. Warshawsky I, Bu G, Schwartz AL. Identification of domains on the 39-kDa protein that inhibit
the binding of ligands to the low density lipoprotein receptor-related protein.  J Biol Chem. 1993;
268: 22046-22054
59. Obermoeller LM, Warshawsky I, Wardell MR, Bu G. Differential functions of triplicated repeats
suggest two independent roles for the receptor-associated protein as a molecular chaperone.  J
Biol Chem. 1997; 272: 10761-10768
60. Bu G. Receptor-associated protein: a specialized chaperone and antagonist for members of the
LDL receptor gene family.  Curr Opin Lipidol. 1998; 9: 149-155
61. Chatterton JE, Phillips ML, Curtiss LK, Milne R, Fruchart JC, Schumaker VN. Immunoelectron
microscopy of low density lipoproteins yields a ribbon and bow model for the conformation of
apolipoprotein B on the lipoprotein surface.  J Lipid Res. 1995; 36: 2027-2037
62. Mahley RW, Innerarity TL, Pitas RE, Weisgraber KH, Brown JH, Gross E. Inhibition of lipopro-
tein binding to cell surface receptors of fibroblasts following selective modification of arginyl
residues in arginine-rich and B apoproteins.  J Biol Chem. 1977; 252: 7279-7287
63. Weisgraber KH, Innerrarity TL, Mahley RW. Role of the lysine residues of plasma lipoproteins in
high-affinity binding to cell surface receptors on human fibroblasts.  J Biol Chem. 1978; 253:
9053-9062
27
Chapter 1
64. De Loof H, Rosseneu M, Yang CY, Li WH, Gotto AMJ, Chan L. Human apolipoprotein B: analysis
of internal repeats and homology with other apolipoproteins.  J Lipid Res. 1987; 28: 1455-1465
65. Chen Z, Saffitz JE, Latour MA, Schonfeld G. Truncated apo B-70.5-containing lipoproteins bind
to megalin but not the LDL receptor.  J Clin Invest. 1999; 103: 1419-1430
66. Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL. Identification of the low density lipopro-
tein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the
carboxyl terminus in familial defective apo-B100.  J Clin Invest. 1998; 101: 1084-1093
67. Boren J, Ekstrom U, Agren B, Nilsson-Ehle P, Innerarity TL. The molecular mechanism for the
genetic disorder familial defective apolipoprotein B100.  J Biol Chem. 2001; 276: 9214-9218
68. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, Grundy SM. Famil-
ial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding.  Proc
Natl Acad Sci U S A. 1987; 84: 6919-6923
69. Rauh G, Keller C, Kormann B, Spengel F, Schuster H, Wolfram G, Zollner N. Familial defective
apolipoprotein B100: clinical characteristics of 54 cases.  Atherosclerosis. 1992; 92: 233-241
70. Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ. Association between a
specific apolipoprotein B mutation and familial defective apolipoprotein B-100.  Proc Natl Acad
Sci U S A. 1989; 86: 587-591
71. Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL. Identification of the low density lipopro-
tein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the
carboxyl terminus in familial defective apo-B100.  J Clin Invest. 1998; 101: 1084-1093
72. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial
hypercholesterolemia: mutational analysis of a membrane protein.  Annu Rev Genet. 1990; 24:
133-170
73. Russell DW, Esser V, Hobbs HH. Molecular basis of familial hypercholesterolemia.  Arterioscle-
rosis. 1989; 9: I8-13
74. Soutar AK. Familial hypercholesterolaemia and LDL receptor mutations.  J Intern Med. 1992;
231: 633-641
75. Myant NB. The metabolic basis of familial hypercholesterolemia.  Klin Wochenschr. 1983; 61:
383-401
76. Li Y, Lu W, Marzolo MP, Bu G. Differential functions of members of the low density lipoprotein
receptor family suggested by their distinct endocytosis rates.  J Biol Chem. 2001; 276: 18000-
18006
77. Li Y, Marzolo MP, van Kerkhof P, Strous GJ, Bu G. The YXXL motif, but not the two NPXY motifs,
serves as the dominant endocytosis signal for low density lipoprotein receptor-related protein.  J
Biol Chem. 2000; 275: 17187-17194
78. Goretzki L, Mueller BM. Low-density-lipoprotein-receptor-related protein (LRP) interacts with a
GTP-binding protein.  Biochem J. 1998; 336: 381-386
79. Goretzki L, Mueller BM. Receptor-mediated endocytosis of urokinase-type plasminogen activa-
tor is regulated by cAMP-dependent protein kinase.  J Cell Sci. 1997; 110: 1395-1402
80. Li Y, van Kerkhof P, Marzolo MP, Strous GJ, Bu G. Identification of a major cyclic AMP-depend-
ent protein kinase A phosphorylation site within the cytoplasmic tail of the low-density lipoprotein
receptor-related protein: implication for receptor-mediated endocytosis.  Mol Cell Biol. 2001; 21:
1185-1195
81. Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W, Nimpf J, Herz
J. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and
scaffold proteins suggest diverse biological functions in cellular communication and signal trans-
duction.  J Biol Chem. 2000; 275: 25616-25624
82. Howell BW, Herz J. The LDL receptor gene family: signaling functions during development.
Curr Opin Neurobiol.  2001; 11: 74-81
83. Willnow TE, Nykjaer A, Herz J. Lipoprotein receptors: new roles for ancient proteins.  Nat Cell
Biol. 1999; 1: E157-E162
84. Nimpf J, Schneider WJ. From cholesterol transport to signal transduction: low density lipopro-
tein receptor, very low density lipoprotein receptor, and apolipoprotein E receptor-2.  Biochim
Biophys Acta. 2000; 1529: 287-298
28
General Introduction
85. Margolis B. The PI/PTB domain: a new protein interaction domain involved in growth factor
receptor signaling.  J Lab Clin Med. 1996; 128: 235-241
86. Prigent SA, Pillay TS, Ravichandran KS, Gullick WJ. Binding of Shc to the NPXY motif is
mediated by its N-terminal domain.  J Biol Chem. 1995; 270: 22097-22100
87. Zhou S, Margolis B, Chaudhuri M, Shoelson SE, Cantley LC. The phosphotyrosine interaction
domain of SHC recognizes tyrosine-phosphorylated NPXY motif.  J Biol Chem. 1995; 270: 14863-
14866
88. Russo T, Faraonio R, Minopoli G, De Candia P, De Renzis S, Zambrano N. Fe65 and the protein
network centered around the cytosolic domain of the Alzheimer’s beta-amyloid precursor pro-
tein.  FEBS Lett. 1998; 434: 1-7
89. Rice DS, Sheldon M, D’Arcangelo G, Nakajima K, Goldowitz D, Curran T. Disabled-1 acts down-
stream of Reelin in a signaling pathway that controls laminar organization in the mammalian
brain.  Development. 1998; 125: 3719-3729
90. D’Arcangelo G, Homayouni R, Keshvara L, Rice DS, Sheldon M, Curran T. Reelin is a ligand for
lipoprotein receptors.  Neuron. 1999; 24: 471-479
91. Stockinger W, Brandes C, Fasching D, Hermann M, Gotthardt M, Herz J, Schneider WJ, Nimpf
J. The reelin receptor ApoER2 recruits JNK-interacting proteins-1 and -2.  J Biol Chem. 2000;
275: 25625-25632
92. Hiesberger T, Trommsdorff M, Howell BW, Goffinet A, Mumby MC, Cooper JA, Herz J. Direct
binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of
disabled-1 and modulates tau phosphorylation.  Neuron. 1999; 24: 481-489
93. Feng Y, Walsh CA. Protein-protein interactions, cytoskeletal regulation and neuronal migration.
Nat Rev Neurosci 2001 Jun ;2 (6 ):408 -16. 2: 408-416
94. Howell BW, Lanier LM, Frank R, Gertler FB, Cooper JA. The disabled 1 phosphotyrosine-bind-
ing domain binds to the internalization signals of transmembrane glycoproteins and to
phospholipids.  Mol Cell Biol. 1999; 19: 5179-5188
95. Weston CR, Davis RJ. The JNK signal transduction pathway.  Curr Opin Genet Dev 2002 Feb
;12 (1 ):14 -21. 12: 14-21
96. Lamberg SI, Stoolmiller AC. Glycosaminoglycans. A biochemical and clinical review.  J Invest
Dermatol. 1974; 63: 433-449
97. Wight TN. Cell biology of arterial proteoglycans.  Arteriosclerosis. 1989; 9: 1-20
98. Srinivasan SR, Radhakrishnamurthy B, Vijayagopal P, Berenson GS. Proteoglycans, lipoproteins,
and atherosclerosis.  Adv Exp Med Biol. 1991; 285: 373-381
99. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, Boren J. Suben-
dothelial retention of atherogenic lipoproteins in early atherosclerosis.  Nature. 2002; 417: 750-
754
100. Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, Camejo G. Cellular consequences of the
association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis.
Arterioscler Thromb Vasc Biol. 1997; 17: 1011-1017
101. Iverius PH. The interaction between human plasma lipoproteins and connective tissue
glycosaminoglycans.  J Biol Chem. 1972; 247: 2607-2613
102. Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions.  Arte-
riosclerosis. 1989; 9: 21-32
103. Camejo G, Olofsson SO, Lopez F, Carlsson P, Bondjers G. Identification of Apo B-100 segments
mediating the interaction of low density lipoproteins with arterial proteoglycans.  Arteriosclero-
sis. 1988; 8: 368-377
104. Weisgraber KH, Rall SCJ. Human apolipoprotein B-100 heparin-binding sites.  J Biol Chem.
1987; 262: 11097-11103
105. Hirose N, Blankenship DT, Krivanek MA, Jackson RL, Cardin AD. Isolation and characterization
of four heparin-binding cyanogen bromide peptides of human plasma apolipoprotein B.  Bio-
chemistry. 1987; 26: 5505-5512
106. Olsson U, Camejo G, Olofsson SO, Bondjers G. Molecular parameters that control the asso-
ciation of low density lipoprotein apo B-100 with chondroitin sulphate.  Biochim Biophys Acta.
1991; 1097: 37-44
29
Chapter 1
107. Olsson U, Camejo G, Hurt-Camejo E, Elfsber K, Wiklund O, Bondjers G. Possible functional
interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the
ApoB/E receptor.  Arterioscler Thromb Vasc Biol. 1997; 17: 149-155
108. Olsson U, Ostergren-Lunden G, Moses J. Glycosaminoglycan-lipoprotein interaction.
Glycoconj. 2001; 18: 789-797
109. Boren J, Olin K, Lee I, Chait A, Wight TN, Innerarity TL. Identification of the principal proteoglycan-
binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interac-
tion without affecting LDL receptor binding.  J Clin Invest. 1998; 101: 2658-2664
110. Betteridge DJ, Cooper MB, Saggerson ED, Prichard BN, Tan KC, Ling E, Barbera G, McCarthy
S, Smith CC. Platelet function in patients with hypercholesterolaemia.  Eur J Clin Invest. 1994; 24
Suppl 1: 30-33
111. Surya II, Gorter G, Mommersteeg M, Akkerman JWN. Enhancement of platelet functions by
low density lipoproteins.  Biochim Biophys Acta. 1992; 1165: 19-26
112. Hackeng CM, Huigsloot M, Pladet MW, Nieuwenhuis HK, Rijn HJMv, Akkerman JWN. Low-
density lipoprotein enhances platelet secretion via integrin-aðIIbbð3 -mediated signaling.
Arterioscler Thromb Vasc Biol. 1999; 19: 239-247
113. van Willigen G, Gorter G, Akkerman JWN. LDLs increase the exposure of fibrinogen binding
sites on platelets and secretion of dense granules.  Arterioscler Thromb. 1994; 14: 41-46
114. Nofer JR, Tepel M, Kehrel B, Wierwille S, Walter M, Seedorf U, Zidek W, Assmann G. Low-
density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhanc-
ing platelet activity in hypercholesterolemia.  Circulation. 1997; 95: 1370-1377
115. Hackeng CM, Franke B, Relou IA, Gorter G, Bos JL, van Rijn HJ, Akkerman JW. Low-density
lipoprotein activates the small GTPases Rap1 and Ral in human platelets.  Biochem J. 2000;
349: 231-238
116. Hackeng CM, Relou IA, Pladet MW, Gorter G, van Rijn HJ, Akkerman JW. Early platelet
activation by low density lipoprotein via p38MAP kinase.  Thromb Haemost. 1999; 82: 1749-
1756
117. Aviram M, Brook JG. Platelet interaction with high and low density lipoproteins.  Atherosclerosis.
1983; 46: 259-268
118. Malle E, Sattler W. Platelets and the lipoproteins: Native, modified and platelet modified lipoproteins.
Platelets. 1994; 5: 70-83
119. Ono K, Han J. The p38 signal transduction pathway: activation and function.  Cell Signal. 2000;
12: 1-13
120. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial
growth factor mediates actin reorganization and cell migration in human endothelial cells.
Oncogene. 1997; 15: 2169-2177
121. Huot J, Houle F, Marceau F, Landry J. Oxidative stress-induced actin reorganization mediated
by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular en-
dothelial cells.  Circ Res. 1997; 80: 383-392
122. Saklatvala J, Rawlinson L, Waller RJ, Sarsfield S, Lee JC, Morton LF, Barnes MJ, Farndale RW.
Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a
thromboxane analogue.  J Biol Chem. 1996; 271: 6586-6589
123. Hackeng CM, Pladet MW, Akkerman JW, van Rijn HJ. Low density lipoprotein phosphorylates
the focal adhesion-associated kinase p125(FAK) in human platelets independent of integrin
alphaIIb beta3.  J Biol Chem. 1999; 274: 384-388
124. Zachary I. Molecules in focus: Focal Adhesion Kinase.  Int J Biochem Cell Biol. 1997; 29: 929-
934
125. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: The platelet paradigm.  Blood. 1998; 91:
2645-2657
126. Aplin AE, Howe A, Alahari SK, Juliani RL. Signal transduction and signal modulation by cell
adhesion receptors: The role of integrins, cadherins, immunoglobulin-cell adhesion molecules,
and selectins.  Pharmacol Rev. 1998; 50: 197-263
127. Schaller MD. Biochemical signals and biological responses elicited by the focal adhesion ki-
nase.  Biochim Biophys Acta. 2001; 1540: 1-21
30
General Introduction
128. Schlaepfer DD, Hunter T. Integrin signalling and tyrosine phosphorylation: just the FAKs?  Trends
Cell Biol. 1998; 8: 151-157
129. Hildebrand JD, Schaller MD, Parsons JT. Identification of sequences required for the efficient
localization of the focal adhesion kinase, pp125FAK, to cellular focal adhesions.  J Cell Biol.
1993; 123: 993-1005
130. Guan JL. Focal adhesion kinase in integrin signaling.  Matrix Biol. 1997; 16: 195-200
131. Guan JL. Role of Focal Adhesion Kinase in Integrin Signaling.  Int J Biochem Cell Biol. 1997; 29:
1085-1096
132. Lipfert L, Haimovich B, Schaller MD, Cobb BS, Parsons JT, Brugge JS. Integrin-dependent
phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets.  J Cell Biol.
1992; 119: 905-912
133. Curtiss LK, Plow EF. Interaction of plasma lipoproteins with human platelets.  Blood. 1984; 64:
365-374
134. Pedreno J, de Castellarnau C, Cullare C, Sanchez J, Gomez Gerique J, Ordonez Llanos J,
Gonzalez Sastre F. LDL binding sites on platelets differ from the “classical” receptor of nucle-
ated cells.  Arterioscler Thromb. 1992; 12: 1353-1362
31
Chapter 1
32
General Introduction
33
Chapter 2
Ingrid A.M. Relou 1,3, Christian M. Hackeng 2,
Jan-Willem N. Akkerman 1,3, Ernst Malle 4
1 Laboratory for Thrombosis and Haemostasis, Department of
Haematology, University Medical Center Utrecht, Utrecht, The
Netherlands
2 Laboratory for Clinical Chemistry, University Hospital Maastricht,
Maastricht, The Netherlands
3 Institute for Biomembranes, Utrecht University, Utrecht, The
Netherlands
4 Institute of Medical Biochemistry and Molecular Biology, Karl-
Franzens University Graz, Graz, Austria
Chapter 2 Low Density Lipoprotein and its
effect on human blood platelets
Cellular and Molecular Life Sciences, in press
34
LDL and human blood platelets
Summary
Events leading to hyperreactivity of human blood platelets are accompanied with
an enhanced risk for atherosclerosis and arterial thrombosis. Lipoprotein disorders
affect platelet functions, and hypersensitive platelets are observed in various stages
of hyperlipidemia. Low Density Lipoprotein (LDL), a circulating complex of lipids
and proteins that is increased in hypercholesterolemia, enhances platelet function
and increases sensitivity of platelets to several naturally occurring agonists. LDL
sensitizes platelets via binding of apoB100 to a receptor on the platelet membrane
and via transfer of lipids to the platelet membrane. The receptor that mediates
binding of LDL to the platelet and initiates subsequent intracellular signaling cas-
cades has not yet been identified. Modification of native LDL generates a platelet-
activating particle and this interaction might contribute to the development of the
atherosclerotic plaque. Lysophosphatidic acid is formed upon mild oxidation of
LDL and is responsible for subsequent platelet activation induced by the modified
LDL-particle. Thus, LDL changes the functions of platelets via a broad spectrum of
interactions.
35
Chapter 2
Introduction
Lipoprotein-related disorders are caused by abnormalities in the synthesis or process-
ing of plasma lipoprotein particles. Cells may bind Low Density Lipoprotein (LDL)
particles, endocytose and transfer them to lysosomes where the receptor releases
the particle. Subsequently, the receptor is recycled back to the cell surface.
Components of LDL particles are hydrolyzed and free cholesterol is used for cell
function and stability or deposited intracellularly as cholesterol ester. After suffi-
cient cell loading with cholesterol, the rate of LDL-uptake becomes downregula-ted
which is apparent as a lower number of cell surface receptors. This process is
mediated by receptors that belong to the family of the LDL-receptors. The LDL-
receptor family consists of a growing number of members that share structural
similarity and function in endocytosis 1.
The classical LDL-receptor detected on fibroblasts is also termed the apolipopro-
tein (apo) B/E receptor. Defects in receptor-ligand interaction correlate with high
plasma LDL concentrations and an increased risk for cardiovascular disease 2. An
example of a defect in the LDL pathway is the R3500Q mutation in the apoB100
protein, which impairs the binding of LDL to the receptor in patients with familial
defective apoB100 3. An example of a defect in LDL-processing is a mutation in the
LDL-receptor gene in patients with familial hypercholesterolemia, again resulting
in diminished LDL-binding.
Human blood platelets play an important role in the pathogenesis of atherosclerosis
and acute coronary syndromes. The increased hypersensitivity and hyperaggrega-
bility of platelets from hypercholesterolemic patients detected in vivo and in vitro
suggest that high levels of atherogenic lipoproteins, e.g. LDL, may alter platelet
function 4-6. Indeed, LDL sensitizes platelets in vitro to a variety of stimulating agents
such as ADP, collagen and thrombin 7-15.
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Table 1. Binding properties of native LDL to human blood platelets
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Binding of native LDL to platelets
Binding of cholesterol-rich LDL to the membrane is the first step in the initiation of
alterations in platelets that make them more responsive to activating agents 5. The
question whether this step involves a specific receptor or merely includes pertur-
bations of the membrane bilayer is still unanswered. Binding studies using 125I-
labeled LDL revealed the presence of specific and saturable binding sites on non-
stimulated platelets, ranging from 1000 to 8000 sites per platelet (Table 1) 16-21.
The fact that the binding capacity, i.e, Kd- and Bmax-values for LDL to the plate-
lets was similar to that reported for LDL-binding to other cells suggested the pres-
ence of similar binding proteins/receptors for LDL on platelets 5. However, reports
on how different lipoprotein classes interfered with each other were controversial
with some reports showing inhibition of LDL-binding by anti-atherogenic High
Density Lipoprotein (HDL) and vice-versa 20, 21, while others were showing minimal
interference 8, 16. Curtiss et al 21 reported competition between HDL and LDL but
suggested the presence of two binding sites for lipoproteins; an HDL binding site
that interacts poorly with LDL and an LDL binding site that reacts with or is altered
by HDL binding. The capacity of HDL to inhibit LDL binding was not mediated by
apoE.  Koller et al 20 also proposed distinct binding sites for LDL and HDL as the
nature of inhibition seemed not simple competition based on analysis of binding
kinetics. However, after ligand blotting, they concluded that LDL and HDL bound
to a single class of lipoprotein-binding proteins in the platelet membrane 22. The
lipoprotein-binding sites showed higher affinity for HDL than LDL and the lipopro-
teins interfered with binding of each other in a non-competitive manner.
LDL-binding to platelets was independent of divalent ions, as EDTA treatment did
not alter LDL-binding 21. This, however, differs from the binding characteristics of
the classical LDL-receptor through which LDL is removed from the circulation via
holoparticle uptake 2. Furthermore, an antibody directed against the ligand binding
domain of the classical LDL-receptor did not alter the binding of LDL to platelets 17.
Taken together, these findings supported the concept that LDL-binding sites on
platelets differ from the apoB/E-receptors on nucleated cells. Studies of LDL-platelet
interaction after enzymatic treatment revealed a different pattern of proteolytic
susceptibility between the ‘platelet LDL-receptor’ and the classical LDL-receptor;
protease-treatment abolished LDL-binding to fibroblasts but not to platelets 23.
Hence, a platelet receptor that is resistant to proteolytic digestion might be involved
in LDL-binding to platelets. Pedreno et al 24 reported that LDL binds to a receptor
which is coupled to a pertussis toxin sensitive G-protein. Ligand-binding assays
demonstrated that high levels of LDL (1.5 g/L) downregulate the number of binding
sites suggesting a conformational change of the receptor or even the possiblity of
internalization of receptors. This downregulation was reversible and time- and dose-
dependent and inhibited by protein kinase C inhibitors.
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Attempts to identify candidate LDL-binding proteins by ligand blotting experiments
revealed that LDL binds to platelet membrane proteins with molecular masses in
between 115 and 156 kDa 19, 22. Purification and immunochemical characterization
identified these proteins as glycoprotein IIb (CD41) and glycoprotein IIIa (CD61).
Both are constituents of the glycoprotein IIb-IIIa complex, also known as integrin
αIIbβ3, which is the receptor for fibrinogen and a few other adhesive proteins 25.
Immunoelectron microscopy revealed colocalization of gold-labeled LDL with fibrin-
ogen on platelets 26, confirming the concept that the fibrinogen receptor could also
act as a possible LDL-receptor on the platelets.  These observations appear in
agreement with findings that LDL increases the exposure of fibrinogen binding sites
on platelets 7, 26 and that platelets from familial hypercholesterolemia patients -
compared with platelets from normolipidemic subjects - bind more fibrinogen 27.
In divergence from the concept that integrin αIIbβ3 serves as an LDL-receptor on
platelets, Hackeng et al 28 showed that specific antibodies directed against integrin
αIIbβ3 failed to inhibit LDL-binding to the platelets. Furthermore, similar binding
characteristics were found with platelets from controls and patients suffering from
type I and II Glanzmann’s thrombastenia that are deficient in integrin αIIbβ3. To-
gether, these observations argue against a role for integrin αIIbβ3 as the putative
LDL-receptor on the platelets 28, 29. Also the fact that a single platelet contains about
50 000 surface-exposed copies of this integrin, which is about 10 fold more than
the number of LDL-receptors identified in ligand binding studies appears in conflict
with such a role.  Although these studies propose that αIIbβ3 might not act as
LDL-receptor on the platelets, they did demonstrate that this integrin contributes
to LDL-induced platelet sensitization via ligand-induced signal generation in a process
known as outside-in signaling 28.
Recently, Riddell et al 30 demonstrated that platelets and the megakaryocytic cell
lines MEG-01 and HEL express LRP8, a new member of the LDL-receptor family.
This receptor differs from the LRP receptor which is absent in platelets 31. Platelet
LRP8 is a variant of the previously identified LDL-receptor family member ApoER2
that is predominantly expressed in the brain.  The extracellular domain of ApoER2
contains 7 - 8 ligand binding domains of which domains 4-6 are absent in platelet
LRP8. LDL-receptor family members function in receptor-mediated endocytosis
and signal transduction. ApoER2 is known to bind apoE, but not the major apolipo-
protein of LDL, apoB100. The cytoplasmic tail of ApoER2 contains only a single
NPxY motif, which is known as an endocytosis motif. However, compared to other
members of the LDL-receptor family, the rate of endocytosis mediated by ApoER2
is low, suggesting that this domain plays a role in intracellular signal transduction
30, 32.
The fact that antibodies directed against the binding domain of apoB100 for the
apoB/E-receptor, the so called B-site, impaired binding of LDL to the platelets 33
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supports the hypothesis that a member of the LDL-receptor family mediates bind-
ing of LDL to the platelet via specific domains in the apolipoprotein moiety. This is
confirmed by the fact that the LDL-receptor binding site for apoB100 induced
platelet signal transduction via the platelet-LDL binding site. This might point to-
wards the presence of a yet unidentified member of the LDL-receptor on the outer
leaflet of human platelets. Alternatively, the platelet LRP8 receptor might be capable
of binding apoB100 and be responsible for LDL-induced platelet sensitization.
After prolonged platelet-LDL contact the signaling pathway induced by LDL-binding
to the platelet LDL-receptor becomes desensitized 33. This is in agreement with
the previously reported reversible downregulation of binding sites for LDL and the
observation that the LDL signaling pathway via a pertussis toxin sensitive G-pro-
tein coupled receptor becomes desensitized 24.
Lipid transfer between LDL and platelets
Apart from apoB100, LDL consists of a lipid portion containing free and esterified
cholesterol, as well as triglycerides and phospholipids. Each of these constituents
have the potential to change the composition of platelet membranes thereby altering
platelet dynamics and function. The combined pools of sphingomyelin, phosphati-
dylcholine and phosphatidylethanolamine comprise more than two-thirds of the total
phospholipid content of lipoproteins. A similar composition is found in platelets 34.
Phospholipids play a role in signal transduction events in platelets. Cytosolic
phospholipase A
2
 cleaves fatty acids from phospholipids e.g. phosphatidyleth-
anolamine and phosphatidylcholine leading to the generation of bioactive eicosanoids.
Thus, for proper signal transduction, phospholipids have to be generated. This can
be accomplished by resynthesis or remodeling of phospholipids at the level of the
cell membrane or by incorporation of phospholipids from circulating lipoproteins.
Thus a second mechanism by which LDL alters platelet functions is by changing
the composition of phospholipids, ether-phospholipids in particular, which are
preferential targets for dietary ω-3 polyunsaturated fatty acids 35-37. Platelets trap
diacyl-, alkylacyl-, and alkenylacyl-glycerophospholipids from vesicles by simple
diffusion 38 and a similar mechanism might occur when lipoproteins act as lipid
donors. Engelmann et al 39 have shown that LDL rapidly donates sphingomyelin,
phosphatidylcholine and phosphatidylethanolamine to platelets 39. Platelet agonists
increase the specific transfer of ethanolamine phospholipids from LDL to the plate-
let membrane via a mechanism that is partially prevented by inhibitors of protein
kinase C 40. Furthermore, LDL directly contributes to the formation of platelet ei-
cosanoids by supplying both phospholipid-bound or free arachidonic acid 41, 42.
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Signaling by LDL
The underlying mechanisms of enhanced platelet activation by LDL are multifactorial
and inhibition of the Na+/H+ antiport that regulates the cytosolic pH and activation of
the phosphatidyl inositol cycle by LDL have been addressed 43-45. Enhanced activation
of protein kinase C, phosphorylation of the protein kinase C substrate pleckstrin (47
kDa), Ca2+ influx and mobilization from the dense tubular system and subsequent
stimulation of phospholipase A
2
 by LDL have been reported 43, 44, 46-48.
Hackeng et al 49 reported that a first step in platelet sensitization by LDL is the
release of arachidonic acid via activation of p38 mitogen activated protein kinase
(p38MAPK) and subsequent activation of cytosolic phospholipase A
2
. P38MAPK is a
member of the family of proline directed serine/threonine kinases, which is activated
by the simultaneous phosphorylation of Thr180 and Tyr182 (Figure 1)  50. This activation
was not inhibited by a wide variety of inhibitors of platelet signaling, including Ca2+
mobilization, phospholipase C-activation, thromboxane A
2
-formation, and extracellular
signal-regulated kinase 1/2-activation indicating that p38MAPK is upstream of several
platelet signal transduction pathways and therefore an early step in the signaling
cascade initiated by LDL. Inhibition of protein kinase C slightly reduced LDL-induced
p38MAPK phosphorylation, suggesting a modulating role for this kinase.
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Figure 1. Signaling pathways in human platelets induced by LDL
LDL interacts with its receptor on the platelet membrane and initiates phosphorylation of Focal Adhesion Kinase
(FAK). A second pathway is mediated by p38MAPK which results in enhanced fibrinogen binding to integrin αIIbß3 via
phospholipase A
2
 (PLA
2
), arachidonic acid (AA), thromboxane A
2
 (TxA
2
), phospholipase Cβ (PLCβ) and protein kinase
C (PKC). In addition, LDL induces an increase in intracellular Ca2+. These signals lead to exposure of αIIbβ3 and
fibrinogen (Fg) binding and secretion via a mechanism enhanced by outside-in signaling via αIIbβ3.
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The LDL-induced p38MAPK phosphorylation is under control of cAMP as addition of
agents that raise intracellular cAMP levels (prostaglandin I
2
 and dibutyryl cAMP)
prevented LDL-induced p38MAPK phosphorylation. The transduction of signals gener-
ated by LDL into the cell was neither mediated by integrin α2β1 nor by FcγRIIa
which are both known to signal towards p38MAPK after receptor activation. Candidate
platelet LDL-receptors such as integrin αIIbβ3, CD36 (platelet glyco-protein IV), and
CD68 (gp110) were not implicated in LDL-induced p38MAPK-activation either.
P125FAK is a focal adhesion kinase implicated in signaling pathways mediated by
integrins, G-protein coupled receptors, tyrosine kinase receptors, and the v-Src
and v-Crk oncoproteins. Phosphorylated p125FAK is the docking site for signaling
proteins such as the p85 regulatory subunit of phosphoinositol 3-kinase and phos-
pholipase Cγ 51, 52. LDL induced p125FAK phosphorylation in a dose- and time-
dependent manner independent of integrin αIIbβ3 since platelets from patients
with Glanzmann’s thrombastenia showed the same phosphorylation pattern of
p125FAK as did control platelets 53. Similar to p38MAPK, LDL-signaling to p125FAK
was independent of integrin α2β1, the FcγRIIa receptor, and the lysophosphatidic
acid (LPA) receptor and not affected by inhibitors of cyclooxygenase-1, protein
kinase C, extracellular signal-regulated kinase 1/2 or p38MAPK. Furthermore,
precipitation of activated small GTPases revealed that LDL activated Rap1 and
Ral but not Ras 54.
In summary, the mechanism by which LDL affects platelets is likely to be based on
two processes. First, there is binding and activation of an LDL receptor on the
platelets that appears to differ from the classical LDL-receptor on nucleated cells.
Second, there is exchange of lipids between LDL particles and the plasma mem-
brane. Both processes appear to alter signal transduction cascades in the platelet
resulting in an increased sensitivity to platelet activating agents.
Lipid lowering treatment
Drugs that inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase – the rate-
limiting enzyme in endogenous cholesterol biosynthesis pathway - have proven
useful in secondary prevention in patients with myocardial infarction or coronary
heart disease 55. In agreement with this observation, platelet reactivity and arachi-
donic acid metabolism in hyperlipoproteinemia are sensitive to lipid-lowering inter-
vention 56, 57. Apart from reducing platelet aggregation via lowering of platelet cho-
lesterol, lovastatin, simvastatin and fluvastatin reduced platelet aggregation via a
second effect of the drug binding on the platelets since the inhibition did not corre-
late with the change in platelet cholesterol. A third possibility is that statins alter the
LDL particle thereby interfering with LDL-binding to platelets 58-60. Fluvastatin also
decreased the membrane activation markers P-selectin (CD62P) and CD63 re-
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flecting a reduced platelet activity in type II hypercholesterolemic patients ex vivo
61. Schrör et al 62 reported that reduction of total and LDL serum cholesterol by
simvastatin normalized the platelet functions in patients who suffered from familial
hypercholesterolemia. Platelets from untreated patients who suffered from familial
hypercholesterolemia showed enhanced aggregation responses, secretion of ATP
and release of thromboxane after stimulation by collagen and ADP 6. Simvastatin
treatment significantly decreased these responses to the range found in normoc-
holesterolemic subjects 62, 63. After 8- and 12-weeks of intake of pravastatin, both
ADP-induced platelet aggregation, thromboxane B
2
 and expression of P-selectin
were reduced 64.
CD40L, which is upregulated in hypercholesterolemia and expressed on activated
platelets, is also downregulated by extensive pravastatin and cerivastatin treatment
65. CD40L is a member of the tumor necrosis factor family of ligands and appears to
be an αIIbβ3 ligand and necessary for stability of arterial thrombi 66. Pravastatin
treatment increased the activity of the Na+/K+ pump in hypercholesterolemic patients
via cholesterol depletion of the platelet membrane 67. Platelet-procoagulant activity
was reduced by administration of simvastatin, atorvastatin, cerivastatin and
prolonged treatment with pravastatin and fluvastatin. However, there was no
correlation with LDL-cholesterol changes which might indicate that there was a
direct effect on the platelets 68. Duration and dose of statin administation appeared
critical for the influence on platelets as short-term pravastatin therapy (4 weeks)
had no effect on thromboxane B
2
 production or even enhanced platelet aggregability
ex vivo and increased plasma serotonin levels 69, 70. 3-Hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors may prevent signaling via the Ras and Rho pathways
in platelets that are dependent on isoprenylation, thereby preventing signaling via
these pathways. In platelets, Ras is activated by the G-protein receptor agonist
thrombin, the glycoprotein VI agonist convulxin and the cytokine receptor Mpl agonist
thrombopoietin 71. In many cell types Ras activation starts signaling to the p42MAPK
(ERK2) and further signal transduction to the nucleus but in the a-nucleated platelet
the role of Ras is still unknown 72. Possibly, active, GTP-bound Ras contributes to
the regulation of glycoprotein IIb-IIIa (integrin αIIbβ3), which is the binding site for
fibrinogen and mediates platelet aggregation.
A second small GTPase that might be affected by cholesterol lowering therapy is
Rho, which signals to myosin light chain phosphatase, cytoskeletal rearrangements
and platelet shape change 73. At present it is uncertain whether these platelet functions
are disturbed when cholesterol synthesis is attenuated by administration of statins.
In summary, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors lower plas-
ma cholesterol levels. Current evidence indicates that this is not the only explanation
for a reduction in platelet function and other mechanisms are likely to contribute to
this inhibition.
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Platelet interaction with modified LDL
Modification of LDL and subsequent uptake by scavenger receptors on monocyte-
derived macrophages results in lipid-laden foam cells and is thought to initiate and
accelerate the development of an arterial lesion. A characteristic of scavenger
receptors is that the binding of modified LDL does not trigger downregulation of
receptor expression and that uptake proceeds without downregulation until the
cells transform to foam cells. The first example of a modified LDL-particle that
bound to scavenger receptors on macrophages was acetylated LDL, a form of
LDL that is not observed under physiological conditions. Acetylated LDL was taken
up by macrophages without inducing downregulating receptor numbers, indicating
that the binding was independent of the LDL receptor 74. There are several modifi-
cations of LDL such as glycation and aggregation of LDL particles that can enhance
uptake by macrophages in vitro and in vivo but most studies have focused on the
oxidation of LDL.
Several scavenger receptor subtypes have been identified such as scavenger re-
ceptor class A (AI and AIII) and class B (B-I and CD36). Scavenger receptors on
macrophages bind acetylated LDL and different forms of oxidized LDL (ox-LDL).
Platelets contain an ox-LDL receptor that does not bind acetylated LDL 75. CD36
has been identified as a scavenger receptor on platelets. It consists of two membrane-
spanning domains with both the N- and C-terminal domains located at the cytosolic
side 76. Monocyte-derived macrophages from CD36-deficient patients showed
decreased binding and uptake of ox-LDL illustrating that CD36 functions in the
binding of ox-LDL. Antibodies directed against the ox-LDL-binding domain of CD36
(155-183) reduced ox-LDL binding to platelets thereby identifying CD36 as an ox-
LDL receptor on platelets 75.
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) - a novel ox-LDL
receptor – has also been recently identified on platelets and megakaryocytic cell
lines 77. LOX-1 is a type-II membrane protein that belongs to the C-type lectin
family and is translocated to the membrane upon thrombin stimulation by fusion of
alpha granule membranes with the plasma membrane. Analysis of binding proteins
for ox-LDL revealed that CD36 and LOX-1 served as major binding proteins in platelets.
As resting platelets exposed little LOX-1, CD36 might be the ox-LDL receptor on
resting platelets. In contrast, LOX-1 might be the dominant receptor involved in ox-
LDL binding to activated platelets 77.
During oxidation of LDL, heterogeneous modification occurs as diverse radical-
mediated chemical changes occur both in the lipid and the apoB100 moiety. Hydro-
peroxides, primary products of lipid peroxidation, oxysterols as well as a variety of
secondary products are generated. Many of these are aldehyde-containing products
e.g. malondialdehyde and hydroxynonenals that modify apoB100 side chains which
may alter the binding properties of LDL and thereby the reactivity of platelets 78, 79.
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In addition, oxidation of apoB-100 leads to modification of amino acid side chains,
cleavage of amide linkages and crosslinking between amino acids.
In vivo, different reactive oxygen and nitrogen species (such as superoxide anion,
hydrogen peroxide, hydroxyl radical, hypochlorous acid, peroxinitrite), lipid hydroper-
oxides and the products of enzymatic pathways including lipoxygenases and mye-
loperoxidase, contribute to the development of atherosclerosis. Oxygen free radicals
that are generated by platelets may enhance or initiate platelet aggregation and
secretion 80, 81. The involvement of lipid peroxidation in platelet signaling is illustrated
by the peroxidation of arachidonate by cyclooxygenase 1 leading to endoperoxide
and thromboxane formation 82, 83. In particular the effect of isoprostanes, eicosanoids
that are non-enzymatic products of peroxidation of arachidonyl-containing phospho-
lipids catalyzed by free radicals, have been shown to enhance platelet aggregation
and secretion 84, 85.
In in vitro studies, copper-oxidized LDL (ox-LDL) is frequently used as an experi-
mental tool to study the effect of oxidation of LDL on platelet functions (reviewed in
5) 86-90. Ox-LDL inhibited the plasma membrane Ca2+-ATPase resulting in an increase
in cytoplasmic Ca2+ and increased platelet sensitivity to agonists 87. Furthermore,
incubation of platelets with ox-LDL induced shape change and pseudopodia formation
91. Ox-LDL activated platelets and accelerated adhesion. This raises the possibility
that oxidation of LDL contributes to thrombosis and arteriosclerosis 91.
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Figure 2. Signaling pathways involved in platelet shape change induced by moxLDL
The platelet-activating component of mox-LDL, lysophosphatidic acid (LPA) binds to its receptor which initiates sign-
aling via G
13
 and G
q
 signaling. Signaling via G
13
 leads to activation of Rho kinase and inhibits myosin light chain
phosphatase. Signaling via G
q
 leads to an increase in Ca++ and together with calmodulin to activation of myosin light
chain kinase. The result of both routes is phosphorylation of myosin light chain, actin-myosin interaction and cytoskel-
eton reorganization during shape change. The third route involves activation of Src and Syk (modified from 72).
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However, in other studies ox-LDL failed to affect platelet function 92. During oxidation
of LDL, both the lipid and the protein moiety undergo chemical changes via radical-
mediated reactions. During the modification chemically-active lipid and apolipoprotein
degradation products are formed in ox-LDL. This extensive damage of LDL inflicted
by copper-induced oxidation leads to an unreproducable pattern of platelet-ox-LDL
interactions. In particular, oxidized derivates of cholesterol generated by different
modes of oxidation such as specific enzymatic oxidation, chemical oxidation, au-
tooxidation and lipid peroxidation may act either as inhibitors or potentiators of
platelet aggregation 93, 94. The degree of oxidation as well as consumption of
antioxidants has not always been characterized by appropriate analytical techniques.
Mildly oxidized/minimally modified LDL (mox-LDL) enhanced platelet aggregability
and release reaction to a greater extent than heavily ox-LDL 89, 92. Weidtmann et al
92 reported that activation of platelets by mox-LDL occurred through a phospholipase
A
2
 and cyclooxygenase-dependent pathway. Native LDL contains minimal amounts
of LPA and upon mild oxidation, the LPA content increases 8-fold 95. In vivo, mild
oxidation of LDL is caused by radical formation by activated macrophages and
endothelial cells. LPA is present in extracellular lipid deposits and foam cells of
human atherosclerotic lesions where modified lipoproteins may accumulate and is
therefore considered a biologically relevant component. LPA is exposed on the
surface of mildly oxidized LDL particles and interacts with LPA-receptors on the
platelet membrane thereby initiating platelet activation. Platelets contain the LPA
receptors LPA
1
, LPA
2
, LPA
3
 96. LPA-receptors are seven transmembrane receptors
coupled to the G-proteins G
i
, which inhibits adenylyle cyclase and thereby formation
of cAMP, G
13
 which signals to the small GTPase Rho and regulates platelet shape
change and G
q
, an activator of phospholipase CβII, which signals to Ca
2+ mobilization
and protein kinase C (reviewed in 96). Antagonists of the LPA-receptor prevented
platelet activation induced by mox-LDL 95. However, LPA was not involved in
sensitization of platelets induced by native LDL as the LPA-receptor blocker N-
palmitoyl-L-serine-phosphoric acid  failed to affect LDL-enhanced fibrinogen binding
to platelets 97. LPA induced platelet activation and induced phosphatidylinositol-4-
phosphate formation via phosphatidylinositol–4-kinase activation, through processes
that were independent of protein kinase C and thromboxane A
2
 98, 99. Retzer and
coworkers 73 reported that mox-LDL induced platelet shape change via the GTPase
Rho and Rho-kinase-dependent phosphorylation of myosin light chain and via moesin
which are both steps required for platelet shape change (Fig. 2). Low concentration
of mox-LDL did not change the intracellular Ca2+ concentration during shape change.
This observation makes it unlikely that the calcium/calmodulin-dependent activation
of myosin light chain kinase is involved during shape change. However, Maschberger
et al 100 published that mox-LDL stimulated two additional signal transduction pathways
in human platelets: the Src family kinase-mediated stimulation of protein tyrosine
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phosphorylation and the Syk induced by low concentrations of mox-LDL as well as
the stimulation of the Ca2+ influx induced by higher concentrations. Activation of
platelets by mox-LDL was inhibited by LPA-receptor antagonists as well as lovastatin
which could have implications in the prevention and therapy of cardiovascular disease
100, 101.
Platelet aggregation was enhanced to a greater extent by LDL from diabetic patients
than by LDL from healthy donors, suggesting that glycation may act as an agent
that alters platelet function 102. However, both the reactivity of platelets to various
aggregating agents and the production of thromboxane B
2
 were similar for the various
LDL-preparations, although their degree of glycosylation varied ac-cording to the
concentration of glucose in the incubation media 102. Phospholipids react directly
with glucose to form advanced glycosylation end products that initiate lipid oxidation
103. In vitro glycated LDL caused a significant increase in platelet aggregation and
enhancement of thromboxane B
2
 synthesis, increase of intracellular calcium
concentrations and inhibition of Na+/K+ -ATPase activity 102, 104, 105. Hence, glycation
induces compositional and structural changes in LDL. Glycated LDL may interact
with platelets differently and may play a role in the vascular complications of diabetes.
Another highly reactive oxidant generated enzymatically via the myeloperoxidase-
H
2
O
2
-halide system of activated phagocytes is hypochlorous acid/hypochlorite
(HOCl/OCl-). Unlike free radical oxidants, HOCl preferentially modifies the apoli-
poprotein moiety of LDL. HOCl-modified LDL induced a dose-dependent increase
of thrombin- and ADP-induced platelet aggregation 106. Also irreversible platelet
aggregation and secretion from the dense granules have been reported 107, 108.
HOCl-LDL binds to similar binding sites on platelets as does native LDL 108. However,
HOCl-LDL stimulated platelet plasma membrane Ca2+-ATPase which resulted in
decreased [Ca2+]i 109. HOCl-modified epitopes are present in vivo and HOCl-modified
apoB100 has been extracted from advanced human atherosclerotic lesions 110. To
date, it is not clear whether highly reactive chloramines and/or methionine sulfoxides
or secondary radicals derived from chloramines of apoB100 contributing to HOCl-
induced lipid peroxidation of LDL are responsible for effects on platelets. In addition,
myeloperoxidase uses nitrite, a major endproduct of nitric oxide metabolism, as a
substrate to nitrate protein tyrosine residues and lipid peroxidation 111. These
observations support the fact that in addition to reactive oxygen species, also reactive
nitrogen species may alter platelet function. Peroxinitrite generated from nitric oxide
radicals and superoxide anion radicals is present in human atherosclerotic lesions
(as indicated by the presence of nitrotyrosine) and nitration was observed in early
subintimal fatty streaks 112. Peroxinitrite rapidly induces tyrosine nitration of platelet
membrane proteins and may even prevent phosphorylation of signaling proteins
involved in platelet activation apparently by cGMP-independent pathways leading
to decreased platelet aggregability 113-115.
46
LDL and human blood platelets
In conclusion, native LDL sensitizes platelets via a receptor-mediated signaling
cascade and via lipid exchange.  The result is an increase in sensitivity to platelet
activating agents and enhanced aggregation and secretion responses. Modification
of native LDL makes LDL an independent platelet activator. Oxidation leads to
formation of LPA which activates platelets via the LPA-receptor. Modification of
lipoproteins resulting in HOCl-LDL and glycated generates platelet-sensitizing par-
ticles. These mechanisms make LDL a potentially prothrombotic factor and explain
the increased risk for atherosclerosis in patients with hypercholesterolemia.
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Summary
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase implicated in signaling
pathways mediated by integrins and G-protein coupled receptors (GPCRs). Upon
stimulation FAK is phosphorylated on six tyrosine residues. Here we report the
site-specific phosphorylation by LDL, which is known to induce integrin-independent
FAK phosphorylation and compared this with the effect of thrombin, which
phosphorylates FAK via integrin αIIbβ3. Stimulation with LDL reveals (i) a major
role for Tyr-925 phosphorylation which surpasses the phosphorylation of the other
residues including Tyr-397 in rate and extent, (ii) αIIbβ3-independent phosphor-
ylation of Tyr-925 and Tyr-397, (iii) complex formation between FAK and the Src-
kinase Fgr but not with c-Src. These patterns differ profoundly with those induced
by thrombin. LDL-induced phosphorylation of Tyr-925 and Tyr-397 was inhibited
by 60 - 75% by receptor associated protein RAP, an inhibitor of members of the LDL
receptor family. Thus, these findings reveal a novel mechanism of FAK phosphor-
ylation by signaling cascades involving a member of the LDL receptor family.
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Introduction
Focal adhesion kinase (FAK) is a non-receptor protein-tyrosine kinase implicated in
signaling pathways involved in cell motility, proliferation and apoptosis 1. FAK is
present in mesenchymal cells, neuronal cells, platelets, lymphocytes, and
monocytes. It consists of a central catalytic domain flanked by large amino- and
carboxy-terminal regions. The carboxy-terminal region is the site of the focal adhe-
sion targeting (FAT) sequence, which mediates the localization of FAK to focal
adhesions 2. After cell activation, FAK translocates to the cytoskeleton at focal
adhesions, where it serves as a docking site for signaling proteins. FAK is acti-
vated by tyrosine-phosphorylation in response to integrin clustering induced by cell
adhesion or antibody cross-linking 3-5. A second mechanism of FAK activation is
via G-protein coupled receptor (GPCR) occupancy by ligands such as bombesin
or lysophosphatidic acid 6, 7.
Upon stimulation, FAK is phosphorylated on six tyrosine residues. In integrin-me-
diated FAK phosphorylation, Tyr-397 is the primary target 8. Phosphorylation of
Tyr-397 triggers the phosphorylation of the other tyrosine residues thereby initiat-
ing downstream signaling cascades. The initial phosphorylation of FAK at Tyr-397
is thought to create a high affinity binding site for SH2 domains enabling formation
of a signaling complex between FAK and members of the Src-family kinases 8.
The inhibitor PP2 markedly reduces the phosphorylation of Tyr-397, indicating
that further phosphorylation of this site depends on Src- kinases 9. Formation of a
FAK-Src complex leads to phosphorylation of both proteins thereby initiating down-
stream signaling pathways 10.
Also in GPCR-mediated FAK phosphorylation Tyr-397 is the primary target. Here,
the phosphorylation of Tyr-397 is unaffected by the inhibitor PP2, indicating that in
integrin-independent FAK phosphorylation other kinases than Src control the phos-
phorylation of Tyr-397 9. Common to both pathways is the finding that the initial
phosphorylation of Tyr-397 is followed by phosphorylation of the other residues
(Tyr-407, Tyr-576, Tyr-577, Tyr-861 and Tyr-925) in a Src-dependent manner.
Phosphorylation of the different Tyr residues is crucial for further downstream
signaling. Phosphorylated Tyr-397 is the docking site for the p85 regulatory subunit
of phosphoinositol 3-kinase and for phospholipase Cγ 11, 12. Tyr-576 and Tyr-577
are located in the central catalytic domain and their phosphorylation is part of an
autoactivation loop resulting in maximal FAK activation 13. Tyr-925 is located in the
FAT domain and its phosphorylation is followed by binding of the adaptor protein
Grb2, which contributes to the adhesion-induced activation of the Ras-ERK1/2
pathway 14. The function of Tyr-407 and Tyr-861 is still elusive.
In platelets, FAK is phosphorylated following stimulation by thrombin provided that
suspensions are stirred and aggregate. FAK phosphorylation is markedly reduced
by monoclonal antibodies against αIIbβ3 and is virtually absent in αIIbβ3-deficient
platelets 15.
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These findings illustrate a dominant role for integrin αIIbβ3 (glycoprotein IIb/IIIa),
which in activated platelet suspensions binds fibrinogen and other adhesive proteins
and facilitates the fibrinogen-mediated formation of aggregates. In non-stirred
suspensions a residual FAK phosphorylation remains detectable probably caused
by direct signaling by ligand occupied thrombin receptors (PAR 1/3/4 receptors) in
agreement with the GPCR-mediated activation observed in other cell types.
We reported earlier that low density lipoprotein (LDL) is a potent activator of FAK in
platelet suspensions and that this activation occurs in stirred as well as non-stirred
suspensions 16. An elevated level of plasma LDL is a risk factor for arterial thrombosis
and patients with hypercholesterolaemia have platelets that become activated in
the circulation (reviewed in 17). LDL triggered the phosphorylation of FAK at
concentrations as low as 0.5 g/L LDL (after 10 minutes) and as rapid as 30 seconds
(at 1.0 g/L LDL). LDL-induced FAK phosphorylation was independent of ligand binding
to integrin α2β1 (one of the collagen receptors), integrin αIIbβ3, and the FcγRIIa
receptor and proceeded normally in platelets with a deficiency of αIIbβ3 present in
Glanzmann thrombastenia patients 16. The platelet LDL-receptor differs from the
classical apoB/E receptor since certain antibodies against the apoB/E receptor fail
to prevent the binding of LDL to platelets and the enhancement of ADP- and collagen
induced platelet aggregation observed in the presence of LDL. In addition, LDL
binding to platelets is normal in individuals lacking the apoB/E receptor, a deficiency
known as familial hypercholesterolemia 18. However, the platelet LDL-receptor is
likely to be a member of the LDL receptor family since an antibody against the B-
site in apoB100 inhibits platelet sensitization by LDL and a peptide mimicking the
B-site initiates signal transduction in platelets 19. Thus, the phosphorylation of FAK
in platelets incubated with LDL may serve as an example of both a GPCR-
independent as well as an integrin-independent signaling mechanism to this kinase.
In the present study we investigated the phosphorylation of FAK in platelets stimu-
lated by LDL in further detail using site-specific antibodies that recognize the
phosphorylated form of the individual residues. The results reveal similarities and
discrepancies with thrombin-induced phosphorylation of FAK and suggest that
LDL activates a member of the LDL-receptor family that initiates a novel mechanism
of FAK phosphorylation.
Materials and Methods
Materials
BSA (demineralized) was from Organon Technika (Eppelheim, FRG). Sepharose 2B and protein A-
sepharose were from Pharmacia Biotech (Uppsala, Sweden). Enhanced chemiluminescence reagent
(ECL) was from NEN-Dupont (Boston, MA, USA). Human α-thrombin was purchased from Kordia Life
Science (Leiden, The Netherlands). Precast polyacrylamide mini gels were obtained from Gradipore
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(Frenchs Forest, Australia). Antiphosphotyrosine mAb 4G10 was from Upstate Biotechnology (Lake
Placid, NY, USA), a monoclonal antibody (moAb) directed against total FAK was from Transduction
laboratories (Lexington, NY, USA), a polyclonal antibody directed against total FAK, a polyclonal
antibody directed against c-Fgr and a polyclonal antibody directed against Src kinases were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). The site-specific antibodies directed against
phosphorylated FAK were purchased from BioSource BV (Camarillo, CA, USA).
The fibrinogen- derived peptide HHLGGAKQAGDV (γ
400-411
) was kindly provided by the department
of Biochemistry, Utrecht University.  SDZ-GPI-562 (GPI-562) was a kind gift of Dr. H-G. Zerwes
(Novartis Pharmaceuticals, Basel, Switzerland) 20. PP1 was obtained from Alexis Biochemicals (San
Diego, CA, USA). Receptor associated protein (RAP) was kindly provided by Dr. P.J. Lenting (University
Medical Center Utrecht) and was prepared as described before 21.
Lipoprotein isolation
Lipoproteins were isolated as described 22. In short, fresh, non-frozen plasma from 4 healthy subjects
each containing less than 100 mg lipoprotein(a)/L was pooled and LDL (density range 1.019-1.063 kg/L)
was isolated by sequential flotation in a Beckman L-70 ultracentrifuge.23 Centrifugations (20 hr,
175000 g, 10°C) were carried out in the presence of NaN
3
 and EDTA. The LDL preparations con-
tained only minimal amounts TBARS (0.20 ± 0.07 nmol/mg), lipid peroxides (6.7 ± 1.9 nmol/mg) and
contaminating plasma proteins (below or within reported values for native LDL). Lp(a) concentrations
(Apotech, Organon Technika, Rockville, U.S.A) were below 14 mg/L.
Lipoproteins were stored at 4°C under nitrogen for not longer than 14 days and before each experiment
dialyzed overnight against 104 volumes 150 mmol/L NaCl. ApoB100 and lipoprotein(a) concentrations
were measured using the Behring Nephelometer 100. The concentration of LDL was expressed as
g apoB100 protein/L.
Platelet isolation
Freshly drawn venous blood from healthy volunteers was collected with informed consent into 0.1 vol.
130 mmol/L trisodium citrate. The donors claimed not to have taken any medication during two weeks
prior to blood collection. Platelet-rich plasma was prepared by centrifugation (200 g for 15 min at 22°C).
Gel-filtered platelets (GFP) were isolated by gelfiltration through Sepharose 2B equilibrated in Ca2+-free
Tyrode’s solution (137 mmol/L NaCl, 2.68 mmol/L KCl, 0.42 mmol/L NaH
2
PO
4
, 1.7 mmol/L MgCl
2
, and
11.9 mmol/L NaHCO
3
, pH 7.25) containing 0.2 % BSA and 5 mmol/L glucose. GFP were adjusted to
a final count of 2 * 1011 platelets/L and incubated with LDL at 37°C without stirring or with thrombin at
37°C with stirring (900 rev. p. m.).
Western blotting
GFP were incubated at 37°C with LDL or thrombin as indicated in the legends to figures. After
incubation, 100 µL aliquots were mixed with cold lysis buffer (1:10 v/v) as described before 16 and
subsequently taken up in Laemmli sample buffer. Samples were heated (5 min, 100°C) prior to SDS-
polyacrylamide gel electrophoresis (8%) and divided in 2 or more samples to allow analysis of the
individual phosphorylation sites together with total FAK as a control for lane loading. Proteins were
electrophoretically transferred (1 hr, 100 volts) to a nitrocellulose membrane in 25 mmol/L Tris, 192
mmol/L glycine and 20% methanol, pH 8.3, using a mini-protean system (Biorad, Richmond, CA,
USA). The blots were blocked in 5% BSA, 0.05% Tween 20 in Tris buffered saline (TBS, pH 7.4) (1 hr,
4°C) and incubated with the site-specific phosphorylated FAK antibody  (1:10000 in 1% BSA, 0.05%
Tween in TBS, 16 hr, 4°C). After washing, the membranes were incubated with horseradish peroxi-
dase labeled anti-rabbit (1:10000, 1 hr, 4°C) and phosphorylated FAK tyrosine residues were visu-
alized using the enhanced chemiluminescence reaction. The total amount of FAK was determined
with a monoclonal antibody directed against FAK.
For semi-quantitative determination of the amount of site-specific phosphorylated FAK, the density of the
bands was analyzed using ImageQuant software (Molecular Dynamics). Phosphorylation induced by
incubation with 1g/L LDL for 10 min was set at 100% and the other samples of the same series were
expressed as % of this control to enable comparison between gels.
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Immunoprecipitation
Platelets were incubated with LDL as indicated. After incubation, 500 ml aliquots were mixed with cold
lysis buffer (1:10 v/v) as described above and precipitated with polyclonal anti-FAK (1 µg) and
protein A-Sepharose for 5 h (4°C). After washing with lysis buffer, samples were taken up in Laemmli
sample buffer. Samples were heated (5 min, 100°C) prior to the western blotting procedure. The blots
were blocked in 5% BSA, 0.05% Tween 20 in TBS (1 hr, 4°C) and incubated with the polyclonal Src
antibody  (1:1000 in 1% BSA, 0.05% Tween in TBS, 16 hr, 4°C) which recognizes Fgr, Fyn, c-Src and
Yes or the polyclonal Fgr antibody which specifically recognizes Fgr. After washing, the membranes
were incubated with peroxidase linked protein A (1:10000, 1 hr, 4°C) and co-precipitation of Src
family tyrosine kinases was visualized using the enhanced chemiluminescence reaction. As a
control for equal lane loading, blots were reprobed with a monoclonal antibody directed against FAK.
Statistics
Data are expressed as means ± SD with number of observations n, and were analyzed with the
Student’s t-test. Differences were considered significant at P < 0.05.
Results
Tyr-925 phosphorylation precedes Tyr-397 phosphorylation in LDL-induced
FAK phosphorylation
In a first series of experiments, the site-specific phosphorylation of Tyr residues of
FAK was investigated in platelets incubated with LDL. Stimulation with 1 g/L LDL
induced a rapid phosphorylation of Tyr-397 reaching more than 90% of maximal
activation after 10 minutes (Figure 1A) or more (not shown). LDL also triggered the
phosphorylation of Tyr-925 but this was faster than that of Tyr-397 and for 90%
complete after 1 minute (Figure 1A). Tyr-577, located in the autoactivation loop, and
Tyr-861 were phosphorylated approximately at the same velocity, showing maximal
phosphorylation after 5-10 minutes (Figure 1B). This is about the same rate as the
phosphorylation of Tyr-397 and slower than the LDL-induced phosphorylation of
Tyr-925. Phosphorylation of Tyr-397 and Tyr-925 was also measured in stirred
platelet suspensions stimulated with thrombin. Here, the phosphorylation of the
two residues occurred almost simultaneously with a slightly faster phosphorylation
of Tyr-397. Also Tyr-577 was phosphorylated at approximately the same velocity
(Figure 1C).
Theoretically, the different phosphorylation kinetics of Tyr-397 and Tyr-925 in LDL-
treated platelets might be due to differences in dose-response relationships, for
instance as a result of heterogeneity of receptors or further signaling cascades to
FAK. Experiments were therefore repeated with different concentrations of LDL in
order to find the optimal concentration for Tyr-397 and Tyr-925 phosphorylation. As
illustrated in Figure 2A, both residues showed the same dose-response curves
with optimal activation at 0.1 g/L LDL or more. Thus, at a saturating concentration
of 1g/L, LDL induced a faster phosphorylation of Tyr-925 than of Tyr-397, a difference
not seen with thrombin. These findings point to a major difference between FAK
phosphorylation by LDL and by thrombin.
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Figure 1. Tyr-925 phosphorylation precedes Tyr-397 phosphorylation in LDL-induced FAK phosphorylation
(A, left) Platelets were incubated with LDL (1 g/L, 37°C) for the indicated time periods. Site-specific FAK phosphoryla-
tion was analyzed by SDS-PAGE and Western blotting using a site-specific antibody directed against phosphorylated
FAK followed by ECL. The upper panel shows a western blot of LDL-induced Tyr-397 phosphorylation, the middle
panel LDL-induced Tyr-925 phosphorylation. The lower panel shows total FAK detected with a moAb against FAK as
a control for lane loading. (A, right) Semi-quantification of the blots was performed based on ImageQuant; data, (P<0.05
for 0.5 - 5 min) are expressed as percentage of the intensity at 10 min incubation with LDL (100%, open square). (B)
platelets were incubated with LDL (1 g/L, 37°C) for the indicated time-periods and phosphorylation of Tyr-861 and Tyr-
577 was detected. Figure C shows phosphorylation of Tyr-397, Tyr-925 and Tyr-577 in platelets stimulated with thrombin
(1 U/mL, 37°C, stirring at 900 rev.p.m). Data are expressed as percentage of the intensity of 2 min stimulation with
thrombin. All data are means ± SD, n > 3.
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Tyr-577 is one of the two sites in the autoactivation loop, which when phosphor-
ylated mediates the further intermolecular phosphorylation of FAK at Tyr-397 24. To
investigate the contribution of this feed back loop, dose–response studies were
performed with different concentrations of LDL and the phosphorylation of Tyr-577
was analyzed. As also shown in Figure 2A, an LDL concentration as low as 0.1 g/L
already induced maximal phosphorylation of Tyr-577. This is in the range of the
dose-response relationships observed for the phosphorylation of the Tyr-397 and
Tyr-925 residues. Thus, the phosphorylation of Tyr-397, Tyr-577 and Tyr-925 in
LDL-treated platelets appears closely connected. In contrast, a 10-fold higher LDL
concentration was required for maximal phosphorylation of Tyr-407 and Tyr-861
(Figure 2B). These findings point to the presence of two groups of Tyr-residues
A
B
Tyr-407 -P
Tyr-861-P
FAK
0 0.1 0.3 0.5 1 1.5 2
Tyr-925 -P
FAK
LDL (g/L)
Tyr-397 -P
Tyr-577 -P
0.0 0.5 1.0 1.5 2.0
0
50
100
Tyr-407
Tyr-861
LDL (g/L)
%
T
yr
-
P
LDL (g/L)
0.
00
5
0.
05 0.
1
0.
5 1
1.
5 2
0.
00
1
0.
010
Figure 2. Dose- response relationship of LDL-induced site-specific FAK phosphorylation
Platelets were incubated with the indicated concentrations of LDL (10 min, 37°C) and samples were split for detection
of phosphorylation of Tyr-925, Tyr-397, Tyr-577, (A), Tyr-407 and Tyr-861 (B) using site-specific antibodies directed
against phosphorylated FAK or a Ab against total FAK for detection of equal lane loading. Data (means ± SD, n > 3) are
expressed as percentage of the intensity found at 10 min incubation with 1 g/L LDL (100%, open square).
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differing in responsiveness to LDL with Tyr-397, Tyr-577 and Tyr-925 being maximally
phosphorylated at low LDL concentrations and Tyr-407 and Tyr-861 requiring a 10
fold higher concentration of LDL for maximal phosphorylation.
To further clarify the differences in site-specific FAK phosphorylation by LDL and
thrombin, platelet suspensions were divided in two parts and stimulated concurrently
with optimal concentrations of LDL or thrombin to achieve maximal phosphorylation
of Tyr residues. Then, samples were collected and analyzed on the same gel. As
illustrated in Figure 3A, B, the phosphorylation of Tyr-925 induced by LDL was
weaker than that induced by thrombin, reaching 49 ± 15% (n=4) of the phosphorylation
induced by thrombin. Similar comparisons for the other phosphorylation sites revealed
that LDL induced about 10% phosphorylation of Tyr-397, Tyr-407, Tyr-577 and Tyr-
861 compared with the respective site-specific phospho-rylations induced by
thrombin.
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Figure 3. LDL and thrombin induce distinct site-specific phosphorylation of FAK
(A) Platelets were incubated with LDL (1 g/L, 10 min, 37°C) or thrombin (1 U/mL, 2 min, 37°C, 900 rev.p.m.) and
samples were divided for detection of equal lane loading and the site-specific phosphorylation of Tyr-397, Tyr-407, Tyr-
577, Tyr-861 and Tyr-925. The control for equal lane loading was performed with a moAb against total FAK. (B) The
phosphorylation patterns induced by LDL and by thrombin were compared in concurrent experiments, analyzed on
single blots and expressed as percentage LDL-induced Tyr phosphorylation related to the thrombin-induced Tyr
phosphorylation which is set at 100% (means ± SD, n=4).
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Together these findings indicate that the site-specific phosphorylation of FAK by
LDL reveals a dominant role for Tyr-925 that is faster and about 5-fold higher than
the phosphorylation of the other Tyr residues. The data also show that the phospho-
rylation of FAK by LDL is incomplete reaching about 50% of the Tyr-925 phosphory-
lation by thrombin and about 10% of the phosphorylation of the other Tyr residues.
Role of Src in LDL-induced phosphorylation of Tyr-397 and Tyr-925
Salazar et al. reported that integrin-mediated but not GPCR-mediated Tyr-397
phosphorylation depends on Src kinase family members 9. To clarify the contribu-
tion of these kinases in LDL-induced FAK phosphorylation, experiments were re-
peated in the presence of the inhibitor pyrazolopyrimidine PP1. Pretreatment with
PP1 induced a decrease in Tyr-phosphorylated sites showing 75% (Tyr-397) to
80% (Tyr-925) inhibition at 1 µmol/L PP1 (Figure 4A). Thus, in this respect LDL-
induced phosphorylation of these residues showed the properties of integrin-medi-
ated FAK phosphorylation. PP1 also inhibited the thrombin induced phosphorylation
of these residues, but the inhibition was incomplete leaving about 50% of the
phosphorylation of Tyr-397 and Tyr-925 undisturbed (Figure 4B). Possibly, this PP1
insensitive phosphorylation reflected the integrin-independent signaling pathway
initiated by thrombin (PAR1/3/4) receptors.
To investigate whether the contribution of Src family kinases in FAK phosphoryla-
tion by LDL was accompanied by association of these proteins, immunoprecipitation
studies were carried out with an anti-FAK antibody followed by western blotting
with an antibody against Src family members. Coprecipitation between FAK and a
Src-member was observed after 1 and 10 minutes stimulation with LDL (Figure 4C).
The protein that co-immunoprecipitated with FAK had a molecular weight of ap-
proximately 55 kDa, indicating that it was not c-Src (60 kDa). This difference was
confirmed in immunoprecipitates of thrombin-treated platelets showing coprecipitation
of FAK with two bands, a similar 55 kDa protein and in addition a 60 kDa protein
probably representing c-Src. Thus, LDL-induced FAK phosphorylation appears to
involve a specific member of the Src family kinases of 55 kDa. The involvement of
Fgr was confirmed via reprobing with a specific Fgr antibody (not shown). A time
course of LDL-induced complex-formation between FAK and Fgr revealed a rapid
association after 0.17 - 0.5 minutes followed by dissociation 10 minutes later (Figure
4D). Thus, FAK and Fgr associate in a period in which the different tyrosine residues
of FAK are phosphorylated.
Role of integrin αIIbβ3 in the phosphorylation of Tyr-397 and Tyr-925
We have shown previously that LDL-induced FAK phosphorylation was unchanged
in the presence of inhibitors of integrin α2β1 and αIIbβ3 and also occurred normally
in platelets deficient in αIIbβ3 16.
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Figure 4. LDL- induced Tyr-397 and Tyr-925 phosphorylation depends on Src family tyrosine kinases
Platelets were incubated with the Src family tyrosine kinases inhibitor PP1 (1, 5 and 10 µmol/L, 15 min) prior to
incubation with LDL (1 g/L, 10 min, 37°C, (A)) or thrombin (1 U/mL, 2 min, 37°C, stirring at 900 rev.p.m., (B)). Tyr-397
and Tyr-925 phosphorylation was detected (means ± SD, n = 4). (C) Complex formation between FAK and Src family
tyrosine kinases was measured by incubating platelets with LDL (1 g/L, 10 min, 37°C) or thrombin (1 U/mL, 2 min,
37°C, stirring at 900 rev.p.m.) followed by immunoprecipitation with polyclonalAb against FAK and western blotting with
an antibody against Src family members. As a control for equal lane loading blots were reprobed with a monoclonal
antibody against total FAK (lower panel). In the experiment depicted in Figure D, platelets were incubated with LDL (1
g/L, 10 min, 37°C) for the indicated time-periods and complex formation between FAK and Fgr was analyzed with a
specific antibody against Fgr.
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To confirm this observation for the phosphorylation of Tyr-397 and Tyr-925, platelets
were incubated with fibrinogen γ-chain derived dodecapeptide (γ
400-411
) and the inhibitor
GPI-562, which are both potent blockers of fibrinogen binding to the activated integrin
20. Both inhibitors failed to affect the phosphorylation of Tyr-397 and Tyr-925 in platelets
treated with LDL in accordance with the previous data based on total FAK
phosphorylation (Figure 5A). In contrast, γ
400-411
 and GPI-562 reduced the
phosphorylation of these residues by 50-60% when platelets were stimulated with
thrombin (Figure 5B). This result is consistent with an integrin-dependent and an
integrin-independent signaling mechanism induced by thrombin receptors.
Receptor Associated Protein RAP inhibits LDL induced Tyr phosphorylation
Recently, a member of the LDL receptor family named LRP8 was identified on
platelets 25. Ligand binding to LRP8 is known to be inhibited by the 39kD receptor-
associated protein (RAP).
Figure 5. LDL-induced Tyr-397 and Tyr-925 is independent of integrin αIIbβ3
Platelets were incubated with the fibrinogen γ
400-411
 peptide (100 µmol/L, 2 min) or the αIIbβ3 blocker GPI-562 (10 nmol/
L, 1 min) prior to incubation with LDL (1 g/L, 10 min, 37°C, (A)) or thrombin (1 U/mL, 2 min, 37°C, 900 rev.p.m. (B)). Tyr-
397 and Tyr-925 phosphorylation was detected as described (means ± SD, n=4).
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Figure 6. The receptor associated protein (RAP) inhibits LDL-induced Tyr-397 and Tyr-925 phosphorylation
Platelets were incubated with RAP (0.001 - 10 µg/mL, 10 min, 37°C) prior to incubation with LDL (1 g/L, 10 min, 37°C;
(A)) or incubated with RAP (10 µg/mL, 10 min, 37°C) prior to incubation with thrombin (1 U/mL, 2 min, 37°C, 900
rev.p.m. (B)). The blots were semi-quantified and the data were expressed as percentage of the Tyr-397 and Tyr-925
phosphorylation in the absence of RAP. Data are means ± SD, n > 3 (P>0.05 between Tyr-397 and Tyr-925 phospho-
rylation). Figure C and D show the results of an immunoprecipitation with anti-FAK antibody followed by western
blotting with anti Fgr antibody (means ± SD, n = 3, P<0.05). As a control for equal lane loading blots were reprobed with
a monoclonal antibody against total FAK (lower panel).
thrombin
0
50
100
Tyr-397
Tyr-925
%
T
yr
-
P
A
B
LDL
0
50
100
%
F
g
r
co
-p
re
ci
p
it
at
io
n
C D
Tyr-925 -P
Tyr-397 -P
FAK
IP FAK
WB Fgr
IP FAK
WB FAK
- + + + +
- - -2 -1 0
LDL
log RAP ( g/mL)µ
+
c
RA
P 
+ 
LD
L
LD
L
LDL
c RAP
0
50
100
%
F
g
r
co
-p
re
ci
p
it
at
io
n
Thrombin
c γ400-411 GPI-562 
0
50
100
Tyr-397
Tyr-925
%
T
y
r-
P
Site-specific Focal Adhesion Kinase phosphorylation
68
To investigate whether FAK activation by LDL was mediated by LRP8, studies were
repeated in presence of this inhibitor. Pretreatment with increasing concentrations
of RAP for 10 minutes induced a dose-dependent inhibition of the phosphorylation
of Tyr-397 and Tyr-925. There was no significant difference in the degree of inhibition
between the two tyrosine residues  (Figure 6A). No such inhibition was found in
thrombin-treated platelets (Figure 6B). Also the formation of a complex between
FAK and Fgr was reduced in the presence of RAP, illustrating the importance of the
association between these proteins for the phosphorylation of Tyr-397 and Tyr-925
(Figure 6C,D). These data suggest that LDL initiates site-specific phosphorylation
of FAK at least in part via activation of a member of the LDL-receptor family.
Discussion
The present report shows that LDL-induced signaling to FAK shows discrepancies
as well as similarities with integrin- and GPCR-mediated FAK phosphorylation.
First, LDL induces a faster and more complete phosphorylation of Tyr-925 than of
Tyr-397, which contrasts with thrombin-mediated responses where the phosphor-
ylation of these residues go hand in hand. Second, LDL-induced phosphorylation of
Tyr-397 and Tyr-925 is completely inhibited by the Src-inhibitor PP1 such in common
with integrin-mediated signaling to FAK but not with GPCR-mediated responses.
Third, LDL-induced phosphorylation of Tyr-397 and Tyr-925 is unchanged by inhibitors
of ligand binding to integrin αIIbβ3 although its sensitivity to PP1 would suggest
otherwise.
LDL induced a faster phosphorylation of Tyr-925 than of Tyr-397 whereas with
thrombin the phosphorylation of the two residues was almost equally rapid. LDL
also induced a 5-fold higher phosphorylation of Tyr-925 than of Tyr-397, Tyr-407,
Tyr-577 and Tyr-861 under equilibrium conditions. Compared with thrombin, the
phosphorylation induced by LDL was incomplete resulting in a 50% (Tyr-925) to
90% (Tyr-397, Tyr-407, Tyr-861) lower Tyr phosphorylation. These findings reveal
major differences between the two agonists in the regulation of kinase and phos-
phatase activities that control the phosphorylation of FAK.
There is general consensus that Tyr-397 is a first target for FAK activation and that
its phosphorylation is a prerequisite for subsequent phosphorylation of the other
Tyr residues. Mutation of Tyr-397 to the nonphosphorylatable residue phenylalanine
impaired FAK phosphorylation, association of Src and initiation of signal transduction
in COS cells. Hence, Tyr-397 phosphorylation seems crucial for the biochemical
and biological functions of FAK 8, 26.
Kinetic studies in LDL-stimulated platelets showed a similar time course of Tyr-
397, Tyr-577 and Tyr-861 phosphorylation and a 5-10 times faster phosphorylation
of Tyr-925. Interestingly, no such a discrepancy was found in thrombin-stimulated
platelets where the phosphorylation of Tyr-925, Tyr-397 and Tyr-577 was equally
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fast. Tyr-576 and Tyr-577 are located in the activation loop and their phosphorylation
is thought to contribute to the phosphorylation of Tyr-397 24. The much faster
phosphorylation of Tyr-925 in LDL-treated platelets suggests the presence of an
additional control step between Tyr-577 and Tyr-925 phosphorylation which is dormant
in thrombin-treated cells.
Dose response studies revealed two types of responsiveness to increasing con-
centrations of LDL. The phosphorylation of Tyr-925, Tyr-397 and Tyr-577 was maximal
at about 0.1 g/L LDL but maximal phosphorylation of Tyr-407 and Tyr-861 required a
10 fold higher concentration. It is difficult to explain this difference at the level of the
kinases and phosphatases that control the phosphorylation status of the different
Tyr residues. In stead, it might be the result of complex regulatory mechanisms at
the level of the LDL-receptor with, for instance, homo- or heterotypic receptor
dimerization or changes in affinity and avidity triggering different signaling routes to
FAK.
Integrin-mediated cell adhesion initiates phosphorylation of Tyr-397 via Src family
tyrosine kinases whereas GPCR-mediated phosphorylation of Tyr-397 is independent
of this kinase family 9. This report shows that LDL initiates the phosphorylation of
Tyr-925 and Tyr-397 via Src tyrosine kinases but is unaffected by inhibitors of ligand
binding to integrin αIIbβ3. This finding accords with the normal FAK phosphorylation
observed in αIIbβ3-deficient platelets 16. FAK activation in platelets has been
demonstrated upon treatment with collagen, an agonist of integrin α
2
β
1 
and
glycoprotein VI 27, 28, thrombin, an inducer of platelet aggregation via integrin αIIbβ3
(this study and 15) and also with agents that cross-link FcγRIIa 29, indicating the
presence of integrin-dependent and -independent signaling pathways to FAK.
In chicken embryo cells, FAK forms stable complexes with c-Src and Fyn via binding
to their SH2 domains thereby targeting the cytoplasmic Src members to focal
adhesions 30. When platelets are stimulated with thrombin, Src translocates from
the Triton X-100- soluble fraction to the cytoskeleton-rich, Triton X-100- insoluble
fraction that is also enriched in FAK. The translocation is absent in αIIbβ3-deficient
platelets illustrating the importance of this integrin in the targeting of Src to focal
adhesions 31. Also in LDL-stimulated platelets FAK associates with a member of the
Src family. The two proteins remain associated during the period in which the different
Tyr residues are phosphorylated and thereafter dissociate. The Src family tyrosine
kinases are cytosolic proteins with molecular weights ranging from 53 kDa to 62
kDa. In platelets stimulated by LDL, FAK associates with a protein of approximately
55 kDa. The anti-Src antibody used in the precipitation experiments is directed
against several members of the Src family, including Fgr (55 kDa), Fyn (59 kDa), c-
Src (60 kDa) and Yes (62 kDa) but only a single band at approximately 55 kDa was
detected. Reprobing with a specific antibody identifies this 55 kDa protein as the
Src family member Fgr. Fgr is a negative regulator of β2 integrin signaling and cell
spreading in monocytes and has recently been identified in human platelets 32, 33.
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In contrast, thrombin-induced FAK phosphorylation appears to involve a more
complex association with Src family members including both Fgr and c-Src. It is
possible that these different associations between FAK and Src family members
explain the different Tyr phosphorylation patterns induced by LDL and thrombin.
They may also explain differences in downstream signaling with LDL failing to induce
the activation of Ras and thrombin being a potent activator of this small GTPase 34,
35.
Thrombin induced the phosphorylation of Tyr-925 and Tyr-397 in stirred platelet
suspensions. This response was inhibited for about 50% in the presence of the
Src inhibitor PP1 and the αIIbβ3 antagonists γ400-411 and GPI-562. Under the
same conditions, thrombin induced the association of FAK with Fgr and c-Src.
These findings suggest that the activated thrombin-receptors (PAR1/3/4 36) initiate
two signaling pathways to FAK. First, there is the GPCR-mediated activation of
FAK via Src-independent signaling steps. The low but significant FAK phosphorylation
induced by thrombin in unstirred platelet suspensions might be a result of this
pathway (data not shown). Second, there is the activation of integrin αIIbβ3 via
inside-out signaling mechanisms followed by ligand binding and further outside-in
signaling to FAK. This second pathway might include formation of a FAK- Fgr- c-Src
complex. Thus, together with the LDL induced formation of a FAK- Fgr complex,
there appear at least three different mechanisms for the regulation of FAK with
possibly important consequences for FAK activity and formation of focal adhesions.
So far, the identity of the platelet receptor that transmits the signaling properties of
LDL to intracellular messenger systems has not been elucidated. The observation
that platelets are activated by a peptide that mimics a part of apoB100, a major
protein constituent of LDL, suggests that the platelet receptor has properties in
common with the apoB/E receptor on fibroblasts 19. In a recent publication Riddell
et al. reported the presence of a member of the LDL receptor family on platelets,
named LRP8 25. The receptor -associated protein RAP, a 39kDa protein that consists
of three homologous domains, is an antagonist for receptor-ligand interactions of
LDL receptor family members. The results show that RAP interfered with the
phosphorylation of Tyr-397 and Tyr-925 induced by LDL resulting in an inhibition of
60 - 75%. In addition, RAP interfered with the formation of the FAK- Fgr complex.
Both observations suggest that LRP8 or a closely related receptor family member
serves a role in the FAK activation by LDL. This might imply that the site-specific
Tyr phosphorylation induced by LDL, which differs from that induced by integrins
and GPCRs, reflects a novel mechanism of FAK activation that is typical for members
of the LDL-receptor family.
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Summary
Low Density Lipoprotein (LDL) increases the sensitivity of human platelets for agonists
by activating p38MAPK. Antibody 4G3 disturbs apoB100 binding to the classical apoB/
E receptor and inhibits LDL-induced p38MAPK activation, whereas an antibody against
a distal domain on apoB100 has no effect. Peptide RLTRKRGLKLA mimics the
binding domain of apoB100 called the B-site and activates platelet p38MAPK. Activa-
tion by B-site peptide is dose-dependent, transient and followed by desensitization,
in accordance with receptor-mediated signalling. A scrambled peptide and a partially
homologous peptide RKLRKRLLRDA mimicking the apoB/E receptor binding site of
apoE in High Density Lipoprotein (HDL) also activate p38MAPK albeit 40% weaker,
but an uncharged peptide lacks p38MAPK activating capacity.  LDL and B-site peptide
bind to the same binding sites and initiate similar signaling to p38MAPK and cytosolic
phospholipase A
2
. Thus, LDL and to a lesser extent HDL activate platelets via
specific domains in the protein moiety that recognize receptors of the LDL receptor
family.
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Introduction
The Low Density Lipoprotein (LDL) particle contains one molecule of apolipoprotein
B100 (apoB100) that enwraps LDL like a belt, with the carboxyl tail crossing
apoB100 close to amino acid 3500 1. The positively charged amino acids arginine
and lysine on apoB100 are essential for recognition of the classical LDL receptor
on nucleated cells, the apoB/E receptor 2-4. ApoB100 contains several positively
charged segments of which residues 3359-3369 are critical for receptor recognition
5. This domain is called the B-site and consists of the amino acids RLTRKRGLKLA.
There is a high similarity with the receptor-binding domain of apoE, present on
HDL, which consists of RKLRKRLLRDA 6. The interaction of the carboxyl tail of
apoB100 with residue 3500 allows the B-site to interact with the receptor 7. This
interaction is critical since an R3500Q mutation found in patients with familial
defective apoB100 results in loss of receptor binding 8.
Native LDL activates endothelial cells 9 and increases the sensitivity of blood platelets
to agonist stimulation 10-14. How LDL interacts with platelets is still unclear. Patients
with an apoB/E receptor defect have platelets that respond normally to LDL.
Antibodies against the apoB/E receptor interfere with LDL binding to lympho-cytes
and fibroblasts but leave LDL binding to platelets unaffected. These observations
suggest that the LDL receptor on platelets differs from the classical apoB/E receptor
present on nucleated cells 15. A recent study identified LRP8, a member of the LDL
receptor family, on platelets and showed that apoE changes platelet functions by
binding to this receptor 16. By analogy, the same or a closely related family member
might function in LDL binding to platelets.
A first step in platelet activation by LDL is the activation of the enzyme p38MAPK,
which is activated within 10 seconds (at 1 g apoB100/L) after addition of LDL and at
concentrations as low as 0.1 g apoB100/L (within 10 minutes) 17. P38MAPK is a member
of the family of proline directed serine/threonine kinases, which is activated by the
simultaneous phosphorylation of Thr180 and Tyr182 18. LDL-induced p38MAPK activation
is insensitive to many inhibitors of signal transduction suggesting that it is an early
step in the activation cascade initiated by LDL. An upstream inhibitor of LDL-
induced p38MAPK activation is cAMP. An important downstream effect is the
phosphorylation and activation of cytosolic phospholipase A
2 
(cPLA
2
) resulting in
formation of thromboxane A
2
 and enhanced platelet functions 17.
There is little insight in the activating properties of LDL. LDL consists of free and
esterified cholesterol, triglycerides and phospholipids, which are all components
that might change cell composition and behaviour. 19 Furthermore, LDL is easily
oxidized which leads to the generation of lysophosphatidic acid, which is an inducer
of platelet shape change 20. On the other hand, modification of lysine residues on
apoB100 impairs LDL binding to platelets 21 and abolishes LDL induced phosphor-
ylation of p38MAPK 17, suggesting that the signaling properties of LDL are located in
apoB100.
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Here we report that an activating property of LDL resides in the B-site of apoB100.
By applying antibodies against apoB100 domains and peptides that mimic the B-
site we find activation of p38MAPK with characteristics that point to receptor medi-
ated platelet activation. A weaker activation is found by a peptide mimetic for the
receptor recognition site of apoE, a constituent of High Density Lipoprotein (HDL)
suggesting that the platelet LDL receptor shares many characteristics with the
classical apoB/E receptor on other cells.
Materials and Methods
Antibodies and Reagents
BAPTA-AM was from Calbiochem Corporation (La Jolla, CA, USA) and SK&F was obtained from Biomol
(Sanvertech, Boechout, Belgium). Dibutyryl cyclic AMP (dbcAMP) was from Sigma (St. Louis, MO, USA)
and iloprost from Schering (Berlin, FRG). PP1 was obtained from Alexis Biochemicals (San Diego, CA,
USA). MoAb directed against cPLA
2
 (4-4B-3C) was from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Renaissance chemiluminescence Western-blot reagent was from NEN-Dupont, Boston, MA, USA.
Polyclonal antibodies against p38MAPK and dual phosphorylated p38MAPK (phosphoplus p38MAPK) and
horseradish peroxidase labelled anti-rabbit IgG were from New England Biolabs (Beverly, USA).
Non-fat dry milk was obtained from Nutricia (Zoetermeer, the Netherlands). The fibrinogen- derived peptide
HHLGGAKQAGDV (γ
400-411
) was kindly provided by the department of Biochemistry, Utrecht University.
SDZ-GPI-562 (GPI-562) was a kind gift of Dr. H-G. Zerwes (Novartis Pharmaceuticals, Basel, Switzerland)
22.
The anti-human apoB100 monoclonal antibodies (moAb) 4G3 and 2D8 were obtained from the University
of Ottowa Heart Institute (Ontario, Canada). The production of these antibodies was described before 23.
Peptides
Peptides were synthesized by standard solid-phase peptide synthesis and purified by C18 reverse-phase
chromatography (HPLC, Genosphere biotechnologies, Paris, France). The purity of the peptides was
>99% as determined by HPLC and the molecular weights were verified by matrix-assisted laser desorption
mass spectrometry by the manufacturer.
The peptide RLTRKRGLKLA (Mw = 1311 Da), designated B-site peptide, represents the apoB receptor-
binding domain; SLTSASGLALA (Mw = 990 Da) is a related peptide in which charged amino acids
have been replaced by uncharged amino acids and was named uncharged peptide. Peptide
TKLRALRKLRG is a scrambled peptide with the same composition as B-site peptide. Peptide
RKLRKRLLRDA (Mw = 1426 Da) mimics the receptor binding site of apoE and was named apoE
peptide.
Lipoprotein Isolation
Lipoproteins were isolated as described previously 10. In short, fresh, non-frozen plasma from 4 healthy
subjects each containing less than 100 mg lipoprotein(a)/L was pooled and LDL (density range 1.019-
1.063 kg/L), HDL (density range 1.063-1.21 kg/L), HDL
2
 (density range 1.063-1.125 kg/L) and HDL
3
(density range 1.125-1.21 kg/L) were isolated by sequential flotation in a Beckman L-70 ultracentrifuge 24.
Centrifugations (20 hr, 175000 g, 10°C) were carried out in the presence of NaN
3
 and EDTA.
The LDL preparations contained only minimal amounts TBARS (0.20 ± 0.07 nmol/mg apoB100), lipid
peroxides (6.7 ± 1.9 nmol/mg apoB100) and contaminating plasma proteins. The concentrations of these
oxidation markers were below or within reported values for native LDL 10. Lp(a) concentrations (Apotech,
Organon Technika, Rockville, U.S.A) were below 14 mg/L.
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Lipoproteins were stored at 4°C under nitrogen for not longer than 14 days and before each experiment
dialyzed overnight against 104 volumes 150 mmol/L NaCl. ApoB100, apoAI and lipoprotein(a)
concentrations were measured using the Behring Nephelometer 100. The concentration of LDL was
expressed as g apoB100 protein/L and the concentration of HDL as g apoAI protein/L.
Platelet Isolation
Freshly drawn venous blood from healthy volunteers was collected with informed consent into 0.1 vol.
130 mmol/L trisodium citrate. The donors claimed not to have taken any medication during two weeks
prior to blood collection.
Platelet-rich plasma (PRP) was prepared by centrifugation (200 g for 15 min at 22°C). Gel-filtered platelets
(GFP) were isolated as described before 17. GFP were adjusted to a final count of 2 * 1011 platelets/L and
incubated with peptides, LDL or HDL at 37°C without stirring.
Binding of 125I-LDL to human platelets
LDL was labelled with 125I according to the method by Mc Farlane 25, modified by Bilheimer 26. GFP in
Tyrode’s solution were incubated with 125I-LDL (60 min, 22°C), and aliquots of 100 µL were layered on top
of 100 µL 25 % (w/v) sucrose in Tyrode solution in microsedimentation tubes (Sarstedt, Nümbrecht,
Germany).
Cells were separated from medium by centrifugation (12000 g, 2 min, 22°C) and both fractions were
counted in a Cobra gamma-counter (Packard, Downers Grove, Il., U.S.A.). Aspecific binding (about 10%
of total binding) was determined by addition of a 30-fold excess unlabeled LDL and substracted from total
binding to obtain specific binding data.
Measurement of p38MAPK and cPLA
2
The phosphorylation of p38MAPK and cPLA
2 
was measured as described elsewhere 17. In short, GFP were
incubated at 37°C with peptides or LDL as indicated. Samples of 100 µL were fixed in 1% formaldehyde
(15 min, 4°C), centrifuged (9000 g, 30 sec) and resuspended in 40 µL Laemmli sample buffer. Samples
were heated prior to SDS-polyacrylamide gel electrophoresis (12%). Proteins were electrophoretically
transferred (1hour, 100 volts) to a nitrocellulose membrane using a mini-protean system (Biorad, Richmond,
CA, USA). The blots were blocked in 5% non-fat dry milk, 0.1% Tween 20 in phosphate buffered saline (1
hr, 4°C) and incubated with the phosphoplus p38MAPK (Thr180/Tyr182) or p38MAPK antibody  (1:2000 in 1%
non-fat dry milk, 0.1% Tween in PBS, 16 hr, 4°C). Both antibodies are raised against residues 171-
186 of human p38MAPK. After washing, the membranes were incubated with horseradish peroxidase labelled
anti-rabbit (1:2000, 1 hour, 4°C) and p38MAPK was visualized using the enhanced chemiluminescence
reaction. For semi-quantitative determination of the amount of dual phosphorylated or total p38MAPK, the
density of the bands was analysed using ImageQuant software (Molecular Dynamics).
For the measurement of cPLA
2 
phosphorylation, samples were withdrawn and collected in Laemmlli
sample buffer (0.001% bromophenol blue, 5% β-mercaptoethanol, 100% glycerol, 2% (w/v) SDS, 62.5
mmol/L Tris pH 6.8). Measurement of cPLA
2
 was based on the mobility shift on SDS-PAGE that
accompanies phosphorylation of the protein.27 The running buffer for electrophoresis of cPLA
2
 was
pH 8.3. cPLA
2
 was detected using the moAb 4-4B-3C.
Immune complexes were detected by enhanced chemiluminescence.
Statistics
Data are expressed as means ± SD with number of observations n, and were analyzed by ANOVA.
Differences were considered significant at P < 0.05.
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Results
Identification of the activating domain in apoB100
In an attempt to identify which part in LDL induced platelet activation via p38MAPK,
antibodies were sought that interfere with LDL binding to the classical apoB/E
receptor. Anti-human apoB100 monoclonal antibody 4G3 is directed against an
amino terminal part of apoB100 close to the apoB receptor-binding site (amino
acids 2980-3084) and called B-site. This antibody inhibits LDL-binding to the apoB/
E receptor on human fibroblasts. Antibody 2D8 is directed against a domain dis-
tant from the apoB/E receptor-binding site of human fibroblasts (aa 1438-1481)
and does not interfere with LDL binding 5, 23.  As illustrated in Figure 1, 4G3 induced
a dose-dependent decrease in p38MAPK phosphorylation by LDL. In contrast, phos-
phorylation of p38MAPK was unchanged when LDL was pretreated with 2D8, sug-
gesting that the domain recognized by this antibody was not involved in p38MAPK
activation by LDL. Hence, despite the differences between the classical apoB/E
receptor and the platelet LDL-receptor, both receptors appeared to be recognized by
the B-site in apoB100.
B-site peptide activates platelet p38MAPK
To better understand the role of the B-site in LDL activation of platelets, a mimick-
ing peptide was synthesized together with peptides with the same amino acid com-
position in random order (scrambled peptide) and a peptide in which charged amino
acids were replaced by uncharged amino acids (uncharged peptide). Samples
were subjected to SDS-PAGE and identified with an antibody directed against phos-
phorylated p38MAPK. Figure 2A depicts the time-dependent phosphorylation of p38MAPK
induced by B-site peptide. Within 30 seconds a strong increase in p38MAPK phos-
phorylation was observed, reaching a maximum between 0.5 and 2 minutes, de-
pending on the donor. P38MAPK phosphorylation induced by B-site peptide was tran-
sient and disappeared within 15 minutes.
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Figure 1. An antibody against apoB100 reduces LDL-in-
duced p38MAPK phosphorylation
LDL was pre-incubated with the moAb 4G3 or 2D8 for 60
minutes at the indicated concentrations. Platelets were in-
cubated with 1g/L LDL (10 min, 37°C) with (closed symbols)
or without (open symbol) antibody pretreatment. Dual
phosphorylated p38MAPK was identified by SDS-PAGE and
Western blotting using a phosphospecific anti-p38MAPK
polyclonal antibody.  The blots were semi-quantified and the
data were expressed as percentage of the p38MAPK
phosphorylation in the absence of antibodies (100%, open
symbol). The data shown are from a single experiment, which
is representative of three experiments with identical results.
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Figure 2. B-site peptide induces phosphorylation of p38MAPK
(A), Platelets were incubated with B-site peptide (100 µmol/L, 37°C) for the indicated time periods. Samples were
drawn and centrifuged (30 sec, 9000 g, 22°C) and resuspended in sample buffer. One part of the samples was applied
to gel and dual phosphorylated p38MAPK was identified with a phosphospecific anti-p38MAPK polyclonal antibody (upper
panel). Another part was applied to gel and total p38MAPK was detected using an antibody against p38MAPK as a control
for equal lane loading (lower panel). Shown are representative blots of five experiments with identical results. (B),
Platelets were incubated with the indicated concentrations of B-site peptide (1 min, 37°C). Dual phosphorylated
p38MAPK was identified and the data were expressed as percentage of the p38MAPK phosphorylation in the presence of
100 µmol/L B-site peptide. Data are expressed as means ± SD, n=4. (C), Platelets were incubated with B-site peptide
(100 µmol/L, 37°C) or LDL (1 g/L, 37°C) for the indicated time periods. Dual phosphorylated p38MAPK was identified and
the data were expressed as percentage of the p38MAPK phosphorylation in the presence of 10 min LDL. Data are
expressed as means ± SD, n=5. (D), Platelets were incubated with B-site peptide or scrambled peptide (100 µmol/L,
37°C) for the indicated time periods. Dual phosphorylated p38MAPK was identified and the data were expressed as
percentage of the p38MAPK phosphorylation observed after incubation with 1 min B-site peptide. Data are expressed as
means ± SD, n=4. (E), Platelets were incubated with B-site peptide or uncharged peptide  (100 µmol/L, 37°C) for the
indicated time periods. Dual phosphorylated p38MAPK was identified as described in Figure 2A. Shown is a representa-
tive blot of three experiments with identical results.
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In the lower panel the same samples were analysed with an antibody directed against
total p38MAPK, showing that similar amounts of p38MAPK were present in all samples.
An optimal effect was observed at 100 µmol/L B-site peptide (Figure 2B). At this
concentration B-site peptide induced 93.6 ± 4.1% (n=5, P>0.5) of the p38MAPK
phosphorylation induced by 1 g/L LDL. However, activation by the peptide lasted
shorter than activation by LDL, indicating that B-site peptide mimicked only part of
the activating properties of native LDL (Figure 2C). The scrambled B-site peptide
had retained part of the activating properties of intact B-site peptide (Figure 2D).
There was a slight and transient activation which reached about 60% of the increase
in phosphorylated p38MAPK triggered by intact B-site peptide. This indicates that part
of the activating properties of B-site peptide are caused by positively charged amino
acids. Indeed, when all charged amino acids were replaced by neutral amino acids
by means of arginine-serine and lysine-alanine replacements, the activating proper-
ties were lost (Figure 2E).
Together these data illustrate that B-site peptide is a rapid and strong activator of
p38MAPK in platelets.
Comparison between B-site peptide and LDL
The observation that B-site peptide mimicked at least part of the p38MAPK activating
properties of LDL suggested that both induced signal generation by binding to a
single class of LDL receptors. To substantiate this conclusion, platelets were incu-
bated for 60 minutes with 30 mg/L 125I-labeled LDL (22°C) to reach equilibrium binding
to LDL binding sites on the platelet surface.
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(A), Platelets were incubated with B-site peptide (10 min, 22°C) as indicated and subsequently treated with 30 mg/L
125I-LDL (60 min, 22°C). Binding data (means ± SD, n=3) were corrected for aspecific binding as determined with a 30-
fold excess of unlabeled LDL and expressed as number of platelet binding sites. The data shown are from a single
experiment, which is representative of three experiments with identical results. (B), Platelets were incubated with B-
site peptide (100 µmol/L, 37°C) for the indicated time periods with and without a second dose of B-site peptide. Dual
phosphorylated p38MAPK was identified as described in Figure 1. Data are expressed as means ±  SD, n = 5.
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Prior addition of B-site peptide (10-160 µmol/L) led to a dose-related displacement
of bound 125I-labeled LDL (Figure 3A). This accords with competition for a single
class of binding sites. A common property of most receptors is that they become
unresponsive after prolonged ligand occupation. Indeed, a 30 minutes incubation
with B-site peptide led to downregulation of p38MAPK activation (Figures 2C and 3B).
A second addition of 100µmol/L B-site peptide failed to trigger a second p38MAPK
phosphorylation response, suggesting that the B-site recognition mechanism had
become desensitized. Together these findings support the concept that LDL and B-
site peptide bind to the same receptors thereby starting signal transduction to
p38MAPK.
To further compare the signaling properties of B-site peptide and LDL, the sensitiv-
ity of p38MAPK phosphorylation for agents that interfere with platelet activating
pathways was investigated.
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Figure 4. LDL- and B-site peptide-induced p38MAPK phosphorylation is under control of cAMP and mediated by
Src family tyrosine kinases
(A), Platelets were incubated with iloprost (2 µmol/L, 15 min), dbcAMP (250 µmol/L, 10 min), BAPTA-AM (10 µmol/L,
2 min) or SK&F (20 µmol/L, 10 min). Subsequently, they were incubated with the B-site peptide  (100 µmol/L, 1 min).
The blots were semi-quantified and the data were expressed as percentage of the p38MAPK phosphorylation in the
absence of inhibitors (means ± SD, n=3). (B), Platelets were incubated with the fibrinogen γ400-411 peptide (100 µmol/
L, 2 min) or the αIIbβ3 blocker GPI-562 (10 nmol/L, 1 min) prior to incubation with B-site peptide (100 µmol/L, 1 min).
The blots were semi-quantified and the data were expressed as percentage of the p38MAPK phosphorylation in the
absence of inhibitors (means ± SD, n=3). (C), Platelets were incubated with PP1 (10 µmol/L or 20 µmol/L, 15 min) prior
to LDL (1 g/L, 10 min) or B-site peptide (100 µmol/L, 1 min) incubation. Dual phosphorylated p38MAPK was identified as
described in Figure 1. Shown is a representative blot of three experiments with identical results.
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We have shown earlier that LDL-induced p38MAPK was inhibited by agents that raise
cAMP whereas the Ca2+-scavenger BAPTA-AM and the Ca2+- entry blocker SK&F
had no effect 17. B-site induced p38MAPK phosphorylation showed the same
characteristics. There was a strong inhibition by the stable PGI
2
- analogue iloprost
and the cell- permeable cAMP analogue dibutyryl cAMP but no effect of treatment
with BAPTA-AM and SK&F (Figure 4A). Another feature of LDL- induced p38MAPK
phosphorylation is lack of involvement of integrin αIIbβ3. B-site peptide-induced
p38MAPK activation also showed no requirement of integrin αIIbβ3 as blockers of
ligand binding to the integrin, fibrinogen γ-chain derived dodecapeptide (γ
400-411
) and
GPI-562 showed no effect (Figure 4B).
The role of Src family tyrosine kinases in B-site and LDL-induced p38MAPK activation
was investigated with the specific inhibitor PP1. At two concentrations (10 µmol/L
and 20 µmol/L) the inhibitor markedly reduced B-site and LDL-induced p38MAPK
phosphorylation, illustrating the involvement of Src family tyrosine kinases (Figure
4C).
One of the downstream effects of LDL-induced p38MAPK phosphorylation is the
phosphorylation of cPLA
2
, which is a first step in the generation of thromboxane
A
2
. Also B-site peptide (100 µmol/L) induced a transient phosphorylation of cPLA
2
but the effect was considerably faster than observed with LDL 27 such in accordance
with the faster phosphorylation of p38MAPK induced by the peptide (Figure 5). B-site
peptide phosphorylation of cPLA
2 
was blocked completely by the p38MAPK inhibitor
SB203580 confirming the role of p38MAPK in the control of cPLA
2
.  These data indi-
cate that B-site peptide initiates the same type of signal transduction in platelets as
LDL.
P38MAPK phosphorylation by the receptor-binding site of apoE
The apoB/E receptor equally recognizes the apoB-100 part of LDL as the apoE part
of HDL and a high degree of similarity between the receptor recognition domains of
both apolipoproteins can be expected. Indeed, also HDL induced p38MAPK phospho-
rylation but the response was weaker than observed with LDL (Figure 6A).
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Figure 5. B-site peptide phosphorylates cPLA
2
Platelets were incubated with B-site peptide (100 µmol/L) for
the indicated time periods. Platelets were incubated with
SB203580 (10 µmol/L, 15 min) prior to B-site stimulation where
indicated. cPLA
2
 was identified by western blotting with a moAb
against cPLA
2
. Shown is a representative blot of four
experiments with identical results.
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Subtypes of HDL, HDL
2
 and HDL
3
, which are described respectively as anti-
aggregatory and proaggregatory 28 induce p38MAPK phosphorylation with HDL
2
 acting
as a weaker agonist (Figure 6B). Residues 142-152 of apoE show a high degree of
homology with the B-site of apoB100. A peptide mimicking this domain called apoE
peptide (RKLRKRLLRDA) also induced phosphorylation of p38MAPK (Figure 6C). The
phosphorylation was fast and transient and also accompanied by loss of respon-
siveness to a second addition of apoE peptide. These properties closely resemble
those observed with B-site peptide.
Discussion
This report shows that at least part of the platelet activating properties of LDL are
located in apoB100. This agrees with earlier studies in which carbamylation of
apoB100 abolished LDL-induced p38MAPK phosphorylation reflecting a crucial role
of the protein moiety in platelet activation by LDL 17. Antibodies against different
domains of apoB100 reveal a central role for the B-site in induction of p38MAPK
phosphorylation. This domain is crucial for LDL binding to the apoB/E receptor on
fibroblasts and apparently also functions in LDL binding to the LDL receptor on
platelets. This is of interest since observations in patients with an apoB/E receptor
defect as well as in vitro studies with antibodies indicate that platelets lack the
classical apoB/E receptor. Possibly, platelets contain a closely related LDL receptor
family member with some properties in common with the apoB/E receptor.
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Figure 6. The receptor-binding domain of apoE phosphorylates p38MAPK
(A), Platelets were incubated with LDL or HDL with the indicated concentrations at 37°C for 10 min. Samples were
applied to gel and dual phosphorylated p38MAPK was identified with a phosphospecific anti-p38MAPK pAb. A representa-
tive blot of three experiments with identical result is shown. (B), Platelets were incubated with LDL, HDL
2
 or HDL
3
 with
the indicated concentrations at 37°C for 10 min. The blots were semi-quantified and the data were expressed as
percentage of the p38MAPK phosphorylation after treatment with 1 g/L LDL. C, Platelets were incubated with apoE
peptide (100 µmol/L, 37°C) for the indicated time periods. Samples were applied to gel and dual phosphorylated
p38MAPK was identified with a phosphospecific anti-p38MAPK pAb. Shown is a representative blot of three experiments
with identical result.
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Earlier studies by Borén et al suggested that the B-site of apoB100 (residues 3359-
3369) was critical site for LDL binding to the apoB/E receptor 29. In contrast, Law
and Scott proposed that multiple sites on apoB100 mediated receptor-binding 30
with the B-site playing a dominant but not an exclusive role. The present study
shows that a B-site mimicking peptide induces signal transduction in platelets.
Phosphorylation of p38MAPK was observed within 30 seconds after addition of B-site
peptide, illustrating rapid binding and activation of platelets. The activation was
maximal at about 100 µmol B-site peptide/L, which is equivalent to 0.13 g protein/
L. At this concentration B-site peptide induced the same amount of p38MAPK phos-
phorylation as 1.0 g LDL protein/L, suggesting that the B-site contains a major part
of the platelet activating properties of LDL. P38MAPK phosphorylation induced by the
peptide was faster and more transient than induced by LDL. The difference might
be caused by different binding affinities of the peptide and LDL. Alternatively, the
B-site might be important for platelet- LDL receptor recognition and initial signal
transduction generation with other components in LDL supporting this process at
later stages of LDL-platelet contact. A B-site peptide with arginine-serine and lysine-
alanine replacements failed to induce p38MAPK activation. A scrambled B-site peptide
has preserved part of the activating properties. This illustrates the importance of
clusters of positively charged amino acids lysine and arginine for platelet activation
by apoB100, such in common which apoB100 binding to the apoB/E receptor 2, 3 .
Also LDL binding to proteoglycans is charge-dependent 31. A minimum of five positive
charges with intervening nonbasic amino acids in a nonapeptide was required for
the binding to proteoglycans 32. Binding affinity depended on number and type of
nonbasic amino acids. In this respect, the B-site and the apoE site investigated in
the present study bind much stronger to proteoglycans than other charged domains
in these apolipoproteins.
The possibility to displace platelet-bound LDL by B-site peptide and the loss of
responsiveness after prolonged incubation with B-site peptide suggests the involve-
ment of a surface receptor that mediates signals to p38MAPK.  The desensitization
might be the result of endocytosis of receptor-ligand complexes as has been reported
for ligand occupied apoB/E receptors on fibroblasts 33. However, in studies by Pedreno
et al 125I-LDL binding was reversible and unaffected by changes in temperature
which would argue against receptor internalization 15, 34. In contrast, Mazurov et al
reported a temperature dependent decrease of fluorescent-LDL bound to platelets
and concluded that bound LDL was internalized 35.
B-site peptide and LDL appear to trigger the same signaling pathway to p38MAPK.
P38MAPK phosphorylation by both agonists was inhibited by cAMP, independent of
Ca2+ increases and abolished by PP1, an inhibitor of Src family tyrosine kinases. In
addition, both agonists induced phosphorylation of cPLA
2
, which is a key step in
enzyme activation leading to formation of thromboxane A
2
. Although B-site peptide
and LDL induced the same degree of p38MAPK activation during initial contact with
the platelet, the peptide failed to sensitize collagen-induced secretion of dense
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granule contents, such in contrast to LDL (data not shown). Thus, the more prolonged
activation observed with LDL might initiate a stronger stimulation of the cPLA
2
pathway leading to more support of platelet functions 12, 14, 28, 36-38.
Since the B-site of apoB100 shows a high degree of homology with the receptor-
binding domain of apoE 39, one might expect a similar activation by a peptide that
mimics this part of apoE. Indeed, apoE peptide induced a similar p38MAPK phospho-
rylation as B-site peptide but the activation was much weaker. A 30 minutes incubation
followed by a second peptide addition revealed a similar desensitization as observed
with B-site peptide. These findings are in concert with the rapid down-regulation of
binding sites for radiolabeled HDL
3
 on platelets as well as desensitization of the
signaling pathway 40, 41. In this respect apoE peptide mimicked the effect of HDL
which was a weaker activator than LDL when concentrations were based on apoA-
I and apoB100 content respectively. Applying molar concentrations and an apoA-I/
apoE ratio of about 30, the same concentration range resulted in a 2-3 fold lower
HDL-apoE concentration compared with LDL-apoB100. Also on this basis, HDL was
a weaker activator of p38MAPK than LDL. HDL
3
 induced a stronger p38MAPK activation
compared to HDL
2
 in concert with the pro-aggregatory effect of HDL
3
 on platelets 28.
However, HDL
2 
is the apoE-rich fraction of HDL whereas HDL
3
 is the apoE-poor
fraction which argues against an unique role of apoE for p38MAPK activation. The
observations suggest that in HDL-induced p38MAPK phosphorylation in addition to
apoE other lipoprotein-related components contribute to platelet sensitization.
Although previous observations suggest that the platelet LDL receptor is different
from the classical apoB/E receptor, the present data reveal many similarities. Both
receptors recognize apoB100 and apoE and the crucial binding domains are the
same. Furthermore, positively charged amino acids are essential for receptor
binding. These characteristics make it likely that platelets contain a member of the
LDL receptor family. A recent study shows that platelets contain LDL receptor-
related protein 8 (formerly termed apoER2).  So far, LRP8 has been exclusively
demonstrated in human brain and placenta and its presence in platelets is
unexpected 42. Binding of apoE to this receptor inhibited platelet aggregation which
is in sharp contrast to the activating effect of apoE peptide on p38MAPK phosphory-
lation 16. The cytoplasmic tail of LRP8 contains several motifs with potential for
cellular signaling. Unfortunately, it is not known whether the extracellular part contains
an apoB100 binding site which would make it a candidate receptor for the effects
presented in the present study.
In conclusion, the results of this study indicate that LDL -and to a lesser extent
HDL- induce platelet activation via specific domains in the protein moiety. The
receptors that bind these domains share many properties with classical apoB/E
receptors which may become desensitized after prolonged contact with these
lipoproteins. This might reflect an important protection mechanism by which circulating
platelets remain dormant despite the continuous contact with LDL and HDL.
Platelet activation by apoB100
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Summary
Contact between LDL and human blood platelets enhances their responsiveness to
various aggregation-inducing agents. Although the sensitization and upstream
signaling has been well characterized, the identity of the platelet surface receptor
for LDL-particles has remained obscure. Recently, we reported that the initiation of
platelet signaling towards p38MAPK is mediated by the LDL-receptor binding domain
of apolipoprotein B100 (apoB100), the B-site. Here, we describe that the activation
of p38MAPK is inhibited by receptor-associated protein. This inhibitor blocks ligand
binding to members of the LDL-receptor family, suggesting a role for a fam-ily member
in LDL-induced platelet sensitization. This was further investigated by confocal
fluorescence microscopy, which revealed a high degree of colocalisation of apoB100
and the LDL-receptor homologue Apolipoprotein E Receptor 2 (ApoER2) at the platelet
surface. In addition, association of LDL to platelets was associated with tyrosine
phosphorylation of ApoER2. Tyrosine phosphorylation of ApoER2 appeared to be
independent of integrin αIIbβ3, but required the presence of cell surface proteoglycans.
Furthermore, LDL-dependent phosphorylation of ApoER2 was inhibited in the
presence of PP1, an inhibitor of Src-like tyrosine kinases. Moreover, phosphorylated
ApoER2 coprecipitated with the Src-family member Fgr in immunoprecipitation
experiments. This suggests that exposure of platelets to LDL induces association
of ApoER2 to Fgr, a kinase that is able to activate p38MAPK. In conclusion, our data
indicate that ApoER2 serves a critical role in LDL-dependent sensitization of platelets.
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Introduction
Platelets and Low Density Lipoproteins (LDL) are key elements in the development
of athero-thrombotic complications. The interplay between both elements is apparent
from the notion that LDL particles markedly enhance the responsiveness of platelets
to various aggregation-inducing agents 1-4. These agonists mediate the release of
growth factors, vasoactive substances and chemotactic agents that are known to
stimulate atherosclerotic plaque formation. Sensitization of platelets by LDL involves
the major LDL constituent apolipoprotein B100 (apoB100) 5, a 4563 amino acid
protein that is wrapped around the LDL particle 6. LDL particles may be recognized
by the classical hepatic LDL receptor through the apoB100 moiety, and in particular
through a region within the apoB100 protein that is enriched in positively charged
amino acids, the so-called B-site 7. Like LDL, a synthetic peptide mimicking this B-
site associates to the platelet surface 5. Moreover, this peptide interferes with LDL
binding to platelets 5, suggesting that both elements share similar binding sites.
This possibility is supported by the observation that binding of either LDL or the B-
site peptide to the platelet results in a near immediate activation of the intracellular
enzyme p38MAPK 5, 8. Activation of this Ser/Thr kinase is associated with downstream
phosphorylation and activation of cytosolic phospholipase A
2
 (cPLA
2
), which leads
to the formation of thromboxane A
2
 9, 10. Finally, enhanced platelet function occurs
via exposure of αIIbβ3 and fibrinogen binding 8.
The mechanism by which LDL particles signal to p38MAPK is yet unclear, but it seems
conceivable that it involves a receptor-dependent pathway. The finding that the
signaling pathway is initiated by the apoB100 component of LDL may point to the
involvement of a LDL-like receptor. However, platelets are known to lack the classical
LDL-receptor as well as LDL-receptor related protein-1 11, 12. Recently, a variant of
ApoE Receptor 2 (ApoER2), which is also known as LDL-receptor related protein-8
(LRP8), has been identified in platelets and megakaryocytic cell lines 13. ApoER2 is
a member of the LDL-receptor family, and is mainly expressed in brain, testes and
vascular cells but not in liver 14, 15. Its structure is most closely related to the LDL-
receptor and the VLDL-receptor 16. However, transcriptional analysis has revealed
that multiple alternative splicing variants of ApoER2 exist 17, 18, one of which being
present in platelets 13. Platelet ApoER2 mRNA encodes a 130 kDa protein, which
consists of a single ligand-binding domain that comprises four complement type A
repeats (compared to seven repeats in full length ApoER2), an epidermal growth
factor-like homology region, an O-linked sugar domain and a single transmembrane
domain that connects the extracellular region to the cytoplasmic tail.
Several studies have shown the ability of ApoER2 to bind and internalize apoE-
containing lipid vesicles 13, 14. However, the contribution of ApoER2 to the general
lipid metabolism is probably limited, since mice genetically deficient for ApoER2 do
not suffer from increased plasma lipoprotein levels 19.
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As also the endocytosis rate of ApoER2 is almost 20-fold lower compared to LDL-
receptor related protein-1 20, it seems conceivable that ApoER2 serves an alternative
physiological function as well. Indeed, increasing evidence is arising that ApoER2
is involved in cellular signaling processes. For example, ApoER2 has been reported
to contribute to the neuronal signaling pathway that governs the layering of the
developing cortex 19. In this process, ApoER2 functions as a receptor for the signaling
molecule Reelin, and transmits the Reelin signal to the intracellular adaptor protein
Dab1, which associates to the cytoplasmic tail of ApoER2 19, 21, 22. This tail contains
a yxNPxY sequence (where y is a hydrophobic amino acid residue), which may
function as a potential binding site for phosphotyrosine binding domains of signaling
molecules, including Dab1. In addition, the cytoplasmic region of ApoER2 contains
three proline-rich areas that correspond to the consensus sequence (PxxP) for Src
homology 3 recognition 13. All of these motifs that potentially link ApoER2 to various
signaling pathways are also present in the platelet variant of this receptor 13.
In the present study, we investigated whether ApoER2 has the potential to transmit
the LDL-signal to intracellular signaling components, with particular reference to
p38MAPK. We found that incubation of platelets with LDL-particles resulted in a near
immediate tyrosine-phosphorylation of ApoER2. This process was mediated by
Src-like kinases and resulted in association to the signaling molecule Fgr. Further-
more, inhibition of ApoER2 by the 39 kDa receptor-associated protein (RAP) inter-
fered with LDL-dependent phosphorylation of p38MAPK. In view of our data we pro-
pose that ApoER2 serves a critical role in the LDL-initiated signaling pathway that
governs platelets with increased sensitivity towards its aggregation-inducing agents.
Materials and Methods
Materials
Polyclonal antibodies against p38MAPK, dual phosphorylated p38MAPK (phosphoplus p38MAPK) and horse-
radish peroxidase labeled anti-rabbit IgG were from New England Biolabs (Beverly, USA). Non-fat dry
milk was obtained from Nutricia (Zoetermeer, the Netherlands). PP1 was from Alexis Biochemicals
(San Diego, CA, USA). Renaissance chemiluminescence Western-blot reagent was from NEN-Dupont,
Boston, MA, USA. The goat polyclonal antibody directed against the ectodomain of ApoER2 was
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The polyclonal antibody directed
against c-Fgr and a polyclonal antibody directed against Src kinases were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Antiphosphotyrosine mAb 4G10 was from Upstate Biotechnology
(Bucks, UK). The anti-human apoB100 monoclonal antibody (moAb) 2D8 was obtained from the
University of Ottowa Heart Institute (Ontario, Canada). The production of these antibodies was de-
scribed before 23. Chondroitinase ABC was obtained from Seikagaku America (Falmouth, MA, USA).
Proteins
RAP fused to glutathione S-transferase (GST-RAP) 24 was prepared as described previously 25. The
peptide RLTRKRGLKLA (Mw = 1311 Da), designated B-site peptide, represents the ApoB receptor-
binding domain.
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The peptide was synthesized by standard solid-phase peptide synthesis and purified by C18 reverse-
phase chromatography (HPLC, Genosphere biotechnologies, Paris, France). The purity of the
peptides was >99% as determined by HPLC and the molecular weights were verified by matrix-
assisted laser desorption mass spectrometry by the manufacturer.
Lipoprotein isolation
Lipoproteins were isolated as described before 26. In short, fresh, non-frozen plasma from 4 healthy
subjects each containing less than 100 mg lipoprotein (a)/L was pooled and LDL (density range 1.019-
1.063 kg/L) was isolated by sequential flotation in a Beckman L-70 ultracentrifuge 27. Centrifugations (20
hr, 175000 g, 10°C) were carried out in the presence of NaN
3
 and EDTA. The LDL preparations contained
only minimal amounts TBARS (0.20 ± 0.07 nmol/mg), lipid peroxides (6.7 ± 1.9 nmol/mg) and contaminating
plasma proteins (below or within reported values for native LDL). Lp(a) concentrations (Apotech, Organon
Technika, Rockville, U.S.A) were below 14 mg/L. Lipoproteins were stored at 4°C under nitrogen for not
longer than 14 days and before each experiment dialyzed overnight against 104 volumes 150 mmol/L
NaCl. ApoB100 and lipoprotein(a) concentrations were measured using the Behring Nephelometer 100.
The concentration of LDL was expressed as g ApoB100 protein/L.
Platelet isolation
Freshly drawn venous blood from healthy volunteers was collected with informed consent into 0.1 vol.
130 mmol/L trisodium citrate. The donors claimed not to have taken any medication during two weeks
prior to blood collection. Platelet-rich plasma was prepared by centrifugation (200 g for 15 min at
22°C). Gel-filtered platelets (GFP) were isolated by gelfiltration through Sepharose 2B equilibrated in
Ca2+-free Tyrode’s solution (137 mmol/L NaCl, 2.68 mmol/L KCl, 0.42 mmol/L NaH
2
PO
4
, 1.7 mmol/L
MgCl
2
, and 11.9 mmol/L NaHCO
3
, pH 7.25) containing 0.2 % BSA and 5 mmol/L glucose. Gel-filtered
platelets were adjusted to a final count of 2 * 1011 platelets/L and incubated with LDL at 37°C without
stirring.
P38MAPK – Assay
Gel-filtrated platelets were incubated at 37°C with B-site peptide or LDL as indicated. After incubation,
100 µL aliquots were mixed (1:10 v/v) with cold lysis buffer (RIPA buffer containing 10% protease inhibitor
cocktail, 5 mM NaVO
3
) and subsequently taken up in Laemmli sample buffer. Samples were heated prior
to SDS-polyacrylamide gel electrophoresis (12%). Proteins were electrophoretically transferred (1 hr,
100 volts) to a nitrocellulose membrane using a mini-protean system (Biorad, Richmond, CA, USA). The
blots were blocked in 5% non-fat dry milk, 0.1% Tween 20 in phosphate buffered saline (1 hr, 4°C)
and incubated with the phosphoplus p38MAPK (recognizing p38MAPK phosphorylated at Thr180 and Tyr182)
or p38MAPK antibody, which recognizes both phosphorylated and unphosphorylated isoforms (1:2000
in 1% non-fat dry milk, 0.1% Tween in PBS, 16 hr, 4°C). Both antibodies are raised against residues
171-186 of human p38MAPK. After washing, the membranes were incubated with horseradish peroxidase
labeled anti-rabbit (1:2000, 1 hr, 4°C) and p38MAPK was visualized using the enhanced
chemiluminescence reaction. For semi-quantitative determination of the amount of dual phosphorylated
or total p38MAPK, the density of the bands was analyzed using ImageQuant software (Molecular
Dynamics).
ApoER2 tyrosine phosphorylation
Platelets were incubated with LDL or B-site peptide as indicated and thereafter mixed with ice-cold
lysis buffer (1:10 v/v) containing RIPA buffer, 10% Sigma protease inhibitor cocktail and 10 mmol/L
Na
3
VO
4
. ApoER2 was precipitated using a goat polyclonal antibody directed against ApoER2 (1µg/mL)
and protein G-Sepharose for 3 hours at 4°C. Precipitates were washed 3 times with lysis buffer and taken
up in non-reducing Laemmli sample buffer. Samples were applied to gel and nitrocellulose membrane
and phosphorylated ApoER2 was visualized by incubation with the antibody directed against
phosphorylated tyrosine residues 4G10 (1 µg/mL, 15 hr, 4°C), peroxidase linked anti-mouse IgG
(1:5000 v/v, 1 hr, 4°C) and enhanced chemiluminescence. For semi-quantitative determination of
ApoER2 phosphorylation, the density of the dots was analyzed using ImageQuant software.
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Immunofluorescence studies
Gel filtered platelets were applied to coverslips after fixation with 1% paraformaldehyde, were washed
with PBS, blocked for 10 min with PBS/1% BSA/0.1% glycine, pH 7.4 and incubated with the monoclonal
anti-ApoB100 2D8 5 and the goat polyclonal  ApoER2 antibody. Afterwards, the coverslips were incubated
with a tetramethylrhodamine B thioisocyanate (TRITC) -labeled anti-mouse antibody (Becton Dickinson,
San Jose, CA, USA) and a fluorescein thioisocyanate (FITC)-labeled anti-goat antibody, diluted 1:20 in
PBS for 45 min at 37°C, followed by washing with PBS. Coverslips were embedded in Mowiol and analyzed
by confocal laser microscopy on a Leica confocal laser microscope.
Statistics
Data are expressed as means ± SD with number of observations n, and were analyzed with the
Student’s t-test for unpaired observations. Differences were considered significant at P < 0.05.
Results
Receptor-associated protein prevents LDL-induced platelet signal transduc-
tion
Ligand binding to members of the LDL receptor family is blocked by the presence
of RAP. To investigate whether platelet signaling induced by LDL also involves a
RAP-sensitive receptor, phosphorylation of p38MAPK by LDL (1 g/L, 5 minutes) was
determined in the absence and presence of GST-RAP (0.15-0.45 µmol/L). Activation
of p38MAPK was monitored employing antibodies directed against total and dual
phosphorylated p38MAPK. As shown in Figure 1, similar amounts of p38MAPK were
present in all samples, and the kinase was efficiently phosphorylated upon incubation
of platelets with LDL. The presence of GST-RAP, however, was associated with a
dose-dependent decrease in p38MAPK phosphorylation, with over 70% inhibition at
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Figure 1. The receptor associated protein (RAP) inhibits LDL-induced p38MAPK phosphorylation
Platelets were incubated with GST-RAP (0.15, 0.30 and 0.45 µM, 10 min, 37°C) prior to incubation with LDL (1 g/L, 5
min, 37°C; (A)). Samples were drawn and centrifuged (30 sec, 9000 g, 22°C) and resuspended in sample buffer.
Samples were split and one part of the samples was analyzed for dual phosphorylated p38MAPK using a phosphospecific
anti-p38MAPK polyclonal antibody (upper panel). Another part was analysed for equal loading by detecting total p38MAPK
using an antibody against p38MAPK (lower panel). (B), The blots were semi-quantified and the data were expressed as
percentage of the p38MAPK phosphorylation in the absence of GST-RAP (open symbol). Data are expressed as means
± SD, n = 4.
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0.45 µmol/L GST-RAP (Figure 1A, B). GST alone (0.45 µmol/L) failed to affect LDL-
induced p38MAPK phosphorylation (Figure 1B). Apparently, LDL-dependent activation
of p38MAPK is mediated by a RAP-sensitive receptor.
ApoER2 and LDL colocalization on the platelet surface
At present, only one RAP-binding receptor has been identified in platelets: ApoER2.
As such, ApoER2 is a candidate receptor for LDL particles at the platelet surface.
To investigate the role of platelet ApoER2 in LDL binding, we first determined the
location ApoER2 and platelet-bound LDL employing confocal immunofluorescence
microscopy analysis. Platelets were incubated with LDL (1 g/L) in the presence or
absence of GST-RAP (0.3 µmol/L). By using antibodies directed against ApoER2
and the LDL-constituent ApoB100, it was found that both proteins were selectively
present at the platelet surface (Figure 2). Merging of both images suggested a high
degree of colocalisation of ApoB100 and ApoER2, indicating that LDL may bind to
or in close proximity of ApoER2. Furthermore, in the presence of GST-RAP only
minor amounts of ApoB100 were detectable at the platelet surface, demonstrating
that GST-RAP interferes with LDL binding to the platelet surface, possibly by pre-
venting binding to ApoER2.
LDL-dependent phosphorylation of platelet ApoER2
LDL-receptor related proteins have been implicated in various signaling events, and
participation in the signaling process may be associated with intracellular phospho-
rylation of these receptors.
LDL ApoER2 Merge
control
RAP
Figure 2. Colocalization of LDL with ApoER2 on the platelet surface
LDL-stimulated platelets were incubated with LDL-TRITC (red, left panel) and ApoER2-FITC (green, middle panel) as
described in “materials and methods” with and without pre-incubation with GST-RAP (0.30 µmol/L, 10 min) as indicated.
The right panel shows a merged picture in which colocalization of ApoER2 and LDL can be visualized (yellow).
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We therefore addressed the possibility that association of LDL-particles to the platelet
surface results in phosphorylation of ApoER2. Platelets were incubated with LDL (1
g/L), and at various time intervals ApoER2 was withdrawn by immunoprecipitation
employing anti-ApoER2 antibodies. Samples were analyzed for the presence of
tyrosine-phosphorylated ApoER2. In non-LDL exposed platelets minor amounts of
tyrosine-phosphorylated ApoER2 could be detected (Figure 3A). However, incubation
of platelets with LDL particles resulted in a marked increase in tyrosine-
phosphorylation of ApoER2, a process that appeared to be maximal within 10-30
seconds.
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Figure 3. Tyrosine phosphorylation of ApoER2 by LDL
Platelets were incubated with LDL (1 g/L, 37°C) for the indicated time periods. Tyrosine phosphorylation of ApoER2
was detected via immunoprecipitation of ApoER2 from platelet lysates and western blotting with an antibody that
recognizes tyrosine-phosphorylated proteins (4G10) (A) B, Platelets were incubated with the indicated concentrations
of LDL (0.2 min, 37°C) and tyrosine phosphorylation of ApoER2 was monitored as described above. C, Platelets were
incubated with the fibrinogen γ
400-411
 peptide (100 µM, 2 min) or the αIIbβ3 blocker GPI-562 (10 nM, 1 min) prior to
incubation with LDL (1 g/L, 0.2 min, 37°C). ApoER2 tyrosine-phosphorylation was detected as described (means ±
SD, n=4). D, Platelets were incubated with LDL (1 g/L, 0.2 min, 37°C) or B-site peptide (100 µmol/L, 0.2 min, 37°C).
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Prolonged incubations resulted in a gradual decay of phosphorylated ApoER2,
although after 20 minutes its levels were still above basal levels (Figure 3A). Phos-
phorylation of ApoER2 also proved to be dependent on the concentration of LDL,
with maximal phosphorylation requiring concentrations exceeding 0.1 g/L (Figure
3B). Tyrosine phosphorylation of ApoER2 by LDL showed no requirement of integrin
αIIbβ3 as blockers of ligand binding to the integrin, fibrinogen γ-chain derived
dodecapeptide (γ
400-411
) and GPI-562 showed no effect (Figure 3C). Since the syn-
thetic peptide corresponding to the B-site of the LDL-component apoB100 induces
p38MAPK activation 5, we further tested whether this peptide induced phosphorylation
of platelet ApoER2. Indeed, incubation of platelets with this peptide was associated
with phosphorylation of ApoER2 reaching approximately equal levels compared to
LDL  (Figure 3C). Thus, both the synthetic apoB100 B-site peptide and native LDL
particles induce reversible phosphorylation of the platelet surface receptor ApoER2.
Recruitment of Src kinases upon LDL binding to ApoER2
Several tyrosine kinases may mediate the LDL-dependent tyrosine phosphoryla-
tion of the cytoplasmic tail of platelet ApoER2. It has previously been reported that
phosphorylation of LRP1 in fibroblastic cells involves the Src family of tyrosine
kinases. Considering the functional homology between LRP1 and platelet ApoER2
and the abundance of the Src kinases in platelets, we tested the role of these
kinases in phosphorylation of ApoER2 using the Src-specific inhibitor PP1. Pre-
incubation of platelets with PP1 (1, 5 and 10 µmol/L) reduced LDL-induced ApoER2
tyrosine phosphorylation upto 80% (Figure 4A). This strongly suggests that Src-like
tyrosine kinases play a dominant role in the phosphorylation of the ApoER2 cyto-
plasmic tail. Upon incubation with LDL particles, a band migrating with an apparent
molecular mass of 55 kDa appeared when precipitates were examined employing
antibodies that recognize several members of the Src family of kinases, including
Fyn, c-Src, Yes and Fgr (data not shown).
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Figure 4. LDL- induced phosphorylation of ApoER2 is dependent on Src family tyrosine kinases
Platelets were incubated with the Src family tyrosine kinases inhibitor PP1 (1, 5 and 10 µmol/L, 15 min) prior to
incubation with LDL (1 g/L, 0.2 min, 37°C). Phosphorylation of ApoER2 is detected via immunoprecipitation.  (means
± SD, n=3 (A)). (B) Complex formation between ApoER2 and Src family tyrosine kinases was measured by incubating
platelets with LDL (1 g/L, 0.2 min, 37°C) followed by immunoprecipitation with anti-ApoER2 and western blotting with
an antibody against Fgr.
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As the molecular mass of Fgr corresponds to 55 kDa, we reprobed the precipitates
employing an antibody specifically directed against Fgr. Minor association of Fgr to
ApoER2 could be detected in platelets that were not exposed to LDL (Figure 4C). In
contrast, incubation with LDL resulted in a transient association of Fgr to ApoER2
with maximal co-precipitation of Fgr at 1-2 minutes. The association appeared slower
than tyrosine phosphorylation of ApoER2.
Glycosaminoglycans are essential for LDL-induced platelet signaling via
ApoER2
Binding of LDL particles to their receptors is facilitated by proteoglycans that are
abundantly present at the cellular surface. These proteoglycans contain sulfate-
rich carbohydrate side chains (dermatan-, heparin- and chondroitin-sulfate) providing
a negatively-charged adhesion surface for clusters of basic amino acid residues
present in apolipoproteins. Since LDL-dependent signaling is mediated by the
positively charged region of apoB100 (i.e. B-site), we investigated the contribution
of proteoglycans to this process. To this end, platelets were incubated with various
concentrations of chondroitinase ABC, which removes dermatan- and chondroitin-
sulfate side chains from proteoglycans, but leaves heparan-sulfate side chains
unaffected. Subsequently, platelets were exposed to LDL (1 g/L) or B-site peptide
(100 µmol/L) and analysed for phosphorylation of ApoER2 and p38MAPK
. 
 As illustrated
in Fig. 5, removal of dermatan- and chondroitin side chains resulted in a significant
decrease in LDL- and B-site -dependent phosphorylation of p38MAPK as well as ApoER2
(approximately 65% and 60% respectively). This suggests that the presence of
these particular side chains at the platelet surface is required for optimal signaling
induced by LDL.
Discussion
Association between platelets and LDL particles is believed to result in the forma-
tion of hyperreactive platelets, enhancing the risk for thrombotic complications and
atherosclerotic plaque formation. Several studies have been directed to the identi-
fication of LDL-activated signaling pathways that are responsible for the increased
responsiveness of platelets to its various agonists 8, 28, 29. Although much insight
has been gained in these signaling pathways, the identification of the platelet sur-
face receptor(s) mediating LDL-binding has remained inconclusive. Previously,
the platelet integrin αIIbβ3 has been suggested to serve as a receptor for LDL, as
inferred from ligand blotting and immunofluorescence studies 30, 31. However, spe-
cific antibodies directed against integrin αIIbβ3 proved unable to inhibit the binding
of LDL to platelets.
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Figure 5. Proteoglycans are involved in initiation of platelet signaling by LDL
A, Platelets were incubated with LDL (1 g/L, 5 min, 37°C) or B-site peptide (100 µmol/L, 1 min, 37°C) with and without
enzymatic treatment with chondroitinase ABC and p38MAPK phosphorylation was detected. B, Platelets were incubated
with LDL (1 g/L, 0.2 min, 37°C) with and without enzymatic treatment with chondroitinase ABC and tyrosine
phosphorylation of ApoER2 was monitored. C, the blots were semi-quantified and the amount of phosphorylation was
expressed as percentage of the phosphorylation detected without enzymatic treatment (means ± SD, n=3).
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Furthermore, similar binding characteristics were found with platelets obtained from
controls and Glanzmann’s thrombastenia patients, who are lacking integrin αIIbβ3
26. Thus, the involvement of αIIbβ3 in LDL binding at the platelet surface is
questionable 26, 32, leaving the possibility that other receptors are involved in LDL
signaling as well.
In order to identify the platelet receptor for LDL particles, we focused on LDL-
dependent activation of the tyrosine kinase p38MAPK 8. Phosphorylation of this ki-
nase was almost completely inhibited in the presence of GST-RAP, pointing to the
involvement of a member of the LDL-receptor family in LDL-dependent activation
of p38MAPK (Figure 1). This possibility is supported by our observations that the
LDL-component apoB100 co-localized at the platelet surface with the platelet surface
receptor, ApoER2, and that GST-RAP also interfered with binding of LDL to the
platelet surface (Figure 2). Furthermore, ApoER2 was rapidly phosphorylated upon
the incubation of platelets with LDL particles. Phosphorylation of the receptor ap-
peared to be mainly dependent on kinases of the Src family (Figure 3), and resulted
in association of ApoER2 with the signaling molecule Fgr (Figure 4). This is in
agreement with our earlier observation that the Src family inhibitor PP1 prevents
LDL-induced p38MAPK phosphorylation 5. Based on these data, we propose that
ApoER2 may serve as a platelet surface receptor for LDL particles.
The finding that ApoER2 serves as a receptor for apoB100-containing LDL particles
may seem unexpected in view of the report by Kim and coworkers 15, who observed
only minimal binding of 125I-labeled LDL and VLDL to CHO-cells expressing full-
length ApoER2. In contrast, efficient binding for apoE-rich β-VLDL particles was
observed. It should be noted, however, that in those experiments the lipoprotein
concentrations did not exceed 5 mg/L, which is far below the physiological LDL
plasma concentration (normal range: 0.6 to 1 g/L) that is used in our experiments.
Moreover, since LDL concentrations exceeding 0.1 g/L are required to induce tyrosine
phosphorylation of ApoER2, the possibility exists that similar concentrations are
required to induce complex formation between ligand and receptor.
Whereas binding of LDL to ApoER2 appears to be mediated by the apoB100 moiety,
binding of β-VLDL to ApoER2 involves the apoE component of these lipoprotein
particles. Interestingly, incubation of platelets with full-length apoE or synthetic
peptides corresponding to the Arg/Lys-rich sequence of apoE resulted in a de-
crease in ADP-induced platelet aggregation, a process that could be inhibited by
RAP 13. Apparently, apoB100 and apoE seem to have different upstream effects
upon binding to ApoER2, in that apoB100 governs platelets an increased response
towards agonists, whereas apoE has the opposite effect. Thus, two ligands initiate
different effects through the same receptor. This conclusion becomes even more
intriguing given the observation that the effects of both ligands can be neutralized
by RAP, in principle a ligand for ApoER2. One possibility that may explain these
different responses, may involve ligand-dependent association of ApoER2 to other
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cell-surface receptors. For instance, LDL-dependent activation of p38MAPK in plate-
lets is followed by a de-activation step of this kinase that is mediated by PECAM-
1 (chapter 6). The mechanism underlying the molecular cross-talk between ApoER2
and PECAM-1 remains to be elucidated, but the possibility exists that both receptors
meet at the platelet surface in a LDL-dependent manner.
Also other platelet surface components may contribute to LDL-dependent signaling,
with particular reference in this respect to proteoglycans. Removal of dermatan-
and chondroitin sulfate side chains of these proteoglycans markedly reduces phos-
phorylation of both ApoER2 and p38MAPK. Several mechanisms may be responsi-
ble for this effect. First, these proteoglycans may associate to ApoER2 at the mem-
brane surface, providing an extended binding site for LDL particles. Alternatively,
these sulfated proteoglycans allow preconcentration of LDL particles at the cellular
surface in order to facilitate complex formation between LDL and ApoER2. Our
observation that LDL-dependent ApoER2 phosphorylation requires a threshold LDL-
concentration exceeding 0.1 g/L, seems to be in favour of this alternative possibility.
Our study strongly suggests that ApoER2 may act as a receptor for LDL at the
platelet surface, but a definite conclusion in this regard requires additional experi-
ments employing purified components and/or ApoER2 deficient (megakaryocytic)
cell lines. Nevertheless, this study demonstrates that LDL-binding to platelets re-
sults in phosphorylation of ApoER2, and this step appears to be critical to activate
further signaling cascades.
Thus, ApoER2 serves a so far unrecognized role in the pre-activation of platelets,
and may therefore be used as a target for the development of therapeutic strategies
aiming to reduce platelet hyperreactivity. In addition, a polymorphism within the
ApoER2 gene has recently been reported to be associated with the development of
Alzheimer disease 33. It would be of interest to investigate whether this polymorphism
or others predispose to thrombotic complications.
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Summary
At physiological concentrations, Low Density Lipoprotein (LDL) increases the sen-
sitivity of platelets to aggregation- and secretion inducing agents without acting as
an independent activator of platelet functions.  LDL sensitizes platelets by inducing
a transient activation of p38MAPK, a Ser/Thr kinase which is activated by the simul-
taneous phosphorylation of Thr180 and Tyr182 and which is an upstream regulator of
cytosolic phospholipase A
2
 (cPLA
2
). A similar, transient phosphorylation of p38MAPK
is induced by a peptide mimicking amino acids 3359-3369 in apoB100 called the
B-site. Here we report that the transient nature of the p38MAPK activation is caused
by PECAM-1, a receptor with an immunoreceptor tyrosine-based inhibitory motif.
PECAM-1 activation by cross-linking induces tyrosine phosphorylation of PECAM-
1 and a fall in phosphorylated p38MAPK and cPLA
2
. Interestingly, also LDL and B-site
peptide induce tyrosine phosphorylation of PECAM-1 and studies with immuno-
precipitates indicate the involvement of c-Src. Inhibition of Ser/Thr-phosphatases
PP1/PP2A (okadaic acid) makes the transient p38MAPK activation by LDL and B-site
peptide persistent. Inhibition of Tyr-phosphatases (vanadate) increases Tyr-
phosphorylated PECAM-1 and blocks the activation of p38MAPK.
Together these findings suggest that following a first phase in which LDL, through
its B-site, phosphorylates and thereby activates p38MAPK, a second phase is initiated
in which LDL activates PECAM-1 and induces dephosphorylation of p38MAPK via
activation of the Ser/Thr phosphatases PP1/PP2A.
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Introduction
The contact between platelets and Low Density Lipoprotein (LDL) particles is known
to enhance their responsiveness to aggregation- and secretion-inducing agents 1-5.
Part of this sensitization is mediated via activation of p38MAPK and cytosolic
phospholipase A
2
 (cPLA
2
), which together with a second stimulus leads to more
liberation of arachidonic acid and formation of thromboxane A
2
 1, 6. A second
mechanism involved in sensitization is the activation of p125 Focal Adhesion Kinase
(FAK) with still poorly characterized effects on the formation of focal adhesions and
cytoskeletal rearrangements 7, 8. Activation of p38MAPK by LDL is rapid (within 10
seconds at 1 g/L LDL) and occurs at LDL concentrations within the physiological
range (0.6 – 1.0 g/L LDL), suggesting that it may affect platelets in the circulation
during diet-induced changes in lipoprotein profile. P38MAPK is a member of the family
of proline directed serine/threonine kinases, which is activated by the simultaneous
phosphorylation of Thr180 and Tyr182 9, 10.
LDL-induced p38MAPK activation is insensitive to many inhibitors of signal transduction
in platelets including the Ca2+ chelator BAPTA, suggesting that it is an early step in
the activation cascade initiated by LDL 6. An exception is an increase in cAMP,
which is a potent inhibitor of p38MAPK activation 6.
The receptor through which LDL initiates p38MAPK and FAK activation in platelets
has not yet been characterized but is probably not identical to the classical apoB/E
receptor that mediates LDL uptake in fibroblast and smooth muscle cells as an
antibody directed against the ligand binding domain of the classical LDL-receptor
did not alter the binding of LDL to platelets 11, 12. Furthermore, LDL binding to plate-
lets existed in platelets from patients with familial hypercholesterolemia, who lack
the apoB/E receptor 11.
We have recently identified an activating domain in LDL that induces p38MAPK acti-
vation in platelets 13. The major apolipoprotein of LDL is apoB100, a 4563 amino
acid long protein that is wrapped around the lipid particle and possesses a recog-
nition site for the apoB/E receptor in the so called B-site 14. A B-site peptide mimetic
consisting of 11 amino-acids with a strong positive charge induced a rapid phospho-
rylation of p38MAPK reaching a peak value after 30 seconds and returning to pre-
stimulation values 5 to 10 minutes later 13. The extent of p38MAPK activation was in
the range found with 1 g/L LDL and also the sensitivity to inhibitors of signaling
steps resembled that of LDL. This is an important observation since variations
between donors, a long isolation procedure and specifically its susceptibility to
oxidative modification have led to conflicting interpretations with respect to the
platelet activating properties of LDL 15.
Since platelet sensitization by LDL might be one of the factors that contribute to the
development of thrombo-atherosclerotic disease, its downregulation is equally
important as it prevents persistent platelet sensitization. At present, there is little
insight in this mechanism.
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The presence of platelet endothelial cell adhesion molecule-1 (PECAM-1 or CD31)
is of specific interest since its cytoplasmic tail contains a so called immunoreceptor
tyrosine-based inhibitory motif (ITIM), which is a characteristic of receptors that
mediate inhibitory signals 16-18. The ITIM family comprises several members such
as PECAM-1, FcgammaRIIb, signal regulating protein, CD22 and killer inhibitory
receptor of which only PECAM-1 is present on human platelets 16, 19. PECAM-1 is a
130 kDa transmembrane glycoprotein of the immuno-globulin superfamily of cell
adhesion molecules 20. Its 574 amino acid extracellular domain is organized into six
Ig-like homology domains 21. There is a single transmembrane domain and a 118
amino acid cytoplasmic tail. The ITIM motif is characterized by the consensus
sequence L/I/V/S-x-Y-x-x-L/V 16. Expression of PECAM-1 is restricted to
hematopoietic and vascular cell types such as platelets, monocytes, neutrophils
and endothelial cells 20. The functions of PECAM-1 are diverse and include roles in
angiogenesis, vasculogenesis, integrin regulation and transendothelial migration of
leukocytes 22. Activation of PECAM-1 is accompanied by phosphorylation of the
cytoplasmic part of the molecule. The cytoplasmic tail of PECAM-1 contains 12
serine, 4 threonine and 5 tyrosine residues 20. Which of these residues are
phosphorylated depends on the type of agonist. Both resting and TRAP-stimulated
platelets show predominantly serine phosphorylation of PECAM-1 provided that the
cells do not aggregate. When suspensions are stirred and aggregates are formed
PECAM-1 becomes tyrosine phosphorylated 23. Contact of platelets with collagen
leads to strong PECAM-1 phosphorylation on tyrosine residues 24. A second means
to activate PECAM-1 in platelets is by cross-linking with the specific antibody
PECAM-1.3, which results in tyrosine phosphorylation of the cytoplasmic tail.
Upon receptor activation, the cytoplasmic ITIM-motif recruits and activates Src-
homology 2 (SH2) domain containing protein-tyrosine phosphatases such as SHP-
1 and SHP-2 25. Both SHP-1 and SHP-2 are essential components in PECAM-1
mediated generation of inhibitory signals and their recruitment and activation de-
pends on phosphorylation of tyrosine residues on the PECAM-1 cytoplasmic tail 26.
Earlier studies have shown that p38MAPK activation by the B-site in LDL is maximal
after 1-2 minutes and followed by a gradual decline to pre-activation values. In the
present study we investigated whether PECAM-1 took part in the downregulation
of LDL-induced p38MAPK activation. Furthermore, we determined whether the
downregulation of p38MAPK activation was mediated by the action of phosphatases.
Materials and Methods
Antibodies and Reagents
The monoclonal antibody PECAM 1.3 and the polyclonal antbody SEW, both directed against PECAM-
1, were kindly provided by Prof. P. J. Newman (The Blood Center of Southeastern Wisconsin,
Milwaukee). Anti-mouse F(ab’)
2
 fragments were from Southern biotechnology Associates, Inc (Bir-
mingham, USA).
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The goat polyclonal anti-PECAM-1 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Monoclonal antibody IV.3 was purified from hybridoma cell culture medium. Antiphosphotyrosine
mAb 4G10 was from Upstate Biotechnology (Bucks, UK). The antibody directed against serine-P
was kindly provided by Dr. B.M.T. Burgering (Laboratory for Physiological Chemistry, University
Medical Center Utrecht, The Netherlands). MoAb directed against cPLA
2
 (4-4B-3C) and a polyclonal
antibody directed against c-Src were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Polyclonal antibodies against p38MAPK and dual phosphorylated p38MAPK (phosphoplus p38MAPK) and
horseradish peroxidase labeled anti-rabbit IgG were from New England Biolabs (Beverly, USA).
Renaissance chemiluminescence Western-blot reagent was from NEN-Dupont, Boston, MA, USA.
Non-fat dry milk was obtained from Nutricia (Zoetermeer, the Netherlands). PP1 was obtained from
Alexis Biochemicals (San Diego, CA, USA). Okadaic acid was obtained from Calbiochem (San
Diego, CA, USA); vanadate from Sigma  (St. Louis, MO, USA). Human α-thrombin was purchased
from Kordia Life Science (Leiden, The Netherlands)
The peptide RLTRKRGLKLA (Mw = 1311 Da), designated B-site peptide, represents the apoB
receptor-binding domain (Arg 3359- Ala 3369) of apoB100. The peptide was synthesized by standard
solid-phase peptide synthesis and purified by C18 reverse-phase chromatography (HPLC,
Genosphere biotechnologies, Paris, France). The purity of the peptide was >99% as determined by
HPLC and the molecular weight was verified by matrix-assisted laser desorption mass spectrometry
by the manufacturer.
Lipoprotein Isolation
Lipoproteins were isolated as described previously 27. In short, fresh, non-frozen plasma from 4 healthy
subjects each containing less than 100 mg lipoprotein(a)/L was pooled and LDL (density range 1.019-
1.063 kg/L) was isolated by sequential flotation in a Beckman L-70 ultracentrifuge. Centrifugations
(20 hr, 175000 g, 10°C) were carried out in the presence of NaN
3
 and EDTA. The LDL preparations
contained only minimal amounts TBARS (0.20 ± 0.07 nmol/mg), lipid peroxides (6.7 ± 1.9 nmol/mg)
and contaminating plasma proteins (below or within reported values for native LDL). Lp(a) concen-
trations, determined with the use of a specific antibody (Apotech, Organon Technika, Rockville,
U.S.A), were below 14 mg/L. Lipoproteins were stored at 4°C under nitrogen for not longer than 14
days and before each experiment dialyzed overnight against 104 volumes 150 mmol/L NaCl. ApoB100
and lipoprotein(a) concentrations were measured using the Behring Nephelometer 100. The concen-
tration of LDL was expressed as g apoB100 protein/L.
Platelet Isolation
Freshly drawn venous blood from healthy volunteers was collected with informed consent into 1:10
v/v 130 mmol/L trisodium citrate. The donors claimed not to have taken any medication during two
weeks prior to blood collection. Platelet-rich plasma was prepared by centrifugation (200 g, 15
minutes, 20°C). Gel-filtered platelets (GFP) were isolated by gel filtration through Sepharose 2B
equilibrated in Ca2+-free Tyrode’s solution (137 mmol/L NaCl, 2.68 mmol/L KCl, 0.42 mmol/L NaH
2
PO
4
,
1.7 mmol/L MgCl
2
, and 11.9 mmol/L NaHCO
3
, pH 7.25) containing 0.2 % BSA and 5 mmol/L glucose.
GFP were adjusted to a final count of 2 * 1011 platelets/L and incubated with LDL and other agonists
with and without stirring (900 rev.min-1) at 37°C as indicated in “Results”.
Measurement of p38MAPK and cPLA
2
GFP were incubated at 37°C with LDL, B-site peptide or thrombin as indicated. After incubation, 100
mL aliquots were mixed (1:10 v/v) with cold lysis buffer (RIPA buffer containing 10% protease
inhibitor cocktail, 5 mM NaVO
3
) and subsequently taken up in Laemmli sample buffer. Samples were
heated prior to SDS-polyacrylamide gel electrophoresis (12%). Proteins were electrophoretically
transferred (1 hr, 100 volts) to a nitrocellulose membrane using a mini-protean system (Biorad,
Richmond, CA, USA). The blots were blocked in 5% non-fat dry milk, 0.1% Tween 20 in phosphate
buffered saline (1 hr, 4°C) and incubated with the phosphoplus p38MAPK (Thr180/Tyr182) or p38MAPK
antibody  (1:2000 in 1% non-fat dry milk, 0.1% Tween in PBS, 16 hr, 4°C). Both antibodies are raised
against residues 171-186 of human p38MAPK. After washing, the membranes were incubated with
horseradish peroxidase labeled anti-rabbit (1:2000, 1 hr, 4°C) and p38MAPK was visualized using the
enhanced chemiluminescence reaction.
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For semi-quantitative determination of the amount of dual phosphorylated or total p38MAPK, the density
of the bands was analyzed using ImageQuant software (Molecular Dynamics).
For the measurement of cPLA
2 
phosphorylation, samples were withdrawn and collected in Laemmlli
sample buffer. Measurement of cPLA
2
 was based on the mobility shift on SDS-PAGE that accompa-
nies phosphorylation of the protein 28. The running buffer for electrophoresis of cPLA
2
 was pH 8.3.
cPLA
2
 was detected using the moAb 4-4B-3C. Immune complexes were detected by enhanced
chemiluminescence.
PECAM-1 tyrosine phosphorylation
Platelets were incubated with LDL, B-site peptide or thrombin as indicated (37 °C). After incubation,
500 ml aliquots were mixed with cold lysis buffer (1:10 v/v) as described above and precipitated with
goat polyclonal anti-PECAM-1 (1 µg) and protein G-Sepharose for 3 hr (4°C). After washing with lysis
buffer, samples were taken up in Laemmli sample buffer. Samples were heated (5 min, 100°C) prior
to the western blotting procedure. The blots were blocked in 5% BSA, 0.05% Tween 20 in tris-
buffered saline (TBS) (1 hr, 4°C) and incubated with monoclonal 4G10 antibody  (1:2000 in 1% BSA,
0.05% Tween in TBS, 16 hr, 4°C) or polyclonal SEW antibody  (1:2000 in 1% BSA, 0.05% Tween in
TBS, 16 hr, 4°C). After washing, the membranes were incubated with peroxidase linked anti-mouse
(1:5000, 1 hr, 4°C) or anti-rabbit IgG  (1:10000, 1 hr, 4°C) and phosphorylation was visualized using
the enhanced chemiluminescence reaction.
Statistics
Data are expressed as means ± SD with number of observations n.
Results
PECAM-1 inhibits LDL-induced phosphorylation of p38MAPK
As reported previously 13, B-site peptide (100 µmol/L) induced a rapid phosphorylation
of p38MAPK reaching a peak value after 30 seconds and which returned to pre-stimu-
lation values after 5 - 10 minutes (Figure 1). Thus, following a first phosphorylation
step, phosphatases were activated that brought p38MAPK back to the range found in
resting platelets. The same rapid phosphorylation of p38MAPK was induced by LDL (1
g/L), reaching a maximum within 1 minute and decreasing to basal levels after 20
minutes or more. This dephosphorylation of p38MAPK is distinctly faster than observed
with LDL preparations isolated in the presence of the anti-bacterial agent thimerosal,
which was common use in earlier studies 6, 29.
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Figure 1. P38MAPK activation by LDL and B-site peptide
Platelets were incubated with LDL (1 g/L, 37°C, closed
symbol) or B-site peptide (100 µmol/L, 37°C, open symbol).
Dual phosphorylated p38MAPK was measured by SDS-PAGE
and Western blotting using a phosphospecific anti-p38MAPK
polyclonal antibody.  The blots were semi-quantified and
the data were expressed as percentage of the p38MAPK
phosphorylation after 1 min (100%, open symbol). Data are
expressed as means ± SD, n = 4.
113
Chapter 6
Thus, following an initial phase in which p38MAPK was phosphorylated, both LDL and
a peptide mimetic of the B-site of apoB100 induced dephosphorylation of p38MAPK,
bringing the enzyme back to the state found in resting platelets.
To investigate whether PECAM-1 played a role in the dephosphorylation of p38MAPK,
the receptor was activated with antibody PECAM-1.3 that is specific for the
ectodomain of PECAM-1. Incubation of platelets with this antibody (1 µg/mL) for 10
min resulted in tyrosine phosphorylation of PECAM-1, illustrating that the receptor
was activated (Figure 2A). No further activation of PECAM-1 was found by cross-
linking PECAM-1.3 antibody with anti-mouse Fab-fragments.
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Figure 2. Activation of PECAM results in downregulation of LDL-induced signaling
Platelets were incubated with anti-PECAM 1.3 antibody (10 µg/mL, 10 min) and PECAM 1.3 antibody and in addition
Fab fragments (30 µg/mL, 90 sec, 37°C) to cross-link the antibody prior to stimulation with LDL (1 g/L, 5 min, 37°C).
PECAM-1 was immunoprecipitated from platelet lysates and applied to gel. With the use of antibody 4G10, the tyro-
sine phosphorylation of PECAM-1 was analyzed. (A). The lower panel shows the samples in which PECAM-1 was
detected with a polyclonal antibody against this receptor as a control for equal lane loading. (B) Platelets were incu-
bated with LDL with mild (PECAM-1.3, 10 µg/mL, 10 min, 37°C) and firm (PECAM-1.3; 10 µg/mL, 10 min, 37°C and
anti-mouse IgG F(ab’)
2
; 30 µg/mL, 1.5 min, 37°C) cross-linking of PECAM-1. Subsequently, p38MAPK- and cPLA
2
-
phosphorylation were detected by western blotting. (B, left) The lower panel shows samples analyzed with an antibody
directed against the total amount of p38MAPK as a control for equal lane loading. The blots were semi-quantified and the
data were expressed as percentage of the p38MAPK or cPLA
2
 phosphorylation without PECAM-1 antibodies. Data are
expressed as means ± SD, n = 3.
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When platelets were first treated with the PECAM-1.3 antibody for 10 minutes and
thereafter stimulated with LDL (1 g/L) for 1 minute, phosphorylation p38MAPK was
reduced to 70% compared with platelets that were not treated with PECAM-1.3
antibody (Figure 2B).
A further cross-linking of PECAM-1 resulted in a reduction in phosphorylation of
p38MAPK to 40%. A similar inhibition by PECAM was observed at the level of cPLA
2
,
which is a downstream target of p38MAPK in LDL-induced signaling 6.
To assess a possible involvement of the FcgammaRIIa-receptor mediated path-
way in the anti-PECAM-1.3 induced activation of PECAM-1 and concomitant de-
phosphorylation of p38MAPK, studies were repeated in the presence of antibody
IV.3, an inhibitor of FcgammaRIIa (data not shown). The inhibition by PECAM-1
activation was unchanged. This observation, together with literature data that show
that p38MAPK is activated by FcgammaRIIa activation rather than inhibited, illustrate
that the inhibition by PECAM of LDL-induced p38MAPK phosphorylation is independ-
ent of FcgammaRIIa.
LDL activates PECAM-1
The observation that PECAM inhibited the LDL-induced phosphorylation of p38MAPK
raised the question whether LDL itself was capable of activating PECAM-1 thereby
downregulating the initial activation of p38MAPK activating pathways. Platelets were
incubated with LDL and the phosphorylation of PECAM-1 was visualized on west-
ern blots after immunoprecipitation of the receptor (Figure 3A). As a control, plate-
lets were stimulated with thrombin (0.5 U/mL, 2 minutes, 37°C) with and without
stirring. Stirring resulted in an enhanced tyrosine phosphorylation of PECAM-1
whereas serine phosphorylation was equal under both conditions such in agree-
ment with earlier observations 23. Western blots with an appropriate antibody re-
vealed that LDL induced tyrosine phosphorylation of PECAM-1 but was incapable
of inducing phosphorylation of serine residues. The LDL (1 g/L) -induced tyrosine
phosphorylation of PECAM-1 was transient, showing a maximum after 1 minute
stimulation and downregulation after prolonged incubation (Figure 3B). Also the B-
site peptide induced tyrosine phosphorylation of PECAM-1 which is in line with the
concept that the B-site mediates the activation of PECAM-1 by LDL. After
immunoprecipitation of PECAM-1 an additional band at approximately 125 kDa was
co-precipitated (Figure 3B). Reprobing of the blots with the polyclonal anti-PECAM-
1 (SEW) revealed that the upper band represents PECAM-1.
The inhibitor of Src kinases, PP1 (10µmol/L), abrogated tyrosine phosphorylation of
PECAM-1 suggesting a role for Src kinases (Figure 3C). Indeed, upon LDL stimula-
tion, a 60 kDa band co-precipitated with PECAM-1 upon LDL stimulation. After
reprobing with a specific antibody this band could be identified as c-Src, indicating
that a complex was formed between c-Src and PECAM-1 upon stimulation by LDL
(Figure 3D).
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Downregulation of LDL-signaling by PECAM-1 depends on serine/threonine
phosphatases
PECAM-1 is known to initiate inhibitory signaling pathways by recruitment of the
tyrosine phosphatases SHP-1 and SHP-2. As p38MAPK is activated upon phosphor-
ylation of both threonine and tyrosine residues, the involvement of serine/threonine
phosphatases as well as tyrosine phosphatases was investigated.
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Figure 3. LDL induces tyrosine phosphorylation of PECAM-1
Platelets were incubated with LDL (1 g/L, 37°C) or thrombin without stirring  (Thrombin -, 0.5 U/mL, 2 min, 37°C) or
thombin under stirred conditions (Thrombin +, 0.5 U/mL, 900 rev. per min., 2 min, 37°C).  PECAM-1 was immunoprecipitated
from platelet lysates and applied to gel. With the use of antibody 4G10 tyrosine phosphorylation (A, left) and with the
use of anti-Ser antibody serine phosphorylation (A, right) of PECAM-1 was visualized. The lower panel shows similar
samples in which PECAM-1 was detected with a polyclonal antibody against this receptor as a control for equal lane
loading. (B) Platelets were incubated with LDL (1 g/L, 37°C), B-site peptide  (100 µmol/L, 37°C) for the indicated time-
periods or with thombin under stirred conditions (Thrombin +, 900 rev. per min., 2 min, 37°C) and the tyrosine
phosphorylation of PECAM-1 was analyzed. (C) Platelets were incubated with the Src family tyrosine kinases inhibitor
PP1 (10 µmol/L, 15 min) prior to incubation with LDL (1 g/L, 5 min, 37°C) and PECAM-1 tyrosine phosphorylation was
detected (D) Complex formation between PECAM-1 and Src family tyrosine kinases was measured by incubating
platelets with LDL (1 g/L, 37°C) for the indicated time-periods or with thrombin (1 U/mL, 2 min, 37°C, 900 rev.p.m.)
followed by immunoprecipitation with polyclonalAb against PECAM-1 and western blotting with an antibody against c-
Src. The 60 kDa band was identified as c-Src. As a control for equal lane loading blots were reprobed with a monoclonal
antibody against total PECAM-1 (lower panel).
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To investigate the contribution of serine/threonine phosphatases, platelets were
incubated for 0.5 minute with 1 µmol/L okadaic acid, a concentration known to
inhibit the serine/threonine phosphatases PP1 and PP2A 30, 31.  This treatment resulted
in a strong potentiation of p38MAPK activation by LDL (1 g/L) and B-site peptide (100
µmol/L) and changed the transient activation into a more sustained activation com-
pared with platelets stimulated with LDL in the absence of the inhibitor (Figure 4A).
We next investigated whether inhibition of tyrosine phosphatases with vanadate
interfered with the phosphorylation states of p38MAPK.  Platelets were preincubated
for 30 minutes with 100 µmol/L sodium vanadate.  This treatment completely abolished
the phosphorylation of p38MAPK by LDL and B-site peptide (Figure 4B). Furthermore,
the tyrosine phosphorylation of PECAM-1 induced by LDL and B-site peptide was
preserved by vanadate treatment and even increased to levels above the range
found in the absence of the inhibitor (Figure 4C). Thus, inhibition of tyrosine
phosphatases augmented the Tyr-phosphorylation of PECAM-1 induced by LDL
and B-site peptide thereby potentiating the dephosphorylation of p38MAPK to such
an extent that any rise in phosphorylated p38MAPK was prevented. This finding
strenghtens the role of PECAM-1 in downregulation of p38MAPK.
Discussion
ApoB100 is the main protein constituent of LDL and consists of 4563 amino acids,
wrapped around the lipid particle. The B-site is the domain in apoB100 that binds
to the apoB/E receptors on cells that remove plasma cholesterol from the circula-
tion. A peptide that mimics this region between Arg 3359 and Ala 3369 of apoB100
induced a transient activation of platelet p38MAPK showing a maximal phosphoryla-
tion after 1 minute stimulation 13. Also LDL induced a rapid and transient phosphor-
ylation of p38MAPK with approximately similar kinetics as observed with the B-site
peptide. It is possible that this downregulation at prolonged incubation times might
reflect a protection mechanism that prevents extensive platelet activation in the
circulation by LDL.
Here we report that the downregulation of phosphorylated p38MAPK is mediated by
PECAM-1. PECAM-1 activation by a specific receptor cross-linking antibody led to
Tyr-phosphorylation of PECAM-1 and p38MAPK dephosphorylation. A second cross-
linking Fab fragment in addition to PECAM-1 antibody did not induce much more
PECAM-1 tyrosine phosphorylation although literature data suggest that Fab frag-
ments are required for optimal PECAM-1 activation 32. Activation of PECAM-1 with
the PECAM-1.3 antibody resulted in a decrease in LDL-induced phosphorylation
of p38MAPK and a further activation of PECAM with additional Fab fragments led to
a further reduction in the phosphorylation of the enzyme. These observations make
PECAM-1 an important inhibitor of LDL-induced p38MAPK phosphorylation.
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P38MAPK is activated by dual phosphorylation of p38MAPK of Thr180 and Tyr182 and the
inhibition by PECAM-1 is therefore likely to impair further signaling to downstream
effectors. Indeed, activation of PECAM-1 also inhibits the phosphorylation of cPLA
2
,
which is a key step in the mobilization of arachidonic acid and further formation of
thromboxane A
2
. This makes PECAM-1 a key factor in the control of LDL-induced
platelet sensitization.
There is little insight in the mechanisms by which PECAM-1 is activated under
physiological conditions. The activation of PECAM-1 could be the result of agonists
present in the circulation that induce a protection mechanism against cardiovascular
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Figure 4. Role of Ser/Thr and Tyr-phosphatases in LDL-signaling to p38MAPK and PECAM-1
Platelets were incubated with LDL (1 g/L, 37°C) or B-site peptide  (100 µmol/L, 37°C) for the indicated time-periods
with and without okadaic acid (1 µM, 30 sec) (A) or sodium vanadate (100 µM, 30 min) (B) and dual phosphorylated
p38MAPK was identified by western blotting. (C) Platelets were incubated with and without sodium vanadate (100 µM, 30
min) prior to incubation with LDL (1 g/L, 37°C) or B-site peptide  (100 µmol/L, 37°C) and tyrosine phosphorylation of
PECAM-1 was analyzed.
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complications. Platelet activation through the collagen receptor glycoprotein VI results
in PECAM-1 tyrosine phosphorylation which may function to negatively limit growth
of platelet thrombi on collagen surfaces 18, 32-34. Also, platelet activation through
thrombin receptors leads to PECAM-1 activation. Activated non-aggregated platelets
exhibit serine phosphorylation of PECAM-1 in contrast to aggregated platelets which
show tyrosine phosphorylated PECAM-1 23. The present experiments suggest a role
for LDL as an agonist for PECAM-1 -mediated platelet inhibition. Incubation of platelets
with LDL or B-site peptide induced tyrosine phosphorylation of PECAM-1 with an
optimum after 1 minute followed by a downregulation after prolonged incubation.
Neither LDL nor B-site peptide induced phosphorylation of serines on PECAM-1,
such in contrast to PECAM-1 stimulation by thrombin. Our data reveal that also in
non-aggregated platelets PECAM-1 can be tyrosine phosphorylated since LDL is
not an aggregation-inducing agent.
Upon incubation of platelets with LDL, a band with a slightly lower molecular weight
compared to PECAM-1 co-precipitates with this receptor. To date, the nature of the
lower molecular weight band is not known, but a possible candidate is ApoER2, a
130 kDa protein which might function as a platelet LDL receptor.
Okadaic acid is an inhibitor of the serine/threonine phosphatases PP1 and PP2A
35. When platelets were preincubated with this inhibitor, the transient phosphoryla-
tion of p38MAPK by LDL and B-site peptide changed into a persistant activation and
reached levels far above the maximal phosphorylation observed in untreated plate-
lets. A recent study on p38MAPK phosphorylation by collagen revealed that PP2A
mediates the dephosphorylation and a similar role might be present in platelets
stimulated by LDL 36. P38MAPK is activated by dual phosphorylation on tyrosine and
threonine residues by dual specific MAPK-Kinases 3 en 6 (MKK3/6) 37, 38. MKK6 is
activated by phosphorylation on Ser151 and Thr155 by an upstream enzyme termed
MKK kinase. Thus, the dephosphorylation of p38MAPK by PP1/PP2A might be the
result of a direct effect of these phosphatases on p38MAPK but an indirect effect
caused at the level of upstream kinases is equally feasible.
Vanadate is an inhibitor of tyrosine phosphatases. When platelets were preincubated
with this inhibitor, the transient Tyr-phosphorylation of PECAM-1 was increased
and more sustained enabling the receptor to transmit a stronger inhibitory signal
into the cell. Apparently, vanadate did not increase the phosphorylated state of
p38MAPK although the enzyme is phosphorylated on threonine and tyrosine residues.
Instead, vanadate treatment completely abolished the increase of phosphorylated
p38MAPK by LDL and B-site peptide. This illustrates the potent inhibitory action of
PECAM-1 which through its strong activation of PP1/PP2A abolished the accumu-
lation of phosphorylated p38MAPK. The results found in vanadate-treated platelets
support the concept that PECAM-1 is a negative regulator of LDL-induced signaling
in platelets. At the same time this property makes it difficult to study whether tyro-
sine phosphatases took part in the dephosphorylation of p38MAPK.
119
Chapter 6
Signal transduction by PECAM-1 depends on the ITIM motif which becomes tyro-
sine phosphorylated. Since PECAM-1 does not appear to be autophosphorylated,
a kinase is thought to phosphorylate the cytoplasmic tyrosine residue 39, 40. A candi-
date responsible for the tyrosine phosphorylation is a member of the Src family
tyrosine kinase 34, 40. Immunoprecipitation studies after incubation of platelets with
LDL showed co-precipitation of c-Src with PECAM-1. P38MAPK activation was not
affected by the okadaic acid treatment until platelets had been stimulated with LDL
for 1 minute or more. This is in accordance with the time-dependent activation of
PECAM-1 by LDL and recruitment of c-Src. This suggests that c-Src recruitment to
the cytoplasmic tail of PECAM-1 induces ITIM-tyrosine phosphorylation and sub-
sequent recruitment of PP2A.
In conclusion, the results reported in this study are best explained by assuming a
model in which LDL affects platelet signaling mechanisms in two phases. During a
first, initial phase LDL binds via its B-site in apoB100 to the putative LDL receptor
on platelets thereby inducing the dual phosphorylation of p38MAPK and activating
the enzyme. This step leads to activation of cPLA
2
 and formation of thromboxane
A
2
. This mechanism explains why aspirin or related drugs abolish at least in part
the sensitization of platelets by LDL. This activation phase is followed by a second
phase in which LDL, either directly or bound in a complex with the LDL receptor,
activates PECAM-1. This results in recruitment of c-Src and phosphatases PP1/
PP2A thereby downregulating the phosphorylation of p38MAPK.
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Cardiovascular disease is the number one cause of death in the western world; in
1999 the mortality rate was 36%. The most common form of cardiovascular dis-
ease is atherosclerosis which is characterized by an excessive deposition of cho-
lesterol in the arterial wall, cell proliferation and cell accumulation and may result in
a total blockade of arteries. Low density lipoprotein (LDL) is positively correlated
with the occurrence of atherosclerosis, making a high LDL level an important risk
factor. There are many reports demonstrating that LDL and platelets are intimately
involved in the process of atherosclerosis. For instance, hypercholesterolemia
patients have increased levels of LDL and hyperreactive platelets and suffer from
thrombosis and atherosclerosis at an early age 1. In this study, we investigated the
binding of the lipoprotein particle to the platelet membrane and the subsequent
initiation of signal transduction.
Platelet activating properties of LDL
Although it has been known for many years that LDL enhances the responsive-
ness of platelets to several aggregatory agonists, there is little insight in which
components in LDL make platelets more responsive to agonist stimulation. In our
studies we have focussed on the pathway involving p38MAPK. From earlier studies it
has become clear that p38MAPK is an early event in LDL-induced platelet signaling 2.
P38MAPK is activated by dual phosphorylation on tyrosine and threonine residues by
dual specific MAPK-Kinases 3 en 6 (MKK3/6) 3, 4. MKK6 can be activated by phos-
phorylation on Ser151 and Thr155 residues by an upstream enzyme termed MKK
kinase 5. Using the phosphorylation of p38MAPK as a read out for LDL-induced plate-
let sensitization, we found that a specific part in the apoB100 protein had platelet-
activating properties. A better understanding of the component of LDL that is re-
sponsible for platelet sensitization provides clues about the receptor that is in-
volved in LDL-induced sensitization of platelets. Studies in other cell types have
made clear that LDL binding depends on basic amino-acid rich regions 6. Specifi-
cally, the region between aa 3359 and aa 3369, the B-site, is crucial for binding to
members of the LDL receptor family. A peptide mimetic was found to bind to the
platelet surface and induce phosphorylation of p38MAPK in platelets (chapter 4). In
initial studies, the kinetics of phosphorylation of p38MAPK by the B-site peptide were
distinct from LDL-induced phosphorylation of this enzyme. B-site peptide induced
a transient activation of p38MAPK with maximal activation between 0.5 and 2 minutes.
LDL induced persistent activation during 30 min or more. The sustained activation
of p38MAPK observed after platelet contact with LDL was explained by assuming an
initial activation phase as a result of the binding of LDL via the B-site followed by a
‘second phase’ of p38MAPK phosphorylation as a result of an effect by other com-
pounds of LDL. This second phase was thought to involve dimerization of receptors
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as apoB100 contains another basic domain, the A-site, that is also implicated in
receptor binding 7. Furthermore, lipid exchange upon LDL-receptor binding as de-
scribed by Engelmann et al 8, 9 might result in platelet signaling. Thus, the differ-
ence found between LDL- and B-site -induced signaling helped to understand
different potential platelet activating properties in LDL.
However, a closer look at the isolation of LDL drew the attention to the compound
thimerosal that was originally used as a preservative of the preparations. Recent
studies show that thimerosal releases calcium from intracellular stores in platelets
and this is caused by the presence of mercury in the molecule 10. Furthermore,
micromolar concentrations of thimerosal caused aggregation of platelets and acti-
vation of cPLA2 11-13. Routinely, the LDL preparations are dialyzed overnight against
5.103 times volume of 0.9% NaCl in order to remove all contaminating reagents
including thimerosal. Apparently, thimerosal is not entirely removed from the LDL
preparation since the presence and absence of thimerosal leads to distinct kinetics
of p38MAPK phosphorylation by LDL (chapter 4/6). Thimerosal-treated LDL induces
persistent activation of p38MAPK and thimerosal-free LDL induces a transient
activation. Without addition of thimerosal, the phosphorylation is maximal after a 1
minute incubation and is downregulated after prolonged incubation. Furthermore,
working with LDL always brings along the risk of oxidation, generating a modified
particle with different effects on platelet function 14  and requires continuous control
tests on oxidation. The data presented in chapter 3, 5 and 6 are based upon LDL
preparations isolated without the use of thimerosal.
The receptor that mediates LDL binding to the platelet surface
The fact that the 39 kDa receptor-associated protein (RAP) prevented LDL-in-
duced phosphorylation of p38MAPK (chapter 5) and FAK (chapter 3) was an indica-
tion that a member of the LDL receptor family might be involved. In mammalian
cells, the LDL receptor family consists of 5 members; the LDL receptor, VLDL
receptor, ApoER2, LRP and megalin (chapter 1). The first member of this family
that was identified was the LDL-receptor (also termed ‘classical’ LDL receptor or
apoB/E receptor), which was characterized on human fibroblasts 15.
The members of the LDL receptor family function in the maintenance of choles-
terol homeostasis since they are the tools by which cells remove LDL from the
circulation 16, 17. The only member of this family that is present on platelets is plate-
let Apolipoprotein E Receptor 2 (ApoER2) 18. Among the different family members
ApoER2 shares the highest degree of structural homology with the LDL receptor
with both receptors containing 8 extracellular ligand binding repeats 19-21. Previous
studies have shown that ligand binding repeats 3-7 are required for optimal binding
of apoB100 to the LDL receptor and that repeat 5 suffices for apoE binding.
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Several splice variants of ApoER2 occur which exhibit distinct numbers of extra-
cellular ligand binding repeats. The platelet ApoER2 variant lacks ligand binding
repeats 4-6 and one would expect that this deletion would make apoE binding
impossible while preserving apoB100 binding 18. However, both ApoER2 and the
splice variant that is present on platelets bind apoE-rich β-VLDL with high affinity,
indicating that apoE is a ligand.
Although ApoER2 shows high structural homology with the LDL receptor, from a
functional point of view it is expected that ApoER2 is closer to the VLDL receptor.
Both have restricted tissue expression and high sequence homology in terms of
grouping of the ligand binding repeats. In human tissues, the ligand binding re-
peats are grouped and separated by a linker. The ligand binding repeats are clus-
tered in a similar way in ApoER2 and the VLDL receptor (5+2 for ApoER2 and 5+3
for VLDL receptor) which differs from the clustering of the LDL receptor (4+3). The
clustering of ligand binding repeats determines which ligands bind to the receptor.
Therefore, one expects that apoER2 shares a broad ligand binding ability with the
VLDL receptor 22. This functional homology does not argue in favor of apoB100 as
an ApoER2 ligand since the VLDL receptor does not bind apoB100. Our studies
show that the platelet ApoER2 binds apoB100 indicating that aspects of both con-
siderations might be important for explaining the function of the platelet LDL receptor
(chapter 5).
In vivo, the LDL receptors share two important functions; supply cells with choles-
terol and removal of cholesterol-rich particles from the bloodstream in order to prevent
their accumulation in the circulation. The function of platelet ApoER2 appears more
complex. ApoER2 has a low capacity of ligand degradation 23. Hence, it has been
suggested that ApoER2 predominantly functions in signal transduction. Signaling
properties of the ApoER2 have been found upon binding of Reelin 24, 25. Reelin is an
extracellular matrix protein that is produced by neurons in specific regions of the
developing brain, where it controls neuronal migration and positioning 26. Reelin is a
ligand for both ApoER2 and the VLDL receptor and initiates signaling in neuronal
cells via tyrosine phosphorylation of the receptor. Subsequently, the adaptor protein
disabled-1 (Dab-1) transmits the signal and start a kinase cascade that controls
cellular motility and shape by acting on the neuronal cytoskeleton 27, 28. Whether LDL
receptor family members function predominantly in signaling or endocytosis is defined
by distinct domains in the cytoplasmic tails of LDL receptor family members. In
contrast to their extracellular domains, the cytoplasmic tails of LDL receptor family
members share very little sequence similarity with the exception of a short amino-
acid motif NPxY. The low sequence homology of the cytoplasmic tails suggests
distinct roles in the initiation of signal transduction. For example, the 59 aa insert
that is exclusively present in ApoER2 contains putative SH2 homology domains.
Reelin-induced signaling via ApoER2 requires Dab1 binding to the NPxY motif in
the cytoplasmic tail and subsequent tyrosine phosphorylation. Upon tyrosine
129
Chapter 7
phosphorylation of Dab1, it can bind several non-receptor tyrosine kinases including
Src family members through an interaction with their SH2 domains 29. The initiation
of signaling by platelet ApoER2 appears to be regulated differently. The fact that the
inhibitor of Src kinases PP1 prevents ApoER2 phosphorylation by LDL suggests
that Src kinases are required for phosphorylation of the NPxY motif. This might
point towards recruitment of Src kinases to the receptor (chapter 5).
Platelets endocytose plasma proteins by both receptor-mediated and pinocytotic
mechanisms under the control of signal transduction pathways. The Src family
member Fgr is found to co-localize with clathrin in platelets cells which is compatible
with a function for this kinase in endocytosis 30. Our studies show that ApoER2
forms a complex with Fgr upon stimulation of platelets with LDL (chapter 5). Thus,
the function of ApoER2 in platelets might involve endocytosis that is under control
of signal transduction via Fgr and p38MAPK. Fgr is the only Src kinase family member
that is not or minimally phosphorylated in resting platelets suggesting that Fgr forms
a bridge between ApoER2 and specific downstream signaling mediators upon binding
of LDL 31.
ApoER2 might also function in the activation of FAK as its phosphorylation is inhib-
ited by RAP. FAK is phosphorylated on six tyrosine residues. LDL induces fast and
persistant phosphorylation of Tyr-925 with maximal phosphorylation at 1-2 minutes
incubation.  Phosphorylation of Tyr-397, Tyr-861 and Tyr-577 was slower with a
maximal phosphorylation after 10 minutes incubation. The time- and concentration
dependence of the early phosphorylation site, Tyr-925, of FAK shows high similar-
ity with ApoER2. ApoER2 functions in the brain in the correct positioning of newly
generated neurons. Neuron migration requires controlled polymerization and
depolymerization of the actin cytoskeleton, suggesting a role for ApoER2 in
cytoskeletal reorganization. The phosphorylation of FAK by LDL might reflect a
similar role for ApoER2 in platelets.
Similar to binding to the LDL receptor, LDL binding to proteoglycans depends on
basic amino acids 32. The consensus sequence for proteoglycan binding includes
five basic amino acids in a nonapeptide with intervening nonbasic amino acids 33.
Treatment of platelets with chondroitinase ABC inhibited LDL- and B-site-induced
signaling to p38MAPK and cPLA2 (chapter 5).  Furthermore, LDL fails to induce tyro-
sine phosphorylation of ApoER2 upon treatment with chondroitinase ABC (chapter
5). Thus, proteoglycans are required to mediate the tyrosine-phosphorylation of
ApoER2 and subsequent signaling induced by LDL, in agreement with other cell
types 34. However, the inhibition by chondroitinase ABC treatment is not complete.
Cleavage of heparan sulfate glycosaminoglycans might reveal that the residual
binding to ApoER2 is mediated by this class of proteoglycans.
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Downregulation of LDL signaling
The fact that platelets do not circulate in the bloodstream as activated particles
despite the contact with LDL might point towards a mechanism that inhibits platelet
signaling. The regulation of protein expression of LDL family members occurs at
the level of transcription but this property is absent in platelets. Hence, the effect of
LDL on platelets must be controlled by negative signals that suppress the activat-
ing pathways.
Platelet-endothelial cell adhesion molecule 1 (PECAM-1, CD31) is a 130 kDa
member of the immunoglobulin gene superfamily expressed on endothelial cells,
platelets, neutrophils and monocytes. PECAM-1 molecules form clusters at sites
of cell-cell contact via a mechanism that appears to be controlled by the extracel-
lular domain 35. PECAM-1 is able to mediate cell-cell adhesion through interaction
with itself (homophilic interaction) or with other receptors (heterophilic interaction).
In addition to its adhesive functions, PECAM-1 has been shown to be a participant
in signaling pathways. The cytoplasmic domain of PECAM-1 contains 5 tyrosine
residues of which two are incorporated in an ITIM motif. The tyrosine residues at
position 663 and 686 become phosphorylated in response to numerous stimuli. As
a result, platelet signaling pathways induced by collagen or other activators be-
come downregulated.  LDL induces tyrosine-phosphorylation of PECAM-1 sug-
gesting that this receptor is responsible for the transient character of p38MAPK acti-
vation and downstream mediators (chapter 6). PECAM-1 is not an autophospho-
rylating protein indicating that a tyrosine kinase is involved and a candidate might
be c-Src 36, 37. Indeed, upon LDL stimulation, PECAM-1 forms a complex with c-
Src. Phosphorylation of tyrosine residues mediated by the action of protein tyro-
sine kinases creates docking sites for the recruitment and activation of SH2-con-
taining signaling molecules. Earlier studies have shown that SH2- domain contain-
ing tyrosine phosphatases are recruited to the ITIM-motifs in the intracellular tail of
PECAM-1 38. Okadaic acid is an inhibitor of Ser/Thr phosphatases, specifically
PP1 and PP2A, and led to a major increase in p38MAPK phosphorylation by LDL and
B-site peptide (chapter 6). Ser/Thr phosphatase PP2A, has recently been shown
to be involved in downregulating the phosphorylation of p38MAPK induced by colla-
gen 39. Protein phosphatase 2A (PP2A), a serine/threonine phosphatase, is widely
distributed in the cytoplasm of mammalian cells. The PP2A holoenzyme is com-
posed of a 36 kDa catalytic subunit that is bound to a 65 kDa regulatory subunit 40,
41
. After immunoprecipitation of PECAM-1 from platelets incubated with LDL, a 36
kDa band was co-precipitated which might point towards involvement of PP2A.
Definite proof for the involvement of PP2A awaits characterization of this band with
a specific antibody.
A possible involvement of integrin αIIbβ3 in LDL-induced platelet sensitization has
been a subject of controversy for many years 42, 43. Experiments with specific anti-
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bodies against integrin αIIbβ3 and studies with platelets from patients with
Glanzmann’s thrombastenia (that are deficient in integrin αIIbβ3) indicated that
this integrin does not function as the LDL receptor on platelets. Nevertheless, integrin
αIIbβ3 is involved in platelet sensitization by LDL as this lipoprotein increases the
sensitivity of platelets via outside-in signaling of αIIbβ3. A 5 minutes pre-incubation
with LDL induced a dose-dependent increase in ADP-induced fibrinogen binding
that required intact lysine residues in apoB100 44. This signaling route might be
downstream of activation of p38MAPK, cPLA2 and thromboxane A2 formation as a
result of LDL and B-site binding to ApoER2. The involvement of PECAM-1 in LDL-
induced platelet sensitization sheds a new light on the role of αIIbβ3 as PECAM-1
might also transduce signals that modulate the function of integrins. After engagement
of PECAM-1, changes in the affinity of integrins have been observed on platelets
and lymphocytes resulting in increased platelet deposition and aggregation to an
extracellular matrix 45.  Oligomerization of PECAM-1 receptors on the surface of
HEL- cell lines results in upregulation of integrin function 46 and cross-linking of
PECAM-1 on the surface of leukocytes results in the activation of adhesion
molecules of both the β1, β2 and β3 integrin family 47-49. This might suggest that
tyrosine-phosphorylation of PECAM-1 by LDL has a complex function. First, PECAM-
1 is involved in downregulation of LDL-induced signaling and second, it may be
responsible for enhanced fibrinogen binding to integrin αIIbβ3 and subsequent
sensitization of platelet function.
Interaction between LDL and platelets
The activatory and inhibitory pathways induced by LDL presented in this thesis
are summarized in two models that will be discussed below (Figure 1).
1. Two independently activated receptors
LDL binds to the platelet surface via binding of the B-site to proteoglycans. These
cell-surface proteins facilitate the subsequent binding of the lipoproteins to the
LDL receptor family member ApoER2. Upon binding of LDL to the receptor, tyro-
sine phosphorylation of the NPxY motif in the cytoplasmic tail occurs. The tyrosine-
phosphorylation recruits the Src family kinase Fgr resulting in activation of p38MAPK,
cPLA2 and thromboxane A2 formation. Simultaneously, LDL binds via the B-site to
PECAM-1 leading to tyrosine phosphorylation of its ITIM motif via recruitment of
c-Src. The tyrosine-phosphorylated cytoplasmic tail leads to binding of Ser/Thr
phosphatases PP1/PP2A that prevent activation of MKK3/6 thereby downregulating
the activation of p38MAPK (Figure 1A).
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2. Receptor cross-talk
The second model proposes receptor heterodimerization upon LDL binding to the
platelet surface. LDL binds to ApoER2 via proteoglycans which results in tyrosine-
phosphorylation of ApoER2. Phosphorylated ApoER2 provides docking sites for a
number of adaptor molecules including tyrosine kinase Fgr which might signal
towards p38MAPK. This might lead to recruitment of membrane-associated c-Src to
the ITIM motif of PECAM-1 resulting in PECAM-1 tyrosine phosphorylation and the
subsequent Ser/Thr phosphatase recruitment as described above. Our observa-
tions are best explained by the second model since in response to LDL the phos-
phorylation of PECAM-1 is slower than that of ApoER2 (chapter 5 and 6). Within
10-30 seconds, ApoER2 phosphorylation is maximal whereas recruitment of c-
Src by PECAM-1 occurs after 30 seconds leading to an optimal phosphorylation
of PECAM-1 after approximately 1-2 minutes of LDL stimulation. After 1 minute
the phosphorylation of p38MAPK by LDL is maximal indicating that prolonged
incubation times of platelets with LDL leads to activation of Ser/Thr phosphatases.
Furthermore, immunoprecipitation of PECAM-1 revealed an approximately 130
kDa band that is tyrosine-phosphorylated upon LDL stimulation (chapter 6). The
130 kDa protein might be ApoER2 as tyrosine phosphorylation of ApoER2 shows
the same kinetics as that of the protein that is co-precipitated with PECAM-1. This
suggests that a complex is formed between ApoER2 and PECAM-1.
Patil et al 50 proposed that PECAM-1 functions as a negative regulator of protein
tyrosine kinase (PTK)-dependent signal transduction pathways initiated by
immunoreceptor tyrosine-based activation motif (ITAM)-containing stimulatory
receptors. Platelets express two ITAM-containing receptors FcgammaRIIa and the
GPVI-FcR-chain complex. The GPVI-FcR-chain complex transmits collagen-specific
activation signals into the cell interior through the action of an ITAM present within
the cytoplasmic domain of the FcR-chain. In contrast, the LDL response is not
regulated by an interaction between ITIM and ITAM containing receptors as the
cytoplasmic tail of ApoER2 lacks an ITAM motif. This illustrates that PECAM-1 can
also interact with receptors that do not belong to the ITAM-family.
ApoER2 activates two independently regulated platelet signaling pathways
The second signaling mediator that is phosphorylated and investigated in detail in
this thesis is FAK, a nonreceptor tyrosine kinase that is known to mediate cytoskeletal
remodeling 51. The question remains whether p38MAPK and FAK are located up-
stream of each-other in LDL-induced signal transduction or whether they belong to
two independently regulated pathways.
The phosphorylation of FAK induced by LDL is fast but sustained in contrast to the
transient character of p38MAPK phosphorylation. This indicates that FAK is not af-
fected by PECAM-1 tyrosine phosphorylation and an argument in favor of p38MAPK
and FAK acting in two separate pathways. Nevertheless, both proteins are under
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control of RAP (chapter 3 and 5) suggesting that the phosphorylation is mediated
by a similar receptor being ApoER2. Compared with p38MAPK, FAK phosphorylation
shows a higher sensitivity to the inhibitor RAP with an IC-50 of approximately 1
µg/mL compared with 20 µg/mL for p38MAPK. Finally, FAK and ApoER2 share complex
formation with the Src kinase Fgr.  This suggests that FAK is phosphorylated as a
result of LDL binding to ApoER2.
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Figure 1. Platelet signaling by LDL
(A), Two independently activated receptors. (B), Receptor cross-talk. For description, see text.
134
General Discussion
FAK regulates p38MAPK activation in response to LDL
It is also possible that FAK and p38MAPK are connected via PYK2. PYK2 (FAK2,
RAFTK) is a member of the non receptor tyrosine kinase FAK family and is present
in various cell types, predominantly brain tissue and haematopoietic cells including
platelets and megakaryocytes 52. PYK2 associates with SH2 domains of Src family
tyrosine kinase 53 and is able to activate p38MAPK via activation of MKK3 providing a
link between FAK and p38MAPK activation 54. The FAK family members FAK and
PYK2 might both be involved in apoER2-induced signaling. A second possibility is
that cross-talk between FAK and PYK2 affects MKK3 and p38MAPK.
Upon formation of a FAK-Fgr complex, both proteins might become activated.
Indeed, LDL-induced phosphorylation of Tyr-397 and Tyr-925 is completely inhib-
ited by the Src-inhibitor PP1 (chapter 3). This illustrates that formation of a FAK-Src
family kinase complex results in phosphorylation of both proteins thereby initiating
downstream signaling pathways. The activation of FAK results in exposure of dock-
ing sites for c-Src. The tyrosine-phosphorylation of PECAM-1 might be established
by c-Src as this kinase was co-precipitated with the receptor (chapter 6) (Figure
1B). Thus, FAK forms a link between signaling induced by binding of LDL to ApoER2
and PECAM-1 activation. This would make FAK the key signaling element in LDL-
induced platelet sensitization. However, further investigations are required to sup-
port this hypothesis.
Fgr might facilitate the interaction between FAK and ApoER2 by forming a bridge
via its SH2 and SH3 domains. The 59 aa insert of ApoER2 contains putative SH3
binding domains that might recruit Fgr upon NPxY tyrosine phosphorylation 18. The
phosphorylation of FAK at specific residues might create a high affinity binding site
for SH2 domains enabling formation of a signaling complex between FAK and
members of the Src-family kinases 55. Whether ApoER2 is phosphorylated via Fgr
as a result of autophosphorylation of FAK or that another tyrosine kinase is re-
sponsible for the tyrosine phosphorylation of ApoER2 can not be distinguished.
The question remains whether platelets are meant to react on the presence of
LDL. The fact that a major cholesterol uptake is not required and platelets do not
show extensive endocytosis argue against this. An alternative explanation might
lie in the fact that platelets are shed from megakaryocytes that thereby define the
properties of platelets. Megakaryocytic cell lines also express platelet ApoER2
which is likely to function in uptake of cholesterol for maintenance of cell function
and maturation. The uptake of cholesterol might be accompanied by the signal
transduction pathways described above. Furthermore, the cytoplasmic extrusions
of megakaryocytes, that regulate migration and shed off platelets contain
homodimerized PECAM-1 on the tips 56. As the cytoplasmic tips of megakaryocytes
are enriched in cholesterol to support membrane flexibility, they probably also
express  ApoER2. This might indicate that the cross-talk between ApoER2 and
PECAM-1 is also present on the extrusions of megakaryocytes.
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LDL and thrombosis
High levels of LDL cholesterol are positively correlated with the risk for arterial
thrombosis. This is illustrated in patients with hypercholesterolemia who have
hyperreactive platelets 57. These platelets show enhanced responsiveness to
aggregatory agonists. With the new insights in sensitization of platelets by LDL,
the enhanced responsiveness might be explained by the short upregulation of the
p38MAPK pathway involving cPLA2 and thromboxane A2. The most important char-
acteristic of p38MAPK activation by LDL is its fast and transient activation. Prolonged
incubation with LDL reveals downregulation of the LDL-induced signaling and even
desensitization upon B-site peptide treatment. This argues against a role of this
pathway in hyperreactive platelets in hypercholesterolemia. Nevertheless, sudden
changes in circulating LDL as a result of dietary intake might induce platelet
hyperresponsiveness.
Alternatively, the continuous hyperreactive state of platelets from hypercholesterol-
emia patients might be caused by the activation of FAK. Activation of FAK is
sustained and results in cytoskeletal reorganization and targeting of adaptor proteins
to the site of action. This would create the optimal conditions for enhancement of
platelet aggregation and secretion by activating agents.
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Achtergrond
Cholesterol is nodig voor de opbouw en instandhouding van de wand van de cel, het
celmembraan, en voor de produktie van hormonen. In het bloed wordt cholesterol
vervoerd in kleine bolletjes, de lipoproteinen. Deze lipoproteinen (lipo= vet, protein=
eiwit) zijn complexen van vetten en eiwitten die, doordat ze ingepakt zijn in een
hydrofiel laagje, door het waterige milieu van het bloed kunnen worden
getransporteerd.  Aan de buitenkant bevindt zich een eiwit wat karakteristiek is
voor het type lipoprotein. Deze zogenaamde apolipoproteinen functioneren in het
herkennen van celoppervlakken waardoor de bestemming van de lipoproteinen
gereguleerd kan worden. Er zijn verschillende soorten lipoproteinen die elk een
bepaalde functie hebben in het vervoeren van vetten van en naar weefsels. In dit
proefschrift wordt het Lage Dichtheid Lipoproteine (LDL) bestudeerd. Het cholesterol
wat door LDL vervoerd wordt staat bekend als het slechte cholesterol. Een hoge
concentratie van LDL cholesterol is een belangrijke risicofactor voor het ontstaan
van hart- en vaatziekten. Een ander lipoproteine, het Hoge Dichtheid Lipoproteine
(HDL) neemt het teveel aan cholesterol in de vaatwand op en transporteert dat naar
de lever. In de lever wordt ervoor gezorgd dat het cholesterol het lichaam kan verlaten
door uitscheiding in de gal. Dit proces wordt het ‘reverse cholesterol transport’
genoemd. Hoge concentraties HDL worden gerelateerd aan een verlaagd risico voor
hart- en vaatziekten.
Bloedplaatjes zijn nodig voor het stelpen van bloedingen. Als je een wond hebt,
worden bloedplaatjes geaktiveerd waardoor ze aan elkaar gaan klonteren met als
gevolg dat een propje wordt gevormd dat de wond afsluit. De bloeding wordt hierdoor
gestelpt. Plaatjesactivatie mag eigenlijk alleen plaatsvinden als er een wond is. Als
er ergens in het lichaam een beschadiging van een bloedvat ontstaat, dan komen
de bloedplaatjes ook in contact met bestanddelen uit de onderliggende lagen in het
bloedvat. Hierdoor worden de bloedplaatjes geactiveerd. Als de klontering van
bloedplaatjes uit de hand loopt kan dit leiden tot het (gedeeltelijk) afsluiten van een
slagader; arteriele trombose. Het afsluiten van een bloedvat kan een hartinfarct of
een herseninfarct veroorzaken. Dit is afhankelijk van de plaats waar het propje van
bloedplaatjes terecht komt. De aktivatie van de bloedplaatjes onstaat doordat de
aktiverende bestanddelen binden aan eiwitten op het plaatjesoppervlak. Deze eiwitten,
receptoren, hebben als functie het doorgeven van een signaal van buiten de cel
naar binnen toe. In de cel wordt het signaal opgevangen door eiwitten die daardoor
gefosforyleerd worden. Fosforylering is de aanzet tot aktivatie van een eiwit. Als
gevolg van de aktivering van een bepaald eiwit wordt het signaal verder doorgegeven
aan andere eiwitten wat uiteindelijk kan leiden tot aktivatie van het bloedplaatje. Dit
proces wordt signaaltransductie genoemd.
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Doel van deze studie
Zowel bloedplaatjes als LDL zijn componenten die betrokken zijn bij het onstaan
van trombose. Nu is het sinds vele jaren bekend dat een interactie tussen LDL en
bloedplaatjes een rol speelt bij trombose. Patienten met een hoge concentratie LDL,
veroorzaakt door erfelijke factoren, hebben bloedplaatjes die heftiger reageren op
aktiverende bestanddelen in hun omgeving. Het gedrag van bloedplaatjes wordt dus
beinvloed door LDL. Deze patienten hebben een hoger risico op hart- en vaatziekten.
Het lijkt er dus op dat als het bloedplaatje in contact komt met LDL, het gevoeliger
wordt voor andere prikkels die in de bloedbaan aanwezig zijn en het een trombus
zou kunnen vormen. De manier waarop dit gebeurt is nog onduidelijk. De meeste
signalen worden door een receptor op het oppervlak van het bloedplaatje de cel in
gestuurd. Het is bekend dat ook LDL aan het oppervlak van het bloedplaatje bindt.
Elk bloedplaatje bevat 2000-7000 bindingsplaatsen voor LDL. Het is echter niet
bekend welke receptor op bloedplaatjes het LDL herkent. Er zijn inde loop der jaren
verschillende kandidatenm aangewezen maar deze bleken toch niet verantwoordelijk
te zijn voor de herkenning van het LDL. Op andere cellen zoals de cellen die de
bloedvatwand bekleden, het endotheel, zijn ‘LDL-receptor familieleden’ aanwezig.
Deze familie bestaat  uit 5 leden; VLDL receptor, Megalin, ApoER2, LRP en de LDL
receptor. Van deze laatste receptor is uitgezocht hoe LDL daar aan kan binden. Het
blijkt dat specifieke stukjes van het eiwit wat aan de buitenkant van het LDL bolletje
zit, het apolipoproteine B100 (apoB100), aan de receptor binden. Hierdoor wordt een
signaal de cel in gestuurd wat ervoor zorgt dat het LDL naar binnen kan. Vervolgens
kan de cel gebruik maken van het cholesterol wat in het LDL zit. Bloedplaatjes
missen deze receptor. Dat is bekend geworden uit studies met Familiale
Hypercholesterolemie (FH) patienten die deze LDL receptor missen. Bij deze patienten
werd nog steeds binding van LDL aan bloedplaatjes gevonden. Verder bleken stoffen
die specifiek deze receptor afdekken (antilichamen) niet in staat om de binding te
beinvloeden. Andere leden van de LDL-receptor familie zijn niet meer aangetoond
op het bloedplaatje waardoor de receptor onbekend bleef.
In deze studie is onderzocht hoe de interactie tussen bloedplaatjes en LDL gaat en
welke signalen vervolgens de cel in gestuurd worden. Uit eerdere studies is gebleken
dat binding van LDL aan het oppervlak van bloedplaatjes ervoor zorgt dat een signaal
de cel in gestuurd wordt wat als eerste naar het eiwit p38MAPK gaat. Dit eiwit wordt
geactiveerd door LDL en signaleert verder naar andere eiwitten wat uiteindelijk leidt
tot een gevoeliger bloedplaatje. Dit proces noemen we sensitizering. Als er een
aktiverende component in contact komt met het bloedplaatje zal er heftiger op
gereageerd worden. Een andere signaleringsweg die aangezet wordt na contact van
bloedplaatjes met LDL loopt via Focal Adhesion Kinase (FAK). Dit is een eiwit wat
na aktivatie diverse signaleringswegen aan kan zetten en ook bij kan dragen tot
sensitizatie van het bloedplaatje. Door verder onderzoek naar de manier waarop de
signaleringseiwitten p38MAPK en FAK geaktiveerd worden en naar de manier waarop
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LDL aan het oppervlak van  bloedplaatjes bindt, kan meer inzicht verkregen worden
in de rol van LDL en bloedplaatjes in het ontstaan van trombose.
Resultaten
Als eerste hebben we naar de wijze van aktivatie van het eiwit FAK gekeken. FAK
bevat 6 fosforyleringsplekken die allerlei signaleringswegen aan kunnen zetten. Door
te bekijken hoe snel en in welke mate deze plekken gefosforyleerd worden, kan
meer inzicht verkregen worden in de rol van FAK in plaatjes sensitizatie door LDL.
Het blijkt dat de volgorde van fosforylering van de sites en de mate waarin dat
gebeurt, anders is dan door een andere activator van bloedplaatjes, trombine. Het
is bekend via welke receptoren trombine zorgt voor aktivatie van FAK. Het feit dat
LDL op een andere manier FAK aktiveert is een aanwijzing dat er een andere, nog
onbekende, receptor bij de binding van LDL aan bloedplaatjes betrokken is.
RAP is een eiwit wat voorkomt dat LDL aan de leden van de LDL receptor familie
kan binden. Het blijkt dat RAP de fosforylering van FAK sterk vermindert wat een
indicatie is dat LDL toch via een lid van de LDL-receptor familie aan het
plaatjesoppervlak bindt. Verder blijkt uit deze studie dat LDL niet dezelfde
signaleringswegen aanzet als andere agonisten waardoor het een unieke beinvloeder
van plaatjesfunktie is.
In hoofdstuk 4 wordt onderzocht welk deel van LDL aan het plaatjesoppervlak bindt.
Het blijkt dat LDL via het eiwit apoB100 het plaatje herkent.  Een specifiek deel van
dit eiwit, de B-site, is belangrijk voor binding aan de klassieke LDL receptor. Een
peptide van dit deel van apoB100, het B-site peptide, is in staat tot het aktiveren
van p38MAPK. Het B-site peptide initieert dezelfde signalering naar p38MAPK en cPLA2
als LDL. Uit bindingsstudies blijkt dat LDL en het B-site peptide ook dezelfde
bindingsplek op het plaatjesoppervlak gebruiken. Hieruit concluderen we dat de B-
site verantwoordelijk is voor herkenning van het oppervlak van bloedplaatjes en het
starten van signaaltransductie. Dit is een sterke aanwijzing dat een lid van de LDL-
receptor familie betrokken is bij de sensitizatie van bloedplaatjes door LDL. Het is
belangrijk om te weten welk deel van LDL aan het oppervlak van bloedplaatjes bindt
omdat zo meer onformatie over de betrokken receptor verkregen wordt. Een extra
voordeel is dat er nu gewerkt kan worden met het B-site peptide om puur het effect
van binding aan het oppervlak te bestuderen. Er wordt namelijk gesuggereerd dat
het LDL wat we isoleren ook andere componenten bevat die bijvoorbeeld aan het
LDL plakken en dat het LDL kan veranderen van samenstelling als het lang bewaard
wordt. Door de experimenten met het B-site peptide, laten we zien dat het effect wat
we meten wel degelijk veroorzaakt wordt door LDL.
Ondertussen werd een lid van de LDL-receptor familie op bloedplaatjes aangetroffen.
Het betrof een variant van ApoER2, waarbij de plaatjesvariant een verkort
extracellulair deel heeft. Deze receptor zou de gezochte LDL receptor kunnen zijn.
Echter, het is beschreven dat wel HDL maar niet LDL aan deze receptor bindt. Toch
blijkt uit hoofdstuk 5 dat ook aktivatie van p38MAPK door RAP geblokkeerd kan worden
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en dat LDL met ApoER2 colocaliseert. Daarom is toch onderzocht of deze receptor
verantwoordelijk is voor de binding van LDL aan het bloedplaatje. Het blijkt dat LDL
de receptor ApoER2 kan aktiveren wat betekent dat deze receptor betrokken is in
het hele proces. Na aktivatie van de receptor worden kinases verzameld. Een kinase
kan een fosfaat groep op een eiwit zetten waardoor het gefosforyleerd wordt. Dit
leidt vervolgens tot aktivatie van het eiwit waardoor het zijn funktie kan gaan uitvoeren.
In hoofdstuk 5 wordt beschreven dat, na stimulatie met LDL, een lid van de Src
kinase familie verantwoordelijk is voor de fosforylering van ApoER2.  Vervolgens
wordt een lid van de Src kinase familie, Fgr, naar de receptor toegebracht wat
uiteindelijk voor het aanzetten van de signaaltransductiewegen naar p38MAPK en
waarschijnlijk ook FAK zorgt. Hoe het exact binnen in de cel in zijn werking gaat, is
nog niet helemaal bekend.
Toch is het vreemd dat normale, fysiologische, concentraties LDL zorgen voor initiatie
van signalering in het bloedplaatje. In de bloedbaan circuleren niet continu gevoelige
bloedplaatjes. Dit zou er op kunnen wijzen dat andere componenten in de bloedbaan
het bloedplaatje rustig houden. Een andere mogelijkheid is dat het bloedplaatje een
soort van compensatie mechanisme ingebouwd heeft waardoor het onder normale
omstandigheden niet uit de hand kan lopen. Het is bekend dat er een remmende
receptor op plaatjes aanwezig is, PECAM-1. In hoofdstuk 6 is onderzocht of deze
receptor verantwoordelijk is voor het uitzetten van het signaal wat een toevoeging
van LDL aan het bloedplaatje veroorzaakt. Het blijkt inderdaad dat deze receptor
geaktiveerd wordt na contact van bloedplaatjes met LDL. Die aktivatie wordt wederom
bewerkstelligd door een lid van de Src kinase familie, c-Src. Na receptor aktivatie
worden fosfatases naar de receptor gehaald. Fosfatases halen de fosfaatgroep van
een eiwit af waardoor dat eiwit stopt met het uitvoeren van zijn funktie. Dit resulteert
in een inactivatie van p38MAPK waardoor het signaal wat door LDL gegenereert was,
weer teniet gedaan wordt.
In hoofdstuk 7 worden alle resultaten op een rijtje gezet en wordt geprobeerd deze
samen te vatten in een model. De hypothese is dat LDL aan ApoER2 bindt wat leidt
tot het verzamelen van kinases. Kinase Fgr zorgt voor de aktivatie van
signaleringswegen en kinase c-Src zorgt voor aktivatie van PECAM-1 die op zijn
beurt de signalering naar p38MAPK uit zet.
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